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1. Factorial Study Summary 
 
Background 
 Little is known about how to optimize resuscitation for patients with out-of-
hospital cardiac arrest.  This is evident from the very low survival rates that are currently 
reported.  The advent of automatic external defibrillators (AEDs) and their potential for 
wide-spread use by less highly trained emergency medical service (EMS) providers and 
lay persons has not resulted in the substantial increased survival rates anticipated.  This 
has led to speculation that more and sooner circulation of oxygenated blood to the brain 
and heart may be important.  Resuscitation Outcomes Consortium (ROC) Investigators 
propose a large clinical trial, using a factorial design, to test two strategies to increase 
blood flow.  One strategy involves the impedance threshold device (ITD), which 
enhances venous return and cardiac output by increasing the degree of negative 
intrathoracic pressure during decompression.  The second involves initiating 
resuscitation with a period of manual compressions and ventilations (Analyze Later), 
rather than attempting defibrillation immediately (Analyze Early). 
 
Rationale 
The rationale for the factorial design is based on several arguments. 
• Most importantly, both interventions are worthy of study in their own right.  Both 
interventions were proposed by several of the participating ROC sites in their 
initial applications. 
• A number of ROC EMS agencies currently use cardiopulmonary resuscitation 
(CPR) first (i.e., Analyze Later) as their standard protocol, whereas others 
analyze the rhythm and shock as required before initiating CPR (i.e. Analyze 
Early.)  Thus, if the ITD intervention were to be studied alone, we would be faced 
with an uncontrolled heterogeneity of practice, possibly changing during the 
course of the trial.  This would necessitate, at a minimum, stratifying by the EMS 
protocol. 
• We anticipate no substantial interactive effect between these two interventions.  
One relates to when assisted circulation takes place, compared with when the 
defibrillatory attempt takes place.  The other has to do with the quantity of flow 
during assisted circulation.  Both include some blood flow prior to any 
defibrillation attempt. 
• The infrastructures to conduct the two trials are virtually identical, thus assuring 
substantial efficiencies in costs, and virtually cutting in half the number of patients 
and the time needed to study the two interventions sequentially, providing there 
are no interactions between the interventions. 
 
Challenges 
The factorial design poses three challenges: 
• Implementation of two interventions may be difficult for the persons who must 
conduct these interventions; the emergency medical technicians and 
paramedics, who must perform their efforts under the duress of life-threatening 
emergent conditions.  This potential challenge has been mitigated by adopting 
cluster randomization for the Analyze Later protocol, whereby each cluster will 
be randomized to either always doing CPR first (Analyze Later) or always doing 
rhythm analysis first (Analyze Early).  These clusters will consist of geographic 
areas or monitor/defibrillators within the EMS agencies. EMS personnel will 
place an active or sham ITD on all patients meeting criteria.  Hence, EMS 
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providers will always follow the same procedures:  a) place an active or sham 
ITD on all patients, and b) analyze the rhythm either early or later consistently 
according to cluster randomization.  No on-the-spot decisions regarding 
randomization will be required for use of either intervention. 
• The cluster randomization will require that all out-of-hospital cardiac arrest 
events be accounted for.  This requirement is actually beneficial, in that it 
provides additional motivation for the implementation of a comprehensive 
epidemiologic database of all life-threatening out-of-hospital events (what we 
have termed the ROC Registry).  Whether the trial benefits from the Registry or 
the Registry benefits from the trial is unclear at this point and will depend in part 
upon the timing of various funding mechanisms. 
• When a factorial design is used, there is an almost irresistible temptation to test 
for an interactive effect (i.e., risk difference for one factor depends on the level 
of the other factor).  While a factorial design is the only reasonably efficient way 
of testing for an interaction between several interventions, to power the trial for 
the specific interaction effect generally requires a substantially increased sample 
size.  As noted previously, we do not anticipate any substantial interaction 
between these two therapies.  Nonetheless, potential interactions will be 
assessed by the DSMB at interim analyses and the sample size adjusted 
accordingly.   
 
Potential Advantage 
 It should be noted that the intervention of Analyze Later probably cannot be 
appropriately compared by randomizing individual episodes.  The issues with 
compliance caused by the confusion of having an EMS provider alternate between the 
basic concept of aggressively doing CPR initially versus assiduously assessing rhythm 
and defibrillating initially can be easily appreciated.  The choice of the cluster will vary 
depending upon the realities of training and the fluidity of personnel within an agency.  
All clusters will be encouraged, and large clusters will be required, to switch from 
Analyze Later to Analyze Early or vice versa at midpoint, or more often through the trial, 
thus serving as their own control. 
 
Outcomes 
 The trials share a common primary outcome, namely survival to hospital 
discharge with modified Rankin score <3, and common secondary outcomes, namely 
survival to discharge as well as functional status at discharge and at 1, 3 and 6 months 
after discharge as well as depression at 3 and 6 months. 
 
Design 
 The trial will be factorial with one intervention based on a double-blind 
randomization of individuals through the use of an active versus a sham ITD (identical to 
the user), and the other intervention based on non-blinded randomized clusters. 
 
Setting 
 The trial will be conducted in all EMS agencies participating in the Resuscitation 
Outcomes Consortium. 
 
Sample Size and Analysis 
 Since we are not testing for an interaction, sample size for each intervention will 
be based on the traditional significance levels of .05 for two-sided and .025 for one-sided 
and a power of 0.9.  Each will require approximately 16-18 months of enrollment.  The 
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specific inclusion criteria, sample size, and analytic techniques are defined with each of 
the specific interventions. 
 
CPR Performance 
 Critical to understanding both interventions is the monitoring of CPR 
performance.  All sites will implement procedures to attempt to collect 100% of data 
sources needed to assess CPR performance.  Three performance measures will be 
abstracted:  the ventilation rate, the compression rate, and the CPR fraction as defined 
in Appendix 2.  It is known, based on the longstanding effort in Seattle, as well as more 
recent efforts in Chicago and Norway, that the data sources will be missing or 
incomplete in approximately 25% of episodes.  Details for the CPR performance 
monitoring are dealt with in Section 4, since the process is applicable to both 
interventions. 
 
Run-in Phase 
 After personnel have been trained in use of the ITD and the methods for 
Analyze Later vs. Analyze Early according to their cluster randomization, they will initiate 
a run-in phase.  Evidence of compliance with the protocol and completion and 
submission of the data will be required before the site can enroll in the active phase of 
the trial.   
 
Anticipated Clinical Impact 
If the ITD demonstrates the hypothesized improvement in survival, we estimate 
that the premature death of approximately 2,700 victims of cardiac arrest1 per year 
would be averted in North America compared to standard CPR.  If the Analyze Later 
approach demonstrates the hypothesized improvement in survival, we estimate 
approximately 4,000 lives will be saved per year in North America.  By implementing a 
factorial study design, these benefits to clinical practice can be achieved more efficiently 
and faster than otherwise would be the case. 
 
Remainder of This Protocol 
The remainder of this protocol is split into three parts. The second section contains the 
materials specific to the ITD intervention. The third section contains the materials 
specific to the Analyze Later intervention. The fourth section contains materials common 
to both interventions and/or specific to the factorial design of the study.
                                                 
1 Number of treatable cardiac arrests  X Proportion of cases with non VF initial rhythm or VF that 
does not respond to initial shock X Absolute difference in survival i.e. (US population 295,483,056 
X 0.53 per 1000 population (52)  + Canadian population 31,127,234 X 0.57 per 1000 population 
(53)) X Absolute difference 
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2. Impedance Threshold Device Trial 
 
Comparison of Standard CPR Plus Active Impedance Threshold Device Versus Standard 
CPR Plus Sham Impedance Threshold Device In Patients With Out-Of-Hospital Cardiac 
Arrest 
 
Study Summary 
 
Background: Most patients with out-of-hospital cardiac arrest do not survive to hospital 
discharge. Survival after cardiac arrest is correlated with the time from its onset to the circulation 
of oxygenated blood to the brain and heart. Compression of the chest during cardiopulmonary 
resuscitation (CPR) increases intrathoracic pressure and compresses the heart. Decompression 
of the chest results in negative intrathoracic pressure, which enhances venous return and 
cardiac output. Collectively these actions circulate blood to the brain and heart. The impedance 
threshold device (ITD) is a novel respiratory device intended to increase the degree of negative 
intrathoracic pressure during decompression. Studies in animal models of cardiac arrest or 
small randomized trials in humans demonstrate that the ITD improves hemodynamics and 
short-term outcomes but it remains unclear whether ITD improves survival to discharge or 
neurological outcome. Therefore we propose a large clinical trial to test whether standard CPR 
supplemented by active ITD is effective compared to standard CPR supplemented by sham 
ITD.  
 
Aims: The primary aim of the trial is to compare survival to hospital discharge with modified 
Rankin score <3 between standard CPR plus active ITD versus standard CPR plus sham ITD in 
patients with out-of-hospital cardiac arrest. The secondary aims of the trial are to compare 
survival to discharge, functional status at discharge and at 1, 3 and 6 months as well as 
depression at 3 and 6 months. 
 
Hypotheses: The null hypothesis is that survival to hospital discharge with modified Rankin 
score <3 is identically distributed with use of standard CPR plus active ITD versus standard 
CPR plus sham ITD in patients with cardiac arrest. The secondary null hypotheses are that 
survival to discharge, functional status at discharge and at 1, 3 and 6 months after discharge as 
well as depression at 3 and 6 months will be identically distributed with use of standard CPR 
plus active ITD versus standard CPR plus sham ITD in patients with cardiac arrest. 
 
Design: Double-blind randomized controlled trial. 
 
Population: Patients with non-traumatic out-of-hospital cardiac arrest, presumed to be local 
age of consent or greater and treated by EMS providers. 
 
Setting: EMS systems participating in the Resuscitation Outcomes Consortium. 
 
Sample Size:  Based on a one-sided significance level of 0.025, power = 0.90, a survival with 
modified Rankin score < 3 to discharge rate of 5.32% with standard CPR and sham ITD, and 
two interim analyses, a maximum of 14,742 evaluable patients are needed to detect a 6.68% 
absolute survival with modified Rankin score < 3 to discharge with standard CPR and active 
ITD.  
 
Anticipated Clinical Impact: If this trial demonstrates a significant improvement in survival with 
use of the ITD, we estimate that the premature deaths of approximately 2,700 victims of cardiac 
arrest per year would be averted annually in North America alone. 
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Specific Aims 
 
Primary Aim:  The primary aim of the trial is to compare survival to hospital discharge with 
modified Rankin score <3 between standard CPR plus active ITD versus standard CPR plus 
sham ITD in patients with out-of-hospital cardiac arrest. 
 
Hypothesis:  The null hypothesis is that survival to hospital discharge with modified Rankin 
score <3 is identically distributed with use of standard CPR plus active ITD versus standard 
CPR plus sham ITD in patients with cardiac arrest. 
 
Secondary Aims: The secondary aims of this trial are to compare survival to discharge, 
functional status scores at discharge and at 1, 3 and 6 months as well as depression at 3 and 6 
months between standard CPR plus active ITD versus standard CPR plus sham ITD in patients 
with out-of-hospital cardiac arrest. 
 
Hypotheses:  The null hypotheses are that survival to discharge, functional status scores at 
discharge and at 1, 3 and 6 months as well as depression score at 3 and 6 months are 
identically distributed with use of standard CPR plus active ITD versus standard CPR plus sham 
ITD in patients with cardiac arrest. 
 
Prespecified Subgroup Analyses:  These include assessment of treatment effect by:  
a) First recorded cardiac arrest rhythm before application of the ITD. 
b) Observational status of an arrest (e.g., witnessed versus unwitnessed). 
c) EMS response time interval of <10 minutes and >10 minutes from 911 call to 
initiation of CPR by EMS. 
 
Background and Significance 
 
Conceptual Framework for ITD 
Despite the widespread availability of basic and advanced life support for patients with 
out-of-hospital cardiac arrest, few survive to hospital discharge.(1-3) In the most efficient EMS 
systems, less than 15% of all patients with out-of-hospital cardiac arrest are discharged from the 
hospital with intact neurological function.(1-3) Furthermore, the median published survival to 
hospital discharge after out-of-hospital cardiac arrest is only 6.4%.(4) 
While there are many variables that impact on the potential for a patient in cardiac arrest 
to survive, the timely circulation of oxygenated blood to the heart and brain is considered 
critical.(2)  An airway device such as a facemask or an endotracheal tube is commonly used to 
assist in oxygenating and ventilating the patient.  However, the inherent mechanical 
inefficiencies of standard CPR limit the ability to circulate blood by even the most highly skilled 
rescuers.(5) 
The purpose of CPR is to pump blood from the chest to the vital organs. Blood flow to 
the vital organs is highly dependent on the amount of blood return to the chest after each 
compression phase.(6, 7)  During standard CPR, chest compression results in an elevation of 
intrathoracic pressure and direct cardiac compression. Both of these mechanisms result in 
forward blood flow out of the chest to perfuse the brain and other vital organs. When the chest 
recoils, intrathoracic pressures decrease relative to extrathoracic pressures, enhancing venous 
return to the right heart. Blood flow back to the chest is highly dependent on the degree of chest 
wall recoil.(8) 
Blood flows through the coronary arteries predominantly during the chest decompression 
phase.  The pressure gradient generated between the aorta and the right atrium during the 
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decompression phase of CPR has been termed the coronary perfusion pressure.(9) The 
pressure gradient between the aorta and left ventricular cavity is also a fundamental 
determinant of blood flow to the heart during CPR. During standard CPR, the coronary perfusion 
pressures are only marginally adequate, resulting in inadequate venous return during the chest 
wall recoil phase.(10, 11) 
Since the description of standard CPR by Kouwenhoven and colleagues in 1960,(12) 
several new CPR techniques have been described. These include circumferential vest CPR,(13, 
14) interposed abdominal counterpulsation CPR, (15-19) and phased abdominal counter-
pulsation CPR.(20) These techniques are not widely applied as they have not been shown to 
significantly improve survival to discharge or other long-term outcomes compared with standard 
CPR in patients with out-of-hospital cardiac arrest. 
This trial is focused on evaluating the ITD (see Appendix 1 for detailed information 
regarding the ITD). This novel device is designed to increase the coronary perfusion pressure 
during the decompression phase of CPR, thereby enhancing delivery of oxygenated blood to 
the heart.  The concept of the ITD was discovered while evaluating the mechanism of another 
new method of CPR termed active compression decompression (ACD) CPR.(21) ACD CPR is 
performed with a hand-held suction device.  When measuring intrathoracic pressures in patients 
undergoing ACD CPR, investigators realized that if the endotracheal tube was transiently 
occluded during the active decompression phase, intrathoracic pressures became markedly 
more negative. This led to the concept of impeding inspiratory gas exchange during the chest 
wall decompression phase of CPR to create a greater pressure differential between the thorax 
and the rest of the body, thereby enhancing venous return to the heart. As such, the impedance 
valve harnesses the kinetic energy of the chest wall recoil, thereby augmenting the “bellows-
like” action of the chest with each compression-decompression cycle.(22) 
The ITD is based on the principle that this impedance leads to a greater negative 
intrathoracic pressure, creating a small vacuum within the thorax relative to the rest of the body, 
leading to increased venous blood return to the heart and increased cardiac output. This 
concept has been evaluated in animals undergoing standard CPR (22) or active compression 
decompression (ACD) CPR,(6) as well as in human patients with prolonged cardiac arrest 
undergoing standard manual CPR (23-25) and ACD CPR.(7) 
 
Preliminary Studies 
 Initial studies to test the impedance valve concept were performed in a pig model of 
cardiac arrest.(6) Two positive end expiratory valves (PEEP) were coupled together and placed 
in reverse in the respiratory circuit. These were designed to prevent respiratory gases from 
entering the lungs during the chest decompression phase of CPR. The pigs were ventilated by 
overcoming the 40 cm H20 resistance of the PEEP valves. After four minutes of cardiac arrest, 
the combination of this impedance valve combined with ACD CPR significantly improved vital 
organ blood flow compared with ACD CPR alone (p < 0.05).  Brain blood flow increased to 
greater than baseline values (normal = 0.35 ml/min/gm) (p <0.05) and blood flow to the heart 
increased to greater than 50% of baseline values (normal = 1.2ml/min/gm) (p <0.05).(6) This 
enhanced myocardial perfusion was associated with lower energy requirements to defibrillate 
the animals at the end of that study. Use of the active ITD resulted in a marked improvement in 
coronary perfusion pressures compared to sham valve.  These studies led to the development 
of the current ITD. 
The first controlled animal studies of the ITD with standard CPR utilized a four-minute 
period of cardiac arrest followed by standard CPR with an automated compression device.(22) 
Standard CPR was performed with and without the ITD in an alternating fashion. Each time the 
ITD was removed from the respiratory circuit, the coronary perfusion pressures and vital organ 
perfusion decreased; and each time the ITD was added back, perfusion pressures stabilized or 
increased.  A similar study evaluated active ITD versus sham ITD for 11 minutes after a six-
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minute period of cardiac arrest without CPR.(5) A sham ITD was used in the control group and 
an active ITD in the other.  
After 6 minutes of cardiac arrest and 6 minutes of standard CPR, radiolabeled 
microspheres were injected to measure vital organ blood flow. The active ITD increased left 
ventricular flow by 100%, and nearly normalized blood flow to the brain compared to the sham 
ITD (Figures 1 and 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After a total of 17 minutes of ventricular fibrillation and 11 minutes of CPR, 3/11 pigs in the 
sham ITD group and 6/11 pigs in the active ITD group were resuscitated by direct current shock. 
In many ways, this six-minute arrest time prior to start of CPR more closely resembles clinical 
field experience where the time from arrest to the start of CPR in the United States ranges 
between 4-8 minutes in cities with highly efficient emergency medical services systems.  
The Milwaukee ROC investigators recently randomized 230 adults who had protected 
airways after out-of-hospital cardiac arrest to receive standard CPR and sham ITD versus 
standard CPR and active ITD.(23, 24) The primary outcome of this study was admittance to 
ICU. Femoral arterial blood pressures were also evaluated by the research team during 
standard CPR at the scene of cardiac arrest in 22 other patients using the same protocol.  
  ICU admissions for all patients were not significantly different with use of the active ITD 
versus sham ITD (25% vs. 17%, respectively, P=NS). However, there was significantly 
increased ICU admissions in patients presenting in pulseless electrical activity (PEA) with use of 
active ITD, 19% (5 of 26) vs. 52% (14 of 27) (P = 0.02; not significant when corrected for 
comparisons in three rhythm groups-.05/3=.017) (Figure 3). In the hemodynamic study, systolic 
blood pressure was significantly increased with the active ITD versus the sham ITD: 85.1 ± 28.9 
mmHg (n = 10) versus 42.9 ± 15.1 mmHg  (n = 12), respectively; P < 0.001. Collectively these 
findings imply that by increasing venous return, and thus cardiac output, the ITD provides a 
novel means to increase circulation during standard CPR and cardiac arrest.  
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Figure 3: Outcomes Presenting in Patients with PEA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a secondary analysis of the same study, the Milwaukee ROC investigators found that 
paramedics and EMTs ventilated patients in cardiac arrest an average of 30 ± 3 breaths per 
minute, nearly twice that recommended by the American Heart Association.(26) Subsequent 
studies in pigs demonstrated that excessive ventilation rates (similar to that observed in the 
clinical setting) significantly decreased coronary perfusion pressures and survival rates.(26) Two 
other studies demonstrated excessive ventilation rates delivered by healthcare professionals 
during in-hospital cardiac arrest.(27, 28) However a recent study demonstrated ventilation at the 
recommended rate during resuscitation by paramedics or nurse anesthetists in a different out-
of-hospital setting.(29) Most chest compressions were too shallow and nearly half the time, 
chest compressions were not delivered at all.  
In another analysis of the Milwaukee pilot study, rescuers were observed to maintain 
some residual and continuous pressure on the chest wall during the decompression phase of 
CPR, preventing full chest wall recoil.(8) Airway pressures were consistently positive during 
those periods. When this incomplete chest wall decompression was reproduced in a porcine 
model of ventricular fibrillation cardiac arrest, it was associated with significantly increased 
intrathoracic pressure and significantly decreased coronary and cerebral perfusion pressures.  
When monitoring CPR performance of professional EMS rescuers using a recording manikin, 
only 16.3% of decompressions were associated with complete recoil. A slight modification in the 
technique of manual CPR increased the frequency of complete chest recoil to 95.0% (OR: 
129.0; CI: 43.4-382.0, P < 0.0001).(8) 
The ITD in combination with conventional manual CPR was evaluated in a case-control 
study in large EMS system in Staffordshire, England.  Survival to emergency department 
admittance was significantly greater among patients with any initial rhythm who received the ITD 
(61/181 [34%]) compared with historical controls (180/808 [22%]) (p<0.01).  No device-related 
adverse effects were observed.(25) 
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In summary, these studies demonstrate that the ITD improves hemodynamics and short-
term outcomes but may be associated with poor performance of other components of CPR. In-
field monitoring facilitates identification of such poor performance and provides opportunities for 
corrective feedback to EMS personnel. 
 
Choice of Intervention  
The investigators chose to evaluate the ITD alone rather than in combination with ACD 
CPR for several reasons.  While the results with simultaneous use of ACD CPR and the ITD are 
promising,(6, 7, 30) use of the ACD CPR device requires more energy than standard CPR to 
perform it correctly.(6, 7, 30)  Also, the sample size required to assess the effect of ACD CPR, 
ITD, combined therapy or standard CPR upon survival to discharge is impractical. Furthermore, 
a double-blind trial of ACD-CPR with or without ITD is not feasible, so the treatment effect from 
such a trial would be susceptible to bias. Therefore we propose a large clinical trial to assess 
the effect of standard CPR plus active ITD versus standard CPR plus sham ITD.  
 
Summary of Rationale 
Survival after out-of-hospital cardiac arrest is poor.  Studies in animal models of cardiac 
arrest demonstrate enhanced myocardial perfusion and vital organ blood flow when using the 
ITD.  Studies in humans with out-of-hospital cardiac arrest demonstrated that the ITD increased 
systolic blood pressure and tended to improve short-term clinical outcomes without any adverse 
effects. A large trial is required to demonstrate whether ITD significantly improves survival and 
functional status. Evaluation of the effect of ITD requires monitoring whether CPR process is 
consistent with currently recommended methods of resuscitation. 
 
Research Design and Methods 
 
Experimental Design 
 
This randomized trial will evaluate manual CPR with either an active or sham ITD in 
adult patients with out-of-hospital cardiac arrest.  Randomization will occur through use of a 
study ITD that is constructed such that the sham and active valves are indistinguishable.  The 
intervention will be implemented by the first qualified provider to arrive at the scene of cardiac 
arrest and continued by subsequent providers in all ROC sites. The first qualified providers will 
most often be EMT-certified responders but will also include responders able to mechanically 
ventilate the patient using either a bag-mask or an advanced airway.  Ventilation rates will be 
consistent with AHA guidelines. 
 
Study Episodes 
Episodes attended by EMS will be included if a study device was taken from its sealed 
container. All such episodes will be followed for purposes of safety evaluation. 
 
Study Population 
 
Inclusion Criteria 
 Persons aged 18 years or more (or local age of consent) who suffer non-traumatic 
cardiopulmonary arrest outside of the hospital in the study communities who receive 
defibrillation and/or chest compressions by EMS providers dispatched to the scene and do not 
meet any of the exclusion criteria below.  Note: The etiology will be presumed to be non-
traumatic in origin unless the apparent cause is due to trauma, drowning, strangulation, 
electrocution, or exsanguination. 
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Exclusion Criteria 
– Do not attempt resuscitation (DNAR) orders; 
– Blunt, penetrating, or burn-related injury; 
– Patients with exsanguinations; 
– Known prisoners; 
– Known pregnancy; 
– Tracheostomy present; 
– CPR performed with the mechanical compression “Autopulse” device. 
– Non-ROC EMS agency/provider. 
 
 
Primary Comparison Population 
The ITD is conjectured to provide an improvement in the rate of neurologically intact 
(MRS ≤ 3) survival to hospital discharge in those patients experiencing OOHCA of cardiac origin 
and treated by EMS within 15 minutes of initial call to 911. There is, however, no 
contraindication to the use of the ITD in the relatively few patients whom experience OOHCA 
due to such noncardiac events as strangulation, drowning, or electrocution. In the emergency 
setting, unnecessarily introducing a need for EMS providers to evaluate eligibility criteria could 
potentially delay the institution of appropriate life saving treatments. Furthermore, if the ITD is 
proven effective and adopted widely, the eventual use of the device may include patients for 
whom the cardiac origin of OOHCA could not be accurately determined. Hence, this study 
protocol allows for the evaluation of the safety of the ITD device in some patients for whom the 
indication of the ITD could not be firmly established in the emergency setting. On the other 
hand, efficacy of the device will be analyzed in only those patients who are determined to meet 
the criteria defining the pre-hospital conditions for which the use of ITD is conjectured to be of 
benefit.  
Efficacy Population: Analysis of primary and secondary efficacy outcomes will be 
conducted on a modified intent-to-treat basis. In order to be included in the efficacy analyses, 
patients must meet the inclusion/exclusion criteria for the ITD/sham device intervention. 
Furthermore, they must also meet the following criteria 
 Not have experienced cardiac arrest secondary to drowning, electrocution, or 
strangulation; 
 Have a response time (time from 911 call to time of arrival of EMS providers at 
scene) less than 15 minutes, and 
 Have the device actually applied. 
With the exception of the criterion regarding actual application of the device, 
determination of whether patients meet these criteria or not will be made on the basis of data 
available prior to randomization (i.e., available prior to opening of the bag containing the 
device). In every case, the determination of whether a patient belongs in the efficacy population 
will be made in a blinded fashion (without knowledge of whether the device bag opened was an 
active ITD or a sham device). Within the efficacy population, analyses will be conducted on an 
intent-to-treat basis. Hence in the rare event that first and second responders in a tiered 
response system might both open a bag containing a device, the patient will be analyzed 
according to the treatment arm corresponding to the first arriving vehicle. 
In the event that the Analyze Late vs Analyze Early (ALvE) intervention is terminated 
early due to demonstrated superiority of one rhythm analysis strategy over the other, the 
efficacy population for the ITD/sham device comparison will be restricted to those subjects 
treated under the rhythm analysis strategy found to be superior. The number of subjects 
accrued to the study will be increased to achieve the planned maximal sample size in the 
superior rhythm analysis strategy arm. 
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 Safety Population: Evaluation of the safety of the ITD will be made using all data from 
patients who were treated with a device, regardless of whether they are a member of the 
efficacy population or not.  
In the event that the Analyze Late vs Analyze Early (ALvE) intervention is terminated 
early due to demonstrated superiority of one rhythm analysis strategy over the other, the safety 
of the ITD will also be evaluated separately in subgroups defined by the rhythm analysis 
strategy arm (AL or AE). 
 
 
Intervention 
Upon arrival of EMS providers at a patient with cardiac arrest, CPR will be initiated. 
Defibrillation will be performed consistent with local practice and cluster assignment.  For 
subjects who are being ventilated with bag-mask or advanced airway (e.g., Combitube, 
laryngeal mask airway [LMA], or endotracheal tube) and receiving chest compressions, EMS 
providers will insert a study valve between the bag and the mask/airway, whichever is available. 
Training will target use of the ITD with initial management of the airway to assure the earliest 
placement of the ITD during CPR.  To assure correct ventilation rate, the rescuers will turn on 
the ventilation timing assist lights on the device once an advanced airway has been established. 
The providers will be instructed to immediately remove the valve if the patient has return of 
spontaneous circulation or is breathing spontaneously, to facilitate rapid elimination of 
inspiratory impedance in a resuscitated patient. (The ITD has a safety check valve that opens if 
the pressure in the airway is <16 cm H2O in the event the rescuer does not recognize that the 
patient is able to breathe on their own).  The providers will be instructed to immediately reapply 
the mask if such a patient ceases to have spontaneous circulation or to breath spontaneously 
(i.e., has recurrent cardiac arrest).   
The EMS providers will be instructed to remove the ITD from the advanced airway if the 
valve fills with fluid; removing this fluid by forcing air through the device with the ventilation bag, 
suctioning the patient, and reapplying the ITD. If the device fills with fluid a second time, EMS 
personnel will be instructed to remove the ITD completely and continue resuscitative efforts 
without use of the device. 
Use of the ITD will be discontinued on arrival to the hospital.   
All other resuscitative measures will follow common guidelines (Appendix 3). 
 
Random Allocation  
 
Study devices will be randomly allocated in a proportion of 1:1 active vs. sham, with 
distribution determined by the CTC based on permuted blocks of concealed size within strata 
defined by participating site and within site by participating agency or subagency. Devices will 
be packaged with a flexible connector to facilitate adjunct equipment such as CO2 monitoring.  
A mask will also be provided to facilitate achievement of a good seal between the patient’s face 
and the ventilatory circuit so as to maintain the intrathoracic pressure. These will be placed at 
each base station where they can be retrieved by the medic. One device will be kept on each 
EMS vehicle. Study site personnel will keep inventory records for each EMS site and conduct 
EMS site visits to confirm inventory status. When a base station has less than three ITDs 
remaining, an additional set will be distributed. Each ITD package will have several stickers 
denoting its number. These will be placed on the medic report and emergency care record. 
Each site must establish a notification process with their EMS system and emergency 
department to notify study personnel of patient enrollment. In this manner, the subjects, 
investigators, study coordinators and all persons caring for the patient will be blinded to the 
treatment assignment. Note that active and sham devices will not be distinguishable visually 
even when removed from the opaque packaging. Patients will be considered to have been 
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randomized as soon as the ITD package has been opened. In the event that two bags are 
opened for the same patient during the same arrest episode, the patient will be assigned to the 
treatment group of the device used by the first-arriving vehicle. 
 
Intervention–Compliance 
 
The location and number of devices supplied to each EMS rig and station for appropriate 
distribution will vary with the structure of the system.   When an ITD is used, ambulance 
personnel will document the unique number of the device on their run report by using pull-off 
labels located within the packaging of the device. Following use, EMS providers will be 
encouraged to place the used device at a predetermined location and replace the used device 
with a new valve. After each use, the research team will be notified and will replace the used 
device.  The coordinating center will maintain a record of where each device is distributed, and 
track their use. 
 
Outcome Measures 
 
Primary  
The primary outcome is survival to hospital discharge with MRS < 3. Patients who are 
transferred to another acute care facility (e.g., to undergo ICD placement) will be considered to 
be still hospitalized. Patients transferred to a non-acute ward or facility will be considered 
discharged.  
 
Secondary  
The secondary outcomes are survival to discharge; MRS at 3 and 6 months following 
hospital discharge; Adult Lifestyle and Function (ALFI) version of the Mini-Mental Status Exam 
(MMSE) at 1, 3 and 6 months;(31, 32) as well as Health Utilities Index III (HUI3) score(33) and 
Geriatric Depression Scale (T-GDS)(34) score at 3 and 6 months (details in Section 4 and 
Appendix 4). 
 
Exploratory 
Cerebral Performance Category (CPC) will be assessed at discharge, 3 and 6 months 
following hospital discharge. 
 
   
In-Hospital Morbidity 
Number of hospital days and time interval from 911 call to patient death will be described 
for all hospitalized patients as measures of morbidity after resuscitation. 
 
Prespecified Subgroup Analyses 
 
a) First recorded cardiac arrest rhythm prior to valve application (VF/VT vs. PEA vs. 
asystole vs. not obtained before device implementation); 
b) Observational status of arrest (Witnessed by EMS vs. witnessed by bystanders vs. 
unwitnessed); 
c) In witnessed cardiac arrests, response time interval from call to initiation of CPR by 
EMS (<10 vs. ≥ 10 minutes);(30) 
d) Analyze Early vs. Analyze Later cohorts. 
 
 
Expected Adverse Events 
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The following will be considered major adverse events if they occur during the resuscitative 
effort or the hospital stay: 
 
Pulmonary Edema- The presence of pulmonary edema in patients who survive long enough to 
receive a hospital-based chest x-ray (first emergency department or ICU chest x-ray). This will 
be defined as formal radiographic interpretation as consistent with the presence on x-ray of 
alveolar pulmonary edema, interstitial pulmonary edema, bilateral pleural effusions, 
cardiomegaly (cardiothoracic ratio > 0.5 on posteroanterior projection), or pulmonary venous 
congestion (upper-zone flow redistribution on posteroanterior projection).(35, 36) This will be 
monitored because failure to remove the ITD immediately following successful resuscitation will 
require the patient to generate more than 16 cm of H2O negative intrathoracic pressure before 
initiating inhalation. This may result in increased work of respiratory effort during the initial 
stages of successful resuscitation. This may result in secondary respiratory failure or pulmonary 
edema and the need for continuing to support the patient’s respiration.  Similarly, in the out-of-
hospital setting, if the valve fills with fluid twice (indicating possibly significant pulmonary 
edema), its use will be discontinued.   
 
All incidences where the valve fills with fluid will be reported to the DSMB.  Additionally, all 
cases of pulmonary edema who did not survive, will have the field report individually reviewed 
for evidence of failure to remove the ITD valve and these cases will be presented to the DSMB. 
 
Pulmonary edema is commonly observed after resuscitation from cardiac arrest.((37) and 
Unpublished Data, ASPIRE Investigators)  However device-related pulmonary edema has not 
been observed in previous published studies of ITD. We anticipate that pulmonary edema 
associated with use of the ITD would be unlikely except if the device were left on a patient who 
is breathing spontaneously. Since the rate of pulmonary edema in the control group is unknown, 
we shall monitor the incidence of pulmonary edema in sham and active ITD groups and assess 
whether there is a significant difference between treatment groups. 
 
Device Failure-  Mechanical failure (i.e., the device breaks). Malfunctions are unlikely due to 
the simple construction and durable materials of the device. There have been no instances of 
the ITD breaking in the Milwaukee feasibility study, ongoing European studies or during clinical 
use in Europe. 
 
Other- The following are commonly observed in patients who experience cardiac arrest or 
resuscitative efforts after its onset, and may or may not be attributable to specific resuscitation 
therapies. These will be monitored and reported but not classified as major adverse events. 
Vomiting During CPR. Vomiting during CPR is a common and anticipated complication of any 
method of CPR. Immediate clearing of the airway is necessary to prevent complications from 
aspiration. Rescuers are experienced in handling this type of complication and have portable 
and stationary suction available to them. The occurrence of vomiting during the application of 
the ITD will be recorded from the prehospital clinical record. Clinical diagnoses of cerebral 
bleeding, stroke, seizures, bleeding requiring transfusion or surgical intervention, rearrest, 
pulmonary edema, serious rib fractures, sternal fractures, internal thoracic or abdominal injuries 
as well as any other major medical or surgical outcomes will be recorded as noted in the 
hospital discharge summary. Since the treating physicians will be blinded as to whether the 
patient received active or sham ITD, there is unlikely to be a treatment-related bias in identifying 
these events. 
 
Unexpected Adverse Device Events (UADE) 
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These will be defined as any serious unexpected adverse effect on health or safety or 
any unexpected life-threatening problem caused by, or associated with, a device, if that effect or 
problem was not previously identified in nature, severity, or degree of incidence in the 
investigation plan or application (including a supplementary plan or application), or any other 
unexpected serious problem associated with a device that relates to the rights, safety or welfare 
of subjects. The death or neurological impairment of an individual patient is not considered an 
adverse event in this study. 
  
Analyses 
 
Primary Efficacy Analysis 
 
The primary analysis of treatment efficacy will be based on a comparison across 
treatment arms active and sham ITD of the observed proportion of patients in the efficacy 
population (see page 12 for definition of efficacy population) with neurologically intact (MRS ≤ 3) 
survival to hospital discharge. We assume that ITD would not be implemented if it were 
associated with worse neurologically-intact survival to discharge. A one-sided level 0.025 
hypothesis test will be used to test the null hypothesis of equal rates of such favorable events 
(H0: πITD = πSHAM) versus the alternative hypothesis that patients on the active ITD arm have a 
higher probability of neurologically intact survival to hospital discharge than do patients on the 
sham device arm (H1: πITD > πSHAM). The test statistic comparing those proportions will be a one-
sided version of Pearson’s chi squared statistic: the Z statistic defined as the difference of the 
proportions (ITD arm minus sham device arm) divided by its estimated standard error computed 
assuming the null hypothesis of equality of proportions.  ( )
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The fixed sample P value corresponding to that Z statistic will be compared to the 
boundaries of the protocol defined group sequential stopping rule when expressed on the fixed 
sample P value scale. At the end of the study, analysis results will be summarized using point 
estimates of the difference in probability of favorable events, 95% confidence intervals, and P 
values adjusted for the true sampling distribution imposed by the group sequential stopping rule. 
(See the discussion of the group sequential monitoring plan below.) 
This analytic approach assumes unbiased random allocation of patients to treatment 
group and relies on the sample size being large enough for asymptotic theory to provide good 
distributional approximations.  With the exception of the inclusion criterion regarding actual 
application of the device, determination of whether patients meet study criteria or not will be 
made on the basis of data available prior to randomization (i.e., available prior to opening of the 
bag containing the device) (see p. 12 for more detail). 
 
 
Secondary Efficacy Analyses 
 
All secondary analyses of efficacy endpoints are directed toward finding supporting evidence for 
the findings of the primary efficacy analysis. As such, they will not be used as the primary basis 
for establishing benefit of the ITD relative to the sham device, nor will they be used as the 
primary basis for obtaining regulatory approval of the ITD. Hence, there is no plan to make any 
statistical adjustment for the multiple comparisons inherent in the secondary efficacy analyses, 
which include: 
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Modified Rankin Score (MRS) at hospital discharge. The mean MRS at hospital discharge will 
be compared across treatment groups using the t test which allows for unequal variances 
across groups. For the purposes of this analysis, patients dying before admission to the hospital 
will be treated the same as admitted patients dying before hospital discharge and will be 
assigned an MRS of 6. 
 
Survival to hospital discharge.  This secondary analysis of treatment efficacy will be based on a 
comparison across treatment arms of the observed proportion of patients in the efficacy 
population with survival to hospital discharge. This analysis shall proceed in a manner entirely 
analogous to that for the primary efficacy endpoint. The test statistic comparing those 
proportions will be a one-sided version of Pearson’s chi squared statistic: the Z statistic as 
defined for the primary analysis. 
 
Neurologically intact survival to hospital discharge adjusted for prognostic variables. A 
secondary analysis of the primary endpoint will adjust for those pre-randomization variables 
which might reasonably be expected to be predictive of favorable outcomes. Generalized linear 
models will be used to model the proportion of subjects with neurologically intact (MRS ≤ 3) 
survival to hospital discharge by ITD/sham device group adjusted for site (dummy variables 
modeling the 11 ROC sites), patient sex, patient age (continuous variable), witness status 
(dummy variables modeling the three categories of unwitnessed arrest, non-EMS witnessed 
arrest, and EMS witnessed arrest), location of arrest (public versus non-public), time or 
response (continuous variable modeling minutes between call to 911 and arrival of EMS 
providers on scene), presenting rhythm (dummy variables modeling asystole, PEA, VT/VF, or 
unknown), and treatment assignment in the Analyze Late vs. Analyze Early intervention. The 
test statistic used to assess any benefit of the ITD relative to the sham device will be computed 
as the generalized linear model regression coefficient divided by the estimated “robust” 
standard error based on the Huber-White sandwich estimator(38, 39) in order to account for 
within group variability which might depart from the classical assumptions. Statistical inference 
will be based on one-sided P values and 95% confidence intervals which adjust for the stopping 
rule used for the primary analysis. 
 
Post-discharge neurological function, quality of life, and depression. Surviving patients will be 
contacted post-discharge to obtain consent for additional follow-up via telephone with 
consenting patients or their proxies regarding cognition, quality of life, and depression.  
Analyses of each of these outcomes at each time point will be compared across treatment 
groups by using the t test which allows for unequal variances.  Analyses will first be conducted 
conditional on survival to the relevant time point by using only data from those patients offering 
consent, as well as using data imputed from discharge data for those surviving patients refusing 
consent. The data missing due to lack of consent for follow-up will be multiply imputed using 
measurements of patient age, sex, length of hospital stay, incidence of major adverse outcomes 
during hospitalization, MRS at hospital discharge, and whether the patient was discharged to 
home or a nursing facility. Additional analyses of neurological function and quality of life will then 
incorporate measurements for patients dying prior to hospital admission, during hospitalization, 
or within 3 or 6 months post discharge. Dead patients will be assigned the worse category of 
neurological function and quality of life for each measurement. 
 
Morbidity. As a measure of morbidity during hospitalization, the number of days hospitalized 
conditional upon survival to discharge will be compared across treatment groups using the t test 
which allows unequal variances. A similar analysis will also be conducted comparing the days of 
hospitalization for patients admitted to the hospital, but dying prior to hospital discharge. Finally, 
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treatment groups will also be compared with respect to the number of days alive post hospital 
discharge during the first 6 months post OOHCA in order to incorporate information about both 
dead and surviving patients. In this analysis, data missing due to lack of consent for follow-up 
will be multiply imputed using data available at hospital discharge, and patients dying before 
hospital admittance or prior to hospital discharge will be scored as 0. 
 
Safety Analyses 
 
The incidence of adverse events will be recorded for all patients in the safety population 
and presented by treatment arm (ITD vs. sham device) to the DSMB for their review during the 
conduct of the study, as well as summarized and compared across treatment arms in the final 
report of study results. Assessment of the statistical significance of differences in the incidence 
of safety endpoints plays a lesser role, due to the need to be cautious in the introduction of new 
treatments in a human population. Hence, emphasis is placed on the presentation of results, 
with statistical tests provided for guidance on the precision of estimates as indicated. Specific 
measures that may reflect the safety of the ITD include: 
 
Delay of treatment. The process of opening and applying the device could delay treatment 
and/or potentially cause harm in patients other than those for whom the device is conjectured to 
provide benefit, as well as in the evaluable patient population. The distribution of time from EMS 
arrival to initiation of CPR will be described using mean, standard deviation, minimum, 25th, 
50th, and 75th percentiles, and maximum. When indicated, statistical tests comparing the 
distribution of times to initiation of CPR will be effected using the t test which allows for unequal 
variances. Similar analyses will be conducted for the time between EMS arrival and first 
assessment for defibrillation, stratified within Analyze Late vs. Analyze Early clusters. 
 
Complications of treatment. The incidence of vomiting during CPR, device filling with fluid, 
mechanical failure of the device, and any UADE will be reported by treatment arm and 
compared as indicated using Pearson’s chi squared statistic. 
 
Serious adverse events. The incidence of each serious adverse event, along with other major 
adverse medical or surgical outcomes identified during review of hospital records, will be 
tabulated by treatment arm and compared when indicated using Pearson’s chi squared test. In 
order to facilitate the identification of differences in rates of such events that might be due to 
greater survival to hospital admission and/or hospital discharge on one of the treatment arms, 
the incidence of any of the above specific events and/or death (either prehospital or during 
hospitalization) will be reported in a combined fashion and compared as indicated by using 
Pearson’s chi squared statistic. 
 
Subgroup Analyses 
 
Analyses will be performed in each subgroup, along with tests for statistically significant 
interactions. However, it is recognized that the study is not powered adequately to detect 
interactions, and thus all subgroup analyses are judged exploratory. 
 
Exploratory Analyses 
 
Data from the clinical trial will also be used to explore two hypotheses unrelated to the treatment 
effect of ITD on neurologically intact survival post OOHCA.  
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Correlation between MRS and other measures of cognition and quality of life. Analyses will 
evaluate the correlation between simultaneous measures using the MRS,  ALFI-MMSE, HUI or 
GDS at 3 and 6 months using linear regression analyses and standard errors computed using 
the Huber-White sandwich estimator. Additional analyses will evaluate the value of MRS at 
hospital discharge as a surrogate variable for the ALFI-MMSE and HUI at 6 months post 
hospital discharge. In this latter analysis, the effect of treatment with ITD vs. sham device on the 
6 month cognitive function and quality of life measures will be analyzed both without and with 
adjustment for MRS at hospital discharge. A descriptive measure of the usefulness of the MRS 
at hospital discharge as a surrogate for the later validated measures will be based on the 
difference in the estimates of treatment effect between the unadjusted and adjusted analyses.  
 
Cerebral Performance Category To assess the validity of the Cerebral Performance Category 
for use in future studies, CPC scores at discharge as well as three and six months after 
discharge will be analysed in a manner similar to the analyses of post-discharge neurologic 
function described above in the secondary efficacy analyses. However the results of any 
analysis of CPC scores will not be used to make labeling claims for ITD. 
 
Association between use of hypothermia and neurologically intact survival. Some patients may 
be treated with hypothermia according to local standards of best medical care. Data will be 
collected on both the pre-hospital and in-hospital use of hypothermia. In order to explore any 
association between the use of hypothermia and the probability of survival to hospital discharge 
proportional hazards regression models will be fit using use of hypothermia as a binary time-
varying covariate, adjusted for treatment with ITD vs. sham device. Test statistics will be based 
on the estimated hazard ratio for the hypothermia covariate and the Wald statistic computed 
from the regression parameter divided by the “robust” standard error computed using the Huber-
White sandwich estimator. Comparisons of neurologic function will use measures derived from 
the MRS, ALFI-MMSE, HUI and GDS over time in a generalized estimating equation (GEE) 
analysis restricted to patients surviving to hospital discharge and incorporating the multiple 
measurements made on each patient. Test statistics will be based on the Wald test using the 
regression parameter estimate for the hypothermia covariate and its “robust” standard error 
computed using the Huber-White sandwich estimator. 
 
Sample Size and Study Duration 
 
The sample size for the factorial trial is driven by the power analysis for the ITD 
intervention. These calculations are based on the estimated probability of survival to hospital 
discharge averaged over the participating ROC sites, which is then adjusted to reflect the 
estimated probability of survival to hospital discharge with acceptable neurological status (MRS 
≤ 3). 
Patients with OOHCA who are treated by participating agencies and subagencies and 
who meet the inclusion/exclusion criteria will be randomized to the ITD or sham device, unless 
resuscitated prior to the placement of such a device. This latter possibility may tend to occur 
with patients who present in VT/VF and who initially achieve ROSC following a first, early 
defibrillation as might be applied under the AE strategy. Thus, in computing sample sizes for the 
ITD intervention, we must consider the distribution of patients by presenting rhythm and their 
assignment to the AE or AL treatment strategies. We also must consider the number of patients 
who have EMS witnessed CA, because all such patients will be treated using an AE strategy, 
regardless of the cluster randomization of the responding unit to the AL vs. AE intervention.  
It is estimated that approximately 50% of patients accrued to the factorial study will 
present in asystole, 25% of patients will present with pulseless electrical activity (PEA), and the 
remaining 25% will present in VT/VF. It is also estimated that approximately 10% of all EMS 
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treated OOHCA will involve EMS witnessed arrest. In the ASPIRE trial, the presenting rhythm of 
EMS witnessed arrest occurred in the ratio of 2.20 asystole: 2.57 PEA : 4.74 VT/VF.  
The anticipated distribution of patients by presenting rhythm and whether CA was EMS 
witnessed or not was estimated based on these assumptions (Table 1). 
 
Table 1: Proportion of all EMS treated OOHCA patients according to presenting rhythm and EMS Witness 
status 
 
Presenting Rhythm EMS Witnessed EMS Unwitnessed Total 
Asystole 0.0231 0.4769 0.500 
Pulseless Electrical Activity (PEA) 0.0270 0.2230 0.250 
VT/VF 0.0499 0.2001 0.250 
TOTAL 0.1000 0.9000 1.000 
 
Eligibility criteria for the ITD intervention excludes subjects for whom no device (ITD or 
sham) was used, and it is anticipated that approximately 30% of the patients presenting in 
VT/VF will not have a device placed when treated under the AE strategy, On the other hand, it is 
anticipated that all such patients would have a device placed when treated under the Analyze 
Later (AL) strategy. Taking into account that patients with OOHCA that is not witnessed by EMS 
will be randomized (by cluster) in a 1:1 ratio to the AE or AL strategies, the expected distribution 
of patients to the various treatment strategies by presenting rhythm was estimated (Table 2). 
 
Table 2: Proportion of all EMS treated OOHCA patients randomized to treatment combinations according to 
presenting rhythm and EMS Witness status 
 
EMS Witnessed CA 
(AL vs. AE Ineligible) Analyze Early Analyze Late 
Total ITD/Sham 
Randomized Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD Sham ITD 
Asystole 0.000 0.012 0.012 0.000 0.119 0.119 0.119 0.119 0.250 0.250 
PEA 0.000 0.014 0.014 0.000 0.056 0.056 0.056 0.056 0.125 0.125 
VT/VF 0.015 0.017 0.017 0.030 0.035 0.035 0.050 0.050 0.103 0.103 
TOTAL 0.015 0.043 0.043 0.030 0.210 0.210 0.225 0.225 0.478 0.478 
 
Based on ranges of estimates in published data and results of the ASPIRE trial, and 
allowing for 1-5% improvement due to better CPR process in the clinical trial setting, It is 
estimated that in the absence of an ITD and when managed according to the Analyze Early 
(AE) strategy, the probability of survival to hospital discharge would be 1.05% for patients 
presenting with asystole, 4.02% for patients presenting with PEA, and 20.2% for VT/VF. These 
assumptions lead to an estimated probability of survival to hospital discharge of 0.0599 when 
treated under the AE strategy with a sham valve. We assume that 88.9% of such survivors 
would have acceptable neurological status (MRS ≤ 3) based on a combination of observed rates 
from the ASPIRE and PAD trials where 35 of 45 and 42 of 45 survivors had CPC scores < 2. 
Therefore we estimate a rate of 0.0532 for neurologically intact survival to hospital discharge 
under treatment with the AE strategy and a sham valve.  
Under the alternative hypothesis used for sample size calculations, the effect of the ITD 
on neurologically intact survival is presumed to vary by presenting rhythm. Because a more 
substantial relative benefit is presumed for those patients receiving CPR for a longer period of 
time, neurologically intact survival is presumed to be 1.4 fold higher for patients treated with the 
ITD if their presenting rhythm was asystole or PEA. For patients presenting in VT/VF a relative 
benefit of 1.20 is hypothesized to account for a lesser benefit for those patients who would 
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respond well to early defibrillation.  Applying these hypothesized effects to the numbers given 
above results in an estimated probability of survival to hospital discharge of 0.0751 for patients 
treated with an ITD under the AE strategy, with a corresponding hypothesized rate of 0.0668 for 
neurologically intact survival to discharge. Details of these calculations are provided below 
(Table 3). 
 
Table 3: Estimated proportions of all EMS treated OOHCA patients surviving to discharge and surviving to 
discharge with MRS ≤ 3 by ITD/sham treatment arm and presenting rhythm. 
 
Presenting Rhythm Stratum Weight 
Sham Device 
Probability of 
Survival to 
Discharge 
ITD / Sham 
Relative 
Benefit 
ITD Probability of 
Survival to 
Discharge 
Asystole 0.5235 0.0105 1.40 0.0147 
PEA 0.2618 0.0420 1.40 0.0588 
VT/VF 0.2147 0.2020 1.20 0.2424 
 
Probability of Survival to Discharge 
(weighted average) 
 0.0599  0.0751 
 
Probability of Neurologically Intact 
Survival to Discharge 
(88.9% of patients surviving to hospital 
discharge) 
 0.0532  0.0668 
 
The number of patients to be accrued to the ITD vs. sham device comparison is based 
on the ability of a one-sided level 0.025 test to reject a null hypothesis that the probability of 
neurologically intact survival to hospital discharge is 0.0532 on both treatment arms. Sample 
size computations are based on a two-sample test of binomial proportions using Pearson’s chi 
squared statistic. The test should have approximately 90% statistical power to reject the null 
hypothesis when the ITD treatment arm would have a 0.0668 probability of neurologically intact 
survival. 
 
The clinical trial will be conducted using a group sequential stopping rule based on up to 
three evenly spaced analyses (two interim analyses and the final analysis). The stopping rule 
corresponds to a Pampallona and Tsiatis design(40) as described in more detail under the 
monitoring plan. Using that stopping rule, a sample size of 14,154 evaluable patients will 
provide 90% power to reject the null hypothesis under the conjectured treatment effect. 
However, it is anticipated that approximately 4% of accrued patients will be judged 
nonevaluable due to non-cardiac origin of cardiac arrest or response time in excess of 15 
minutes. Hence, a maximum of 14,742 patients will be potentially treated with the ITD or sham 
device in order to obtain 14,154 evaluable patients for testing the effect of ITD on the primary 
endpoint of neurologically intact survival to hospital discharge.  
 
The 11 participating ROC sites are estimated to have approximately 10,000 OOHCA 
treatable by EMS each year, so it is estimated that accrual of 15,742 patients (1,000 during the 
run-in phase, 14,742 during the actual trial) will require 18 months. 
 
In the event that the Analyze Late vs. Analyze Early (ALvE) intervention is terminated 
early due to demonstrated superiority of one rhythm analysis strategy over the other, the 
number of subjects accrued to the study will be increased to achieve the planned maximal 
sample size in the superior rhythm analysis strategy arm. The primary analyses of the 
effectiveness of the ITD will then be evaluated in just those patients who were treated with the 
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rhythm analysis strategy deemed to be superior. The stopping rule will be applied to the data in 
the efficacy population restricted to that superior ALvE treatment arm.  
 
 
Human Subjects 
 
Risks to Subjects 
 
Population 
This study will enroll approximately 15,742 adult patients who have sustained a nontraumatic 
out-of-hospital cardiac arrest and are known or presumed to be at the local age of consent.  
 
Potential Risks 
ITD administration during standard manual CPR has been tested in three animal 
studies(5, 22, 41) and three human studies(23-25) with no serious device-related adverse 
effects reported. ITD increases negative intrathoracic pressure and coronary perfusion 
pressure, which has raised a concern for potential increased pulmonary edema. However 
previous studies have not observed device-related adverse events. 
Other potential concerns are mechanical failure of the device. We will report any 
evidence of pulmonary edema, or device failure as a serious adverse event.  If failure of the 
device or pulmonary edema occurs (the device fills with fluid twice) in the out-of-hospital setting, 
application of the device will be immediately stopped and appropriate clinical management 
undertaken. As part of the training of the prehospital providers for the study, potential signs and 
symptoms of serious adverse events will be clearly described. 
 
Potential Benefits to Subjects and Society 
There are several potential benefits to subjects who receive an active ITD. These 
include increased venous return, coronary perfusion pressure, cardiac output and admittance to 
intensive care with the use of the ITD during standard CPR in humans. We contend that use of 
the ITD may significantly increase survival to hospital discharge. The efficacy of this device can 
only be assessed by performing clinical studies such as the one proposed in this application. 
 
Inclusion of Women or Minorities 
There will be no exclusion on the basis of gender, race or ethnicity. Known pregnant 
women and prisoners will be excluded. Since this is the first large human trial using the ITD with 
standard CPR, there is no available evidence to determine whether or not there is a clinically 
important sex/gender and/or race/ethnicity difference with its use.  Investigators will compare 
primary and secondary study outcomes between the treatment and control groups broken down 
by sex/gender and race/ethnicity categories.  
 
Inclusion of Children 
The ITD has not been applied during standard CPR in humans < 21 years of age.  For 
this reason, clinical equipoise has not been established in the pediatric population.  Therefore 
the ROC Investigators believe that it is inappropriate to first use the ITD during standard CPR in 
children in a randomized trial such as that proposed in this protocol.  Accordingly, victims of 
cardiac arrest less than the local age of consent (which varies from 17 to 21 years in ROC sites) 
will not be entered in the study. 
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3. Analyze Later versus Analyze Early 
 
Analyze Later Trial - Comparison of a Strategy of Analyze Later Combined with CPR Early 
Versus a Strategy of Analyze Early Combined with CPR Later in Patients With Out-Of-
Hospital Cardiac Arrest  
 
Study Summary 
 
Background: While patients with the shockable rhythms of VF and pulseless VT (PVT) have 
the best chance of survival of amongst out-of-hospital cardiac arrest victims, the vast majority of 
such patients do not survive to hospital discharge. The traditional approach to these patients 
has been to analyze the cardiac rhythm and deliver defibrillatory shocks as quickly as possible 
with the onset of CPR delayed. Recent thinking suggests three phases for VF cardiac arrest: a) 
an early “electrical” phase where rapid defibrillation is effective, b) an intermediate phase where 
“priming” the heart with CPR enhances the effectiveness of defibrillation, and c) a late phase 
where defibrillation is rarely effective. Some now advocate delaying electrical shocks and 
providing early CPR in cases of VF where defibrillation cannot be carried out immediately. 
Three clinical studies have each attempted to evaluate this hypothesis of early CPR and 
delayed analysis. While two studies supported early CPR and one did not, none were definitive 
and all had important limitations. We believe there is an urgent need for a large and definitive 
clinical trial to determine the optimal strategy for rhythm analysis and CPR in patients with out-
of-hospital cardiac arrest. 
 
Aims: The primary aim of the trial is to compare survival to hospital discharge with modified 
Rankin score < 3 between a strategy of Analyze Later consisting of CPR first followed by rhythm 
analysis versus a strategy of Analyze Early consisting of early rhythm analysis in patients with 
out-of-hospital cardiac arrest. The secondary aims of the trial are to compare survival to 
discharge, functional status at discharge and at 1, 3 months and 6 months as well as 
depression at 3 and 6 months. 
 
Hypotheses: The null hypothesis is that survival to hospital discharge with modified Rankin 
score < 3 is identically distributed between Analyze Later versus Analyze Early in patients with 
cardiac arrest. The secondary null hypotheses are that survival to discharge, functional status at 
discharge and at 1, 3 months and 6 months as well as depression at 3 and 6 months will be 
identically distributed between Analyze Later versus Analyze Early in patients with cardiac 
arrest. 
 
Design: Cluster randomized trial with cluster units defined by geographic region, or 
monitor/defibrillator machine. 
 
Population: Patients with non-traumatic out-of-hospital cardiac arrest, known or presumed to 
be local age of consent or greater and treated by EMS providers. 
 
Setting: EMS systems participating in the Resuscitation Outcomes Consortium. 
 
Sample Size:  Based on a two-sided significance level of 0.05, p=0.99, a survival to discharge 
with modified Rankin score < 3 rate of 5.41% after Analyze Early, and two interim analyses, a 
maximum of 13,560 evaluable patients are needed to detect a 7.45% absolute survival to 
discharge with modified Rankin score < 3 after Analyze Later.   
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Anticipated Clinical Impact: If this trial demonstrates a significant improvement in survival with 
a strategy of Analyze Later, we estimate that the premature death of 4,000 victims of cardiac 
arrest per year would be averted annually in North America alone. 
 
Specific Aims 
 
Primary Aim:  The primary aim of this study is to compare survival to hospital discharge with 
modified Rankin score <3 in a variety of communities in patients with out-of-hospital cardiac 
arrest between a protocol of compressions equivalent to approximately 3 minutes prior to 
cardiac rhythm analysis (Analyze Later) compared with cardiac rhythm analysis as soon as 
possible after 50 compressions (Analyze Early). 
 
Hypothesis:  The null hypothesis is that survival to hospital discharge with modified Rankin 
score <3 is identically distributed with use of Analyze Later versus Analyze Early in patients with 
cardiac arrest. 
 
Secondary Aims: The secondary aims of this trial are to compare survival to discharge, 
functional status scores at discharge and at 1, 3 and 6 months as well as depression at 3 and 6 
months between Analyze Later versus Analyze Early in patients with out-of-hospital cardiac 
arrest. 
 
Hypotheses:  The null hypotheses are that survival to discharge, functional status at discharge 
and at 1, 3 and 6 months as well as depression at 3 and 6 months are identically distributed with 
use of Analyze Later versus Analyze Early in patients with cardiac arrest. 
 
Prespecified Subgroup Analyses: These include assessment of treatment effect by:  
a) Rhythm immediately post electrode placement: VF/VT, PEA, asystole, and not obtained. 
b) Response time from 911 call to arrival at the patient’s side <4 minutes and > 4 minutes. 
c) CPR being performed by bystanders. 
 
Background and Significance 
 
Conceptual Framework for Analyze Later 
Our current paradigm of cardiac arrest defines VF as “shockable,” with the optimal 
therapeutic approach being immediate direct countershock.(42) Integral to this approach is the 
concept that defibrillation attempts should occur without delay upon recognition of VF, either by 
prehospital personnel or the analysis software contained within AEDs, which can then be 
applied by first responders with limited training or even laypersons.(43) This approach has 
defined current Advanced Cardiac Life Support (ACLS) algorithms and shaped the development 
of EMS systems, with prehospital providers that can rapidly respond to victims of cardiac arrest, 
and the placement of AEDs in public areas for use by non-medical personnel. (44-48) The 
ability to provide early defibrillation has resulted in improved survival for cardiac arrest victims 
with an initial rhythm of VF in some EMS systems and has defined the current standard of care. 
(4, 49) 
One of the major limitations to this cardiac arrest paradigm is its consideration of VF as 
homogenous, without regard for variability in VF morphology or elapsed time since the arrest.  
In contrast, experimental models of VF arrest support three distinct phases, each with a different 
optimal therapeutic approach.(50) The early moments following arrest define an “electrical 
phase” during which little ischemic injury has occurred and rapid defibrillation attempts appear 
to be most efficacious.  After some time period, probably around 3-4 min, the optimal 
therapeutic approach no longer appears to be immediate countershock but instead includes a 
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period of chest compressions prior to defibrillation attempts.  It is unclear whether this is related 
to a “priming” effect with the delivery of substrate necessary for successful return of 
spontaneous circulation (ROSC) or the removal of toxic metabolites that have accumulated 
during the ischemic period.  Effective chest compressions, traditionally held to provide 
approximately 30% of normal cardiac output during the first several minutes of CPR, may 
provide sufficient myocardial perfusion and improve the metabolic state of those myocytes in 
patients with ventricular fibrillation.  Immediate defibrillation attempts during the circulatory 
phase may be unsuccessful due to persistent or recurrent VF or may result in terminal PEA or 
asystole.  Interestingly, outcomes in patients”shocked” into PEA or asystole are significantly 
worse than when these are the presenting rhythms. (51) 
After some additional elapsed time period, even chest compressions prior to defibrillation 
attempts do not appear to change outcome.  This may be due to the initiation of irreversible 
ischemic changes that ultimately lead to substantial myocyte and neuronal cell death.  This 
“metabolic phase” is thought to start after about 10 min of total arrest duration, with no currently 
available therapies demonstrating efficacy once this phase is reached. 
 
Preliminary Studies 
 The effect of early rhythm analysis versus later rhythm analysis has been evaluated in 
animal and human studies. Animal models demonstrate improved ROSC and neurological 
outcomes with delayed countershock following a period of chest compressions in VF of 
moderate duration.(52-55) Several investigators have utilized this period of chest compressions 
as a therapeutic window in which to deliver various pharmacological agents designed to 
increase the likelihood of successful ROSC and improve neurological outcomes.  Yakaitis et al 
compared immediate countershock to delayed defibrillation following administration of 
epinephrine and 5 min of chest compressions in a dog model of VF.(52) Immediate defibrillation 
was superior with VF of 1- or 3-min duration, while the delayed approach was optimal with VF of 
5- or 9-min duration.  Niemann et al observed improved outcomes with delayed countershock 
following administration of epinephrine and 5 min of chest compressions alone with a VF 
duration of 7.5 min but not 5 min in a swine model.(53) Menegazzi et al observed substantially 
higher ROSC and better neurological outcomes with administration of a pharmacologic 
“cocktail” followed by chest compressions alone prior to defibrillation attempts versus immediate 
countershock in a swine model of VF of 8-min duration.(54, 55)  
Other parameters besides duration of ischemia may better indicate the likelihood of 
successful defibrillation in VF arrest victims.  Various VF morphologic features have been 
identified as potentially useful in predicting successful defibrillation in animal models of VF.(56-
58) Limited human data exist to support morphological analysis of VF/PVT as a predictor of 
successful ROSC.(58-60) In addition, animal and human data suggest that chest compressions 
alone can modulate these morphological features to a more favorable configuration for 
successful ROSC. (57-59) Berg et al used a swine model of VF to demonstrate that CPR alone 
can modulate VF median frequency to a value predictive of successful defibrillation; 
improvements in ROSC and cardiac function at 1 hour were also observed with CPR prior to 
defibrillation attempts.(57)  Eftestol et al demonstrated improvements in spectral flatness 
measure, centroid frequency, and amplitude spectrum relationship. Improvement in ROSC was 
also observed in patients with at least 3 min of chest compressions prior to countershock.  None 
of these morphological features have demonstrated adequate predictive value to justify their 
clinical use; however, these data further support the therapeutic value of chest compressions 
prior to defibrillation in VF of moderate duration.  Finally, the duration between cessation of 
chest compressions and direct countershock appears to influence success of ROSC and 
ultimate survival.(61, 62) This suggests that prehospital providers should attempt to minimize 
delays after chest compressions due to rhythm analysis or ventilation prior to defibrillation 
attempts. 
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Clinical Studies 
 Three clinical studies have compared outcomes from out-of-hospital cardiac arrest due 
to VF when a period of CPR has or has not been prescribed prior to the first attempts at 
defibrillation.(63-65) 
 Cobb et al. conducted an observational, population-based study(63) of 639 patients 
treated for out-of-hospital VF at a time when AED application and use was given the highest 
priority compared with 478 patients for whom 90 seconds of chest compressions and ventilation 
(CPR) were mandated before AED application and use.  An a priori hypothesis was that the 
survival benefit would be most evident in those cases with the greater delay from collapse to 
delivery of the first shock.  Survival to hospital discharge and favorable neurological status at 
discharge (defined as full or nearly full neurological recovery, or requiring some but not 
complete dependence upon others for assistance in activities of daily living) were the primary 
outcomes of the study.   
 Survival to hospital discharge was greater during the intervention period (mandated CPR 
prior to shock) than in the preintervention period (high priority for AED use):  30% vs. 24% 
(p=0.04).  There was a non-significant trend toward a more favorable neurological outcome 
observed during the intervention period (79% of patients with mandated CPR versus 71% of 
patients in whom AED use was prioritized, p=0.11).  A significant interaction also described a 
relatively greater survival benefit for CPR before defibrillation as the response interval of the first 
arriving unit increased, particularly in cases in which the response interval of the first arriving 
unit was 4 minutes or longer (p=0.04) (Figure 4). 
 
Figure 4: Survival versus Response Time Interval With and Without Initial CPR 
 
 
 
 Although its hypotheses were prospectively defined, this study was observational, and 
hence subject to the influence of factors, including the potential biases inherent in non-
randomized studies that tend to overestimate treatment effects.  For example, a change in the 
sequence of CPR could have been accompanied by an unconscious change in emphasis of 
CPR over shock or even over other interventions during resuscitation.  As the authors 
themselves stated, their “observations represent an encouraging pilot study and that the 
development of randomized clinical trials be considered to evaluate further the influence of CPR 
before the delivery of a shock for patients who have a significant delay prior to treatment”. 
 Wik et al. (64) conducted a randomized trial of 200 patients with out-of-hospital cardiac 
arrest due to VF to compare standard care with immediate defibrillation (n=96) or 3 minutes of 
basic CPR prior to defibrillation (n=104).  In both treatment groups, if three sequential 
defibrillations were unsuccessful, 1 minute of CPR was given for VF/VT or three minutes for 
other rhythms before a new rhythm analysis.  Based on the report by Cobb et al that was 
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published  subsequent to the start of the study but before analysis of outcomes, the authors 
hypothesized that survival benefit would be most evident in cases with longer response 
intervals, and analyzed subgroups with response times either up to or longer than 5 minutes.  
 The primary outcome of survival rate to hospital discharge did not differ significantly 
between the two treatment arms of the study (22% in those randomized to CPR-first versus 
15% in the standard group, p=0.17).  Nor were there significant differences in ROSC, 1 year 
survival, “good neurological recovery” at hospital discharge or 1 year after cardiac arrest 
between treatment groups. For those with a response time interval (time from dispatch to arrival 
of first EMS provider) of 5 minutes or less, there were no significant differences in ROSC, 
survival to hospital discharge, 1 year survival, or neurological outcome of survivors.  Among 119 
patients with response times longer than 5 minutes, more patients in the CPR first than in the 
standard group achieved ROSC (58% vs. 38%, p=0.04), survived to hospital discharge (22% vs. 
4%, p=0.006) and survived to 1 year (20% vs. 4% p=0.01). 
 However the criterion for statistical significance in this trial (p<0.05) was not adjusted for 
sequential monitoring performed at six, 18 and 30 months, nor for subgroup analysis.  The 
reported confidence intervals surrounding the estimated benefit were also wide.  Hence the 
findings of this study have to be interpreted with caution, and the observed results not 
interpreted as definitive of benefit from a CPR first strategy.  Moreover, this study had a long 
interval from collapse to EMS arrival (approximately 12 minutes), limiting the generalizability of 
the conclusions. 
 Jacobs et al. conducted a prospective prehospital randomized trial performed in 
Western Australia which randomized 256 patients to a strategy of 90 seconds of CPR before 
defibrillation versus immediate defibrillation.(65) Survival to hospital discharge was not 
significantly different in the CPR first group, 4.2%, compared with 5.1% in the immediate 
defibrillation group.  There was no significant difference in survival to hospital discharge among 
patients with a response interval of <5 versus >5 minutes (12% in the CPR first group, 
compared with 0% in the immediate defibrillation group among patients with a response interval 
<5 minutes (p= 0.24); and 3.5% vs. 4.9%, respectively, among patients with a response interval 
of >5 minutes (p=0.7).  Unfortunately this trial was underpowered due to failure to recruit a total 
sample size of 390 patients, lower than expected baseline survival rates, and exclusion of 41 
eligible cases.  Notably, the overall low survival rate and longer response intervals observed in 
this trial should have favored a greater benefit from CPR before defibrillation if the interactions 
observed by Wik and Cobb et al. between survival and benefit from CPR hold true.   
 
Summary of Rationale 
  
 Survival after cardiac arrest is poor.  The most treatable arrhythmias immediately 
following cardiac arrest are VF and PVT.  Current ACLS algorithms emphasize the importance 
of immediate defibrillation attempts in these patients.  While it has been recognized for many 
years that chest compressions on OOH-CA patients who received “bystander CPR” result in 
positive outcomes,(66) this impact has been relegated to a secondary or even tertiary role in 
resuscitation sequencing.  Small randomized or observational studies suggest that CPR before 
defibrillation may increase survival but the results to date are inconclusive. Although there is 
some evidence that favors immediate defibrillation in cases where the response time is < 2 
minutes, such response times are rare and the frequent delay in recognition of the OOH-CA and 
calling 911, as well as the complexity of the resuscitation protocol, convince us that response 
time should not be used as an intervention modifier. We believe that there is clinical equipoise 
with regard to the competing strategies of Analyze Early vs. Analyze Later. A large, randomized 
clinical trial is needed to examine the impact of delayed defibrillation on survival to hospital 
discharge in patients who are presumed to be without circulation for several minutes. Since the 
only cost of the intervention is training or retraining providers, the proposed study has the 
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potential to have substantial impact upon prevention of premature cardiac death at 
comparatively little cost. 
 
Research Design and Methods 
 
Study Design Overview 
 
 This protocol will be a single-blinded (i.e. blinded to data management team) cluster 
randomized crossover controlled trial with two intervention groups: a) an Analyze Early group, 
and b) Analyze Later group. Subjects in the Analyze Early group will be assigned to receive 50 
(or more) compressions of CPR prior to early ECG analysis and defibrillation shocks if indicated 
and those in the Analyze Later group will receive compressions equivalent to approximately 3 
minutes of CPR prior to ECG analysis and rescue defibrillation.  The intervention will be 
implemented by the first qualified provider to arrive at the scene of cardiac arrest and continued 
by subsequent providers in all ROC sites.  Qualified providers are defibrillation-capable first-
responders, emergency medical technicians (EMTs), and paramedics. 
We will include all out-of-hospital locations within the participating study communities 
within the Resuscitation Outcomes Consortium.  Outcomes will be assessed in the field and at 
the receiving hospitals. 
 
Study Population 
 
Inclusion Criteria 
 All persons of local age of consent or older who suffer non-traumatic cardiopulmonary 
arrest outside of the hospital in the study communities with defibrillation and/or delivery of chest 
compressions provided by defibrillation equipped EMS providers dispatched to the scene and 
do not meet any of the exclusion criteria below. 
 
Exclusion Criteria 
– Do not attempt resuscitation (DNAR) orders; 
– Blunt, penetrating, or burn-related injury; 
– Patients with exsanguinations; 
– Known prisoners; 
– Known pregnancy; 
– EMS-witnessed arrests; 
– Non-EMS rhythm analysis (AED placed by police or lay responder is an exclusion but CPR by 
lay or other non-EMS responders is not); 
– Non-ROC EMS agency/provider. 
 
EMS responders will generally provide CPR according to the cluster randomization even 
for patients with exclusions.  Those with a clear exclusion will not be included in the primary 
analysis.  However, all eligible patients are considered enrolled into the Analyze Later protocol 
regardless of how they are treated and will be included in the primary analysis. 
 
Primary Comparison Populations 
 
The Analyze Late treatment strategy is conjectured to provide an improvement in the 
rate of neurologically intact (MRS ≤ 3) survival to hospital discharge in those patients 
experiencing OOHCA of cardiac origin unwitnessed by EMS and not previously defibrillated. 
EMS witnessed OOHCA should be treated by an Analyze Early strategy. There is, however, no 
contraindication to the use of either Analyze Late or Analyze Early in the relatively few patients 
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experiencing OOHCA due to such noncardiac events as strangulation, drowning, or 
electrocution. In the emergency setting, unnecessarily introducing a need for EMS providers to 
evaluate eligibility criteria and randomize individual patients could potentially delay the institution 
of appropriate life saving treatments. Furthermore, if either the Analyze Late or Analyze Early 
strategy is proven superior to the other and therefore adopted widely, the eventual use of the 
superior treatment strategy would likely be applied to all OOHCA unwitnessed by EMS. Hence, 
this study protocol uses cluster randomization and allows for the evaluation of the safety of the 
treatment strategies in some patients for whom there is no conjecture of clear benefit. On the 
other hand, efficacy of the treatment strategies will be analyzed in only those patients who are 
determined to meet the criteria defining the pre-hospital conditions for which the Analyze Late 
strategy is conjectured to be of benefit.  
Efficacy Population: Analysis of primary and secondary efficacy outcomes will be 
conducted on a modified intent-to-treat basis. In order to be included in the efficacy analyses, 
patients must meet the inclusion/exclusion criteria for the Analyze Late vs. Analyze Early 
intervention. In particular, they must not have DNAR orders, have blunt or penetrating traumatic 
injury or burns, be visibly pregnant, a prisoner, a minor, or have had OOHCA witnessed by 
EMS. Furthermore, in order to be evaluable, they must also have not have experienced cardiac 
arrest secondary to drowning, electrocution, or strangulation.  
Safety Population: Evaluation of the safety of the Analyze Late versus Analyze Early 
strategies will be made using all data from patients who were treated, regardless of whether 
they are a member of the efficacy population or not.  
 
Random Allocation 
 
 The intervention will be randomly allocated according to the cluster assignment (i.e., 
Analyze Later or Analyze Early). Each ROC site has been subdivided into multiple clusters (see 
Sample Size section below) by various means. We believe that randomization by event or by 
individual patient is not feasible because the intervention is a psychomotor skill and there would 
be a significant risk of carryover effect from event to event. In addition, randomization by event 
would add unacceptable complexity for EMS providers who already must deal with 
randomization of the ITD protocol. Each RCC will be subdivided into a goal of at least 20 
clusters by the following means: a) according to EMS agency or geographical boundaries, or b) 
according to individual defibrillator devices, rig, or station.  
 The randomization of clusters will be stratified by site. Within each site, clusters will be 
organized in blocks of varying size (hidden from investigators) according to the number of 
patients expected to be treated over the course of the study in that cluster. Within each block, 
clusters will be assigned in equal numbers to order of treatment. All clusters will crossover 
between intervention assignments at least once (i.e. have at least two distinct treatment 
periods).  Some clusters will crossover more than once (e.g. have four or more distinct 
treatment periods). There will always be an even number of treatment periods.  Among clusters 
having a single crossover, equal numbers will be assigned to Analyze Late first and Analyze 
Early second as are assigned to Analyze Early first and Analyze Late second. Among clusters 
having four treatment periods, equal numbers within each block will be assigned to each of the 
following four orders of treatment: Late-Early-Late-Early, Late-Early-Early-Late, Early-Late-Late-
Early, and Early-Late-Early-Late. Randomization assignment will be performed at the Data 
Coordinating Center prior to the start of the study. Clusters will not be informed as to which 
group they are assigned until it is time to crossover to another intervention. Responders will, 
however, know that each intervention will be tested in the first two periods, and each 
intervention will be tested in the last two periods in each cluster. 
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Intervention 
 
 Detailed descriptions and algorithms demonstrating the sequence of action for Analyze 
Early versus Analyze Later with use of an ITD are presented in Section 4. For those clusters 
allocated to Analyze Later, defibrillator analysis will not be initiated until after delivery of 
compressions equivalent to approximately 3 minutes of CPR, after which a rescue shock will be 
administered, if indicated. For those clusters allocated to Analyze Early, defibrillator analysis will 
not be initiated until the chest compression count reaches 50 (e.g., 30-60 seconds), or as soon 
thereafter as possible, after which a rescue shock will be administered if indicated. 
 
Both Early and Later Arms 
Chest Compressions: Initiation of chest compressions will not be delayed.  Recognition that a 
patient is in cardiac arrest will immediately prompt one rescuer to initiate and count chest 
compressions.  If the scene is first attended by two EMS rescuers, chest compressions will be 
performed by one while the second will set up the monitor/defibrillator and place the defibrillator 
pads.  Then ventilation with the ITD will proceed.  If three rescuers are present, ventilation and 
defibrillation readiness can proceed simultaneously (see Appendix 3 for Resuscitation 
Standards). 
Minimum Interruptions:  Training will emphasize that chest compressions should not be 
interrupted, except for required ventilations.  If endotracheal intubation or other advanced airway 
procedures are deemed medically necessary, the providers should proceed, but continue chest 
compressions with minimum interruption.  However, training will emphasize that interruption of 
chest compressions while securing the airway may dilute the theoretical benefit of the initial 
intervention.  Interruption of chest compressions for airway manipulations will be documented 
when feasible. 
ITD Use:  Training will emphasize that rescuers will use the ITD during initial airway 
management (either facemask or advanced airway). 
 
Analyze Later Arm 
AED analysis will not be initiated until the chest compression count reaches 300, after 
which a rescue shock will be administered if indicated. 
 
Analyze Early Arm 
 Analysis will be initiated as soon as defibrillation pads are in place and 50 compressions 
have occurred and a rescue shock will be administered if indicated. The rescuers will note the 
compression count or time that has been reached by the rescuer assigned to CPR.  After the 
initial analysis, the standard resuscitation protocol will be followed. 
 
Arrival of Additional EMS Personnel 
 In tiered response systems, or when backup EMS crews arrive on scene, first-
responders delivering the chest compressions consistent with cluster assignment prior to initial 
ECG analysis should complete this intervention even if paramedics arrive on scene, and, if the 
subject has defibrillation pads in place, continue using the first crew’s equipment until the first 
ECG analysis (and shock, if indicated). 
 Additional personnel are encouraged to assist with ongoing activities that do not interrupt 
chest compressions or initial rhythm analysis.  For example, airway management, rotation of 
chest compressions, and placement of AED/monitor electrodes may benefit from additional 
personnel.  If sufficient personnel arrive, they may also begin attempts at IV access. 
 
Adherence to Protocol 
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 Personnel will be discouraged from terminating the protocol prematurely. As intention-to-
treat principles apply, any breach of protocol will not alter the study group to which a patient has 
been assigned. 
 
Intervention – Compliance 
 The time interval from power-on to first ECG analysis (power-to-analysis interval) and to 
first rescue shock (power-to-shock) will be calculated from the time stamps on the electronic 
record. Explicit criteria will be used to define successful delivery of the intended therapy and this 
information will later be fed back to the EMS providers (Table 4). 
 
Table 4:  Intervention Compliance Time Intervals 
 
   Power-to-analysis interval  Power-to-shock interval 
Analyze Early 30-60 seconds   <90 seconds 
Analyze Later 180-200 seconds   180-220 seconds 
 
Outcome Measures 
 
Primary  
The primary outcome is survival to hospital discharge with modified Rankin score < 3. 
Patients who are transferred to another acute care facility (e.g., to undergo ICD placement) will 
be considered to be still hospitalized. Patients transferred to a non-acute ward or facility will be 
considered discharged.  
 
Secondary Outcomes 
The secondary outcomes are survival to discharge; MRS at 3 and 6 months following 
hospital discharge; Adult Lifestyle and Function (ALFI) version of the Mini-Mental Status Exam 
(MMSE) at 1, 3 and 6 months;(31, 32) Health Utilities Index III (HUI3) score(33) at 3 and 6 
months following hospital discharge; and Geriatric Depression Scale (T-GDS)(34) score at 3 
and 6 months (details in Section 4 and Appendix 4). 
 
Exploratory 
Cerebral Performance Category (CPC) will be assessed at discharge, 3 and 6 months 
following hospital discharge. 
 
In-Hospital Morbidity 
Number of hospital days and time interval from 911 call to patient death will be described 
for all hospitalized patients as measures of morbidity after resuscitation. 
 
Analyses Methods 
 
Primary Efficacy Analysis 
 
The primary analysis of treatment efficacy will be based on a comparison across 
treatment arms of the observed proportion of patients in the efficacy population with 
neurologically intact (MRS ≤ 3) survival to hospital discharge. A two-sided level 0.05 hypothesis 
test will be used to test the null hypothesis of equal rates of such favorable events (H0: πAE = 
πAL) versus the alternative hypothesis that patients on the Analyze Late arm have a different 
probability of neurologically intact survival to hospital discharge than do patients on the Analyze 
Early arm (H1: πAE ≠ πAL). The data will be analyzed in the context of a generalized linear mixed 
effects model which includes a fixed effect for treatment arm and random effects for each 
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randomization cluster. The test statistic comparing treatment arms will be the Wald statistic 
computed as the regression parameter estimate for the treatment indicator divided by its 
estimated standard error. The fixed sample upper one-sided P value corresponding to that Z 
statistic will be compared to the boundaries of the protocol defined group sequential stopping 
rule when expressed on the fixed sample P value scale. At the end of the study, analysis results 
will be summarized using point estimates of the difference in probability of favorable events, 
95% confidence intervals, and P values adjusted for the true sampling distribution imposed by 
the group sequential stopping rule. (See the discussion of the group sequential monitoring plan 
below.) 
 
Secondary Efficacy Analyses 
 
All secondary analyses of efficacy endpoints are directed toward finding supporting evidence for 
the findings of the primary efficacy analysis. As such, they will not be used as the primary basis 
for establishing superiority of one treatment strategy over the other. Hence, there is no plan to 
make any statistical adjustment for the multiple comparisons inherent in the secondary efficacy 
analyses, which include: 
 
Modified Rankin Score (MRS) at hospital discharge. The mean MRS at hospital discharge will 
be compared across treatment groups using a general linear mixed model including the binary 
variable indicating AL vs. AE assignment and random effects for the randomization clusters. For 
the purposes of this analysis, patients dying before admission to the hospital will be treated the 
same as admitted patients dying before hospital discharge and will be assigned an MRS of 6. 
 
Survival to hospital discharge.  This secondary analysis of treatment efficacy will be based on a 
comparison across treatment arms of the observed proportion of patients in the efficacy 
population with survival to hospital discharge. This analysis shall proceed in a manner entirely 
analogous to that for the primary efficacy endpoint.  
 
Neurologically intact survival to hospital discharge adjusted for prognostic variables. A 
secondary analysis of the primary endpoint will adjust for those pre-randomization variables 
which might reasonably be expected to predictive of favorable outcomes. Generalized linear 
mixed models will be used to model the proportion of subjects with neurologically intact (MRS ≤ 
3) survival to hospital discharge by AL vs. AE group adjusted for randomization cluster (random 
effect), site (dummy variables modeling the 11 ROC sites), patient sex, patient age (continuous 
variable), witnessed arrest (binary variable), location of arrest (public versus non-public), time of 
response (continuous variable modeling minutes between call to 911 and arrival of EMS), 
presenting rhythm (dummy variables modeling asystole, PEA, VT/VF, or unknown), and 
treatment assignment in the ITD/sham device intervention. The test statistic used to assess any 
benefit of one strategy over the other will be computed as the generalized linear mixed model 
regression coefficient for the AL vs. AE treatment assignment divided by the estimated standard 
error. Statistical inference will be based on one-sided P values and 95% confidence intervals 
which adjust for the stopping rule used for the primary analysis. 
 
Post-discharge neurological function, quality of life, and depression. Surviving patients will be 
contacted post-discharge to obtain consent for additional follow-up via telephone with 
consenting patients or their proxies regarding cognition, quality of life, and depression. Primary 
emphasis will be placed on analysis of outcomes at 6 months post hospital discharge, though 
additional analyses will also compare these secondary endpoints 3 months after hospital 
discharge. Analyses of each of these outcomes at each time point will be compared across 
treatment groups using a general linear mixed model including the binary variable indicating AL 
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vs. AE assignment and random effects for the randomization clusters.  Analyses will first be 
conducted conditional on survival to the relevant time point by using only data from those 
patients offering consent, as well as using data imputed from discharge data for those surviving 
patients refusing consent. The data missing due to lack of consent for follow-up will be multiply 
imputed using measurements of patient age, sex, length of hospital stay, incidence of major 
adverse outcomes during hospitalization, MRS at hospital discharge, and whether the patient 
was discharged to home or a nursing facility. Additional analyses of neurological function and 
quality of life will then incorporate measurements for patients dying prior to hospital admission, 
during hospitalization, or within 3 or 6 months post discharge. Dead patients will be assigned 
the worse category of neurological function and quality of life for each measurement.  
 
Morbidity As a measure of morbidity during hospitalization, the number of days hospitalized 
conditional upon survival to discharge will be compared across treatment groups using the t test 
which allows unequal variances. A similar analysis will also be conducted comparing the days of 
hospitalization for patients admitted to the hospital, but dying prior to hospital discharge. Finally, 
treatment groups will also be compared with respect to the number of days alive post hospital 
discharge during the first 6 months post OOHCA in order to incorporate information about both 
dead and surviving patients. In this analysis, data missing due to lack of consent for follow-up 
will be multiply imputed using data available at hospital discharge, and patients dying before 
hospital admittance or prior to hospital discharge will be scored as 0. 
 
Safety Analyses 
 
The incidence of adverse events will be recorded for all patients in the safety population 
and presented by treatment arm (AL vs. AE) to the DSMB for their review during the conduct of 
the study, as well as summarized and compared across treatment arms in the final report of 
study results. Statistical significance of differences in the incidence of safety endpoints plays a 
lesser role, due to the need to be cautious in the introduction of new treatments in a human 
population. Hence, emphasis is placed on the presentation of results, with statistical tests 
provided for guidance on the precision of estimates as indicated.  
Since both interventions, Analyze Early and Analyze Late, are in current use, there is no 
anticipation that the study itself will present any safety issue, for example, because of new or 
difficult procedures.  Indeed, one would expect a study benefit in any treatment arm because of 
the increased training and monitoring of CPR performance. Nevertheless specific measures that 
will be monitored include: 
 
Delay of treatment. Witnessed episodes of cardiac arrest with response times (911 call to 
arrival) of less than 4 minutes might be expected to respond to early defibrillation.  This 
subgroup of patients will be carefully monitored for potential harm from an Analyze Later 
strategy.  The Data and Safety Monitoring Board will be asked to make recommendation 
concerning protocol modification, should any safety issue appear. 
  
Compliance with protocol. Patients with EMS witnessed arrest are to be treated with early 
analysis for defibrillation regardless of cluster randomization to AL or AE. The adherence of 
EMS providers to this aspect of the protocol will be closely monitored. In addition, sites will be 
monitored with respect to adherence to the guidelines for either the Analyze Late or Analyze 
Early strategies according to the cluster randomization scheme. In particular, adherence to 
protocol will be monitored and reported separately for times immediately preceding and 
following sites’ crossover from one strategy to the other.  The Data and Safety Monitoring Board 
will be asked to make recommendation concerning protocol modification, should any safety 
issue related to protocol adherence appear. 
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Serious adverse events. The incidence of each serious adverse event, along with other major 
adverse medical or surgical outcomes identified during review of hospital records, will be 
tabulated by treatment arm and compared when indicated using Pearson’s chi squared test. In 
order to facilitate the identification of differences in rates of such events that might be due to 
greater survival to hospital admission and/or hospital discharge on one of the treatment arms, 
the incidence of any of the above specific events and/or death (either prehospital or during 
hospitalization) will be reported in a combined fashion and compared as indicated using 
Pearson’s chi squared statistic. 
 
Subgroup  Analyses 
 
Analyses will be performed in each subgroup, along with tests for statistically significant 
interactions. However, it is recognized that the study is not powered adequately to detect 
interactions, and thus all subgroup analyses are judged exploratory. 
 
Sample Size, and Study Duration 
 
The sample size for the factorial trial is driven by the power analysis for the ITD 
intervention. A full description of the assumptions that were used to estimate the sample size 
required for that intervention is given in section 2. The anticipated distribution of patients by 
presenting rhythm and whether arrest was EMS witnessed or not was estimated based on these 
assumptions (Table 5.) 
 
Table 5: Proportion of all EMS treated OOHCA patients according to presenting rhythm and EMS Witness 
status 
 
Presenting Rhythm EMS Witnessed EMS Unwitnessed Total 
Asystole 0.0231 0.4769 0.500 
Pulseless Electrical Activity (PEA) 0.0270 0.2230 0.250 
VT/VF 0.0499 0.2001 0.250 
TOTAL 0.1000 0.9000 1.000 
 
Eligibility criteria for the AL vs. AE intervention excludes subjects for whom the arrest 
was witnessed by EMS. The distribution of patients to the various treatment strategies by 
presenting rhythm was estimated by taking into account that patients with EMS Unwitnessed 
OOHCA will be randomized (by cluster) in a 1:1 ratio to the AE or AL strategies (Table 6). 
 
Table 6: Proportion of all EMS treated OOHCA patients randomized to treatment combinations according to 
presenting rhythm and EMS Witness status 
 
EMS Witnessed CA 
(AL vs. AE Ineligible) Analyze Early Analyze Late 
Total  
AE vs AL 
Randomized Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD AE AL 
Asystole 0.000 0.012 0.012 0.000 0.119 0.119 0.119 0.119 0.250 0.250 
PEA 0.000 0.014 0.014 0.000 0.056 0.056 0.056 0.056 0.125 0.125 
VT/VF 0.015 0.017 0.017 0.030 0.035 0.035 0.050 0.050 0.103 0.103 
TOTAL 0.015 0.043 0.043 0.030 0.210 0.210 0.225 0.225 0.478 0.478 
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Based on ranges of estimates in published data and results of the ASPIRE trial, and 
allowing for 1-5% improvement due to greater quality control on CPR process in the clinical trial 
setting, It is estimated that in the absence of an ITD and when managed according to the 
Analyze Early (AE) strategy, the probability of survival to hospital discharge would be 1.05% for 
patients presenting with asystole, 4.02% for patients presenting with PEA, and 20.20% for 
VT/VF. These assumptions lead to an estimated probability of survival to hospital discharge of 
0.0609 when treated under the AE strategy with a sham valve. Assuming that 88.9% of such 
survivors would have acceptable neurological status (MRS ≤ 3), we thus estimate a rate of 
0.0541 for neurologically intact survival to hospital discharge under treatment with the AE 
strategy and a sham valve.  
Under the alternative hypothesis used for power calculations, the effect of the Analyze 
Late strategy on neurologically intact survival is presumed to vary by presenting rhythm. While 
patients with initial rhythms of asystole and PEA cannot expect to benefit from an Analyze Early 
versus Analyze Later protocol in the sense of potentially obtaining early defibrillation, they could 
benefit from the Analyze Later strategy by having fewer delays in blood circulation due to taking 
time for early analysis. We therefore hypothesize a 3% relative increase in survival for patients 
in the AL arm over the AE arm for these two rhythms. A relative benefit of 1.50 is hypothesized 
for those patients in the VT/VF, with the benefit occurring primarily in patients who would not 
respond rapidly to early defibrillation, though that group cannot be identified a priori. Applying 
these hypothesized effects to the numbers given above results in an estimated probability of 
survival to hospital discharge of 0.0838 for patients treated with an AL strategy in the absence 
of an ITD, with a corresponding hypothesized rate of 0.0745 for neurologically intact survival to 
discharge. Details of these calculations are provided below (Table 7). 
 
Table 7: Estimated proportions of all EMS treated OOHCA patients surviving to discharge and surviving to 
discharge with MRS ≤ 3 by AL vs. AE treatment arm and presenting rhythm 
 
Presenting Rhythm Stratum Weight 
Analyze Early 
Probability of 
Survival to 
Discharge 
AL / AE 
Relative 
Benefit 
AL Probability of 
Survival to 
Discharge 
Asystole 0.5299 0.0105 1.03 0.0108 
PEA 0.2478 0.0420 1.03 0.0433 
VT/VF 0.2224 0.2020 1.50 0.3030 
 
Probability of Survival to Discharge 
(weighted average) 
 0.0609  0.0838 
 
Probability of Neurologically Intact 
Survival to Discharge 
(88.9% of patients surviving to hospital 
discharge) 
 0.0541  0.0745 
 
In the process of accruing 14,154 evaluable patients to the ITD/sham device 
intervention, it is estimated that approximately 15,436 patients with OOHCA will be treated by 
EMS at one of the participating ROC sites, with approximately 13,893 of these patients (90%)  
not having EMS witnessed arrest and therefore receiving Analyze Late or Analyze Early. 
Estimating that 98% of these patients will be judged evaluable, 13,560 patients will be used for 
the comparison of Analyze Late versus Analyze Early strategies. We therefore consider the 
ability of a two-sided level 0.05 test with 13,560 subjects to reject a null hypothesis that the 
probability of neurologically intact survival to hospital discharge is 0.0541 on both treatment 
arms, with statistical power computed under the alternative hypothesis that the AL arm would 
instead have a 0.0745 probability of neurologically intact survival. The data will be analyzed in 
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the context of a generalized linear mixed effects model which includes a fixed effect for 
treatment arm and random effects for each randomization cluster. The test statistic comparing 
treatment arms will be the Wald statistic computed as the regression parameter estimate for the 
treatment indicator divided by its estimated standard error. Power computations are based on 
formulas appropriate for a two-sample test of binomial proportions using Pearson’s chi squared 
statistic. We incorporate into those computations an assumed 5% loss of efficiency due to the 
cluster randomization with crossover.  
 
The clinical trial will be conducted using a two-sided level 0.05 group sequential stopping 
rule based on up to three analyses (two interim analyses and the final analysis) after accruing 
approximately one-third, two-thirds, and all of the maximal sample size. The stopping rule 
corresponds to an O’Brien-Fleming design as described in more detail under the monitoring 
plan. Using that stopping rule, a sample size of 13,560 evaluable patients will provide 
approximately 99% power to reject the null hypothesis under the conjectured treatment effect.  
 
The 11 participating ROC sites are estimated to have approximately 10,000 OOHCA 
treatable by EMS each year, so it is estimated that accrual of 13,560 evaluable patients for the 
Analyze Late versus Analyze Early comparison will require 16 -18 months. 
 
Effect of Clustering and Crossover Upon Required Sample Size 
 It is anticipated that the number of cardiac arrest episodes in each cluster will vary, as 
the underlying size of the geographic area and population served are variable. Some sites will 
cross a large geographic area over from one intervention to the other during the trial to reduce 
the expected number of episodes; others will cross monitor/defibrillators from one intervention to 
the other. Most cluster designs assume equal-sized clusters, but the presence of unequal 
cluster size has implications for sample size (Appendix 5). 
 
The clusters and annual expected number of cardiac arrests episodes in each site are 
shown below (Table 8). Since most clusters employ crossover, and those that do not have small 
expected numbers, the effective sample size of each cluster should be at least 95% efficient 
compared to individual randomization.  This is a conservative assumption since utilizing the 
crossover design is actually more efficient then even individual randomization. 
 
 Having close to 20 or more clusters at each site with no overly large cluster, as well as 
using crossover and randomizing so that each intervention is being used by half of the clusters 
at any time will provide reasonable balance between temporal factors, as well as system and 
patient factors. 
 
 We can think of no likely crossover effect except that compliance might be compromised 
by habit or forgetfulness at the time of crossover.  We will be monitoring compliance, and if non-
compliance is >2-fold higher in the 2 weeks following crossover than in the several months 
before at a site level, then all episodes from that 2-week period at that site will be dropped from 
the primary analysis.  Of course, measures would be taken by the local site to address the 
“crossover compliance” issue. 
 
 Other designs were taken into consideration, particularly individual episode 
randomization.  Devices (AEDs) are not currently capable of being programmed to randomize 
individual episodes and then provide correct prompts.  Other forms of individual randomization 
(e.g. envelope) would therefore result in expecting EMS providers to ignore existing prompts.  
The consensus of the ROC investigators was that this would create serious compliance issues 
and individual randomization was not seen as a viable option.  The simplest design is to invoke 
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cluster design without crossover.  This method is less efficient then crossover, or individual, 
randomization.  Therefore clustering design with crossover is seen as the most efficient design 
from the choice of feasible and practical designs. 
 
 
Table 8:  Summary of ROC Site Cluster Plans 
 
 
Pop Served 
(#) 
Annual CA 
Treated (#) Cluster Type # of Clusters 
Toronto 2,456,800 1,777  geographic,  214 
   agency, station  
     
Alabama 1,278,936 485 rig 75 
     
Portland 1,444,219 604 agency, station 166 
   defib  
     
Pittsburgh 670,911 690 rig 124 
     
Seattle/King Co 1,763,000 888 agency, geographic 23 
     
Dallas 2,023,705 1,331 rig 151 
     
Ottawa 3,000,000 1,468 geographic,  246 
   agency, defib  
     
Milwaukee 928,018 794 station 61 
     
BC 3,115,331 1,364 geographic 32 
     
San Diego 2,900,000 2,161 rig 334 
     
Iowa 956,188 875 geographic 15 
     
Totals 20,537,108 12,437  1441 
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4. Factorial Implementation of Both Protocols 
 
Summary 
 
The background, significance, aims, and hypotheses of the ITD and Analyze Later versus 
Analyze Early trials have been previously described.  Investigators intend to implement these 
studies simultaneously (though staggered start and stop times may occur because of 
resource/regulatory logistics), capitalizing on the common infrastructure necessary to 
accomplish the studies, thereby improving efficiency and speed of their completion.  The 
following describes study issues common to both the ITD and Analyze Later versus Analyze 
Early studies including Study Setting, Study Population, Resuscitation Guidelines, Monitoring of 
CPR Process, Outcome Measures, Data Collection, Training, Data Safety Monitoring Strategy 
(DSMB), and Human Subjects. 
 
Setting 
 
The Resuscitation Outcomes Consortium (ROC) includes ten Regional Clinical Centers. These 
ROC sites are served by approximately 200 EMS agencies. The baseline characteristics of 
these ROC sites are summarized in Table 9. Of greater than 12,000 cardiac arrest episodes 
among the sites, annually, approximately 10,000 are treatable by EMS. 
Table 9: Distribution of Initial Cardiac Rhythm and Outcome for Cardiac Arrest Episodes   Among ROC Sites 
 
  
Dallas Iowa Milwaukee Ottawa Ottawa Pittsburgh Portland Seattle Seattle Alabama Toronto San Diego Total 
EMS System Biotel     OPALS BC     King County 
Seattle 
EMS         
Year 
Reported 2003 2003 2004 2002 2003 
Average of 
1998-2002 2003 2003 2003 2004 2002 2004 
  
  
Population 
Served 2M 956k 928k 3M 3.1M 671k 1.4M 1.2M 600k 1.3M 2.5M 2.9M 20.6M 
VF or PVT 297 294 162 470 431 235 151 158 95 106 462 648 3509 
   Survived to 
   discharge 50 44 32 62 74 33 37 44 29 24 39 97 565 
   Received 
   <=1 shock 178 217 158 281 258 141 112 116 70 73 120 427 2151 
Asystole 676 349 437 601 577 289 211 235 147 285 817 1102 5726 
   Survived to 
   discharge 14 5 10 5 12 12 3 6 0 5 7 33 112 
PEA 358 232 195 397 356 166 242 162 91 94 498 411 3202 
   Survived to 
   discharge 25 12 18 9 7 10 15 16 12 6 12 21 163 
             Totals 
Cardiac 
arrests 1331 875 794 1468 1364 690 604 555 333 485 1777 2161 12437 
Survived to 
discharge 89 61 60 76 93 55 55 66 41 35 58 151 840 
Note:  Shaded numbers are estimated          
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Study Population 
 
 Except for some specific situations, the inclusion and exclusion criteria for both ITD and 
Analyze Later protocols will be the same. 
 
Inclusion Criteria 
 All persons of local age of consent or older who suffer non-traumatic cardiopulmonary 
arrest outside of the hospital in the study communities with defibrillation and/or delivery of chest 
compressions provided by EMS providers dispatched to the scene and do not meet any of the 
exclusion criteria below.  
 
Common Exclusion Criteria 
– Do not attempt resuscitation (DNAR) orders; 
– Blunt, penetrating, or burn-related injury; 
– Patients with exsanguinations; 
– Known prisoners; 
– Known pregnancy. 
– Non-ROC EMS agency/provider. 
 
ITD Exclusion Criteria 
– Tracheostomy present; 
– CPR performed with the mechanical compression “Autopulse” device; 
 
Analyze Later Exclusion Criteria 
– EMS witnessed arrests; 
– Non-EMS rhythm analysis (AED placed by police or lay responder); 
 
Resuscitation Guidelines 
 
The ROC Investigators have developed and will disseminate consensus guidelines on 
how the patient with cardiac arrest should be treated in the prehospital, emergency department 
and hospital setting (see Appendix 3). 
 
Monitoring of CPR Process  
 
A long-term goal of the Resuscitation Outcome Consortium (ROC) is for all participating first 
EMS responders and ALS providers to have technology on, or adjunctive to, their automated 
(AED) and/or manual monitor/defibrillators that can monitor individual components of 
resuscitation. These data will serve as the basis for regular, systematic monitoring and review of 
the CPR process for purposes of quality improvement at each ROC site before and during 
clinical trials.  Such processes will assure the safety of CPR performance in the field. Also 
feedback of this knowledge is essential to care delivery since improved quality assurance has 
been associated with improved outcomes after resuscitation.(67) Finally, it is essential to 
efficient trial conduct since low baseline rates of survival are associated with larger sample sizes 
to detect a clinically important difference.  
 
Rationale 
Recent studies have demonstrated that CPR is frequently not performed according to 
evidence-based guidelines in the out-of-hospital and in-hospital setting.(28, 29) Although these 
studies lacked power to detect a significant relationship between CPR process and patient 
outcome, a related study demonstrated that a greater rate of chest compressions was 
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associated with a greater likelihood of achieving restoration of spontaneous circulation.(68) The 
importance of monitoring and improving CPR process was confirmed by the observation of 
potentially deleterious hyperventilation in the Milwaukee pilot study of ITD.(26)  
A variety of evolving technologies offer the ability to monitor CPR process either directly 
or indirectly through AEDs.  These include chest impedance (69) (used to monitor chest 
compression rate and ventilation rate(70)), chest acceleration(71) (used to monitor chest 
compression rate, depth, release, and duty cycle), and audio recording (used to monitor audible 
events during resuscitation).   Each of these measures has advantages and limitations.   For 
example, a recent prehospital study reported that even when obtaining data related to CPR 
process was emphasized, technical and signal quality limitations prevented its analysis in more 
than 25% of episodes(29).  In addition, there is also considerable site heterogeneity across the 
Consortium that precludes the use of a single manufacturer or a single CPR monitoring 
technology.  Accordingly, the Consortium has defined and will monitor a minimal data set 
pertinent to the CPR process but allow each participating site to individually specify and 
implement the means by which such data will be obtained.  Please see Appendix 2 for a list of 
how each EMS Agency will monitor CPR process. 
 
Method of Monitoring CPR Process 
Overview- In preparation for the start of formal CPR process monitoring and the proposed ROC 
cardiac arrest trial, an educational program will be developed and implemented at each site to 
refresh provider skills on chest compression and ventilation, with emphasis on uninterrupted 
chest compressions, minimizing of "hands-off" intervals, and avoidance of hyperventilation. 
All ROC clinical trial sites will implement a high-quality system for monitoring individual 
components of CPR, to include, at a minimum, the rate of chest compressions, the rate of 
ventilation, and the proportion of pulseless resuscitation time during which chest compressions 
are provided (i.e. CPR fraction).  Recent studies show no significant differences in these 
parameters during the first five minutes of resuscitation as compared with the entire 
resuscitation episode.(28, 29) It is anticipated that during the initial period interruption of CPR 
due to rhythm analysis or other procedures is more likely than throughout the resuscitation 
episode. After insertion of an advanced airway and initiation of ventilation that is asynchronous 
with chest compressions, hyperventilation is more likely than during the early resuscitation 
period. Therefore CPR process will be quantified during the first analyzable five minutes for 
100% resuscitations as well as ventilations throughout the resuscitation episode in those who 
receive an advanced airway, until a sustained return of spontaneous circulation or resuscitation 
efforts are terminated.  Sites will be encouraged to monitor the entire episode. 
Sites will be required to demonstrate an ability to adequately acquire and analyze these 
CPR process data, identify and attempt to correct any observed deficiencies, and meet 
minimum performance standards (Appendix 2 CPR Process Monitoring:  CPR Performance 
Standards) before being eligible to enroll patients in the present trial.  In addition, ongoing 
monitoring and review of CPR process, will be used throughout the conduct of the trial. 
 
Monitoring Devices- A range of monitoring/defibrillator devices will be deployed across the 
ROC sites that have capabilities to monitor CPR process.  These devices and their capabilities 
are summarized in Appendix 2 CPR Process Monitoring:  CPR Process Monitoring Devices. 
 
Specific Methods- BLS and ALS providers will be trained to turn on the power of their AED or 
monitor immediately upon recognition of a subject in cardiac arrest.  Monitoring hardware will be 
applied to the patient as soon as possible.  This power-on event will initiate the recording by the 
device, and serve as a surrogate marker for “time zero” of initiating CPR.  Each site will make 
efforts to maintain synchronization of monitor clocks with a common time standard (e.g. atomic 
clock time). 
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 At the completion of every resuscitation attempt, the electronic record from the BLS and 
ALS devices used during the call will be obtained by the investigators.  All electronic records will 
be reviewed manually by using the commercial software specific to the device, assisted where 
available, by proprietary automated analysis software.  The record will be annotated from the 
time of power-on (“zero time”), and the parameters of resuscitation quantified during these 
periods (Appendix 2).  Determination of whether a resuscitation effort meets minimally 
acceptable CPR performance standards for the Consortium will be based on whether it meets 
acceptable chest compression rate, ventilation rate and CPR fraction criteria as defined in 
Appendix 2.   
 Use of immediate (real-time) feedback software will be at the discretion of individual 
ROC sites and EMS agencies.  Depending on system configuration, providers may be prompted 
by such software to modify the rate or depth of chest compressions, and to minimize 
interruptions in the provision of CPR.  When such feedback is deployed, prompts will conform to 
the same target ranges specified in ROC CPR performance standards.  Regardless of whether 
or not real-time feedback is provided, all resuscitations will be reviewed for adherence to the 
same performance standards, and a mechanism in place for remediation, if necessary.  CPR 
process data derived from resuscitations during which real-time feedback was provided will be 
designated by an appropriate identifier.  These sites may separately examine the impact of 
using real-time feedback in their systems. 
 
 
 
Outcome Measures 
 
Primary  
 The primary outcome for both studies is survival to hospital discharge with modified 
Rankin score < 3. Patients who are transferred to another acute care facility (e.g., to undergo 
ICD placement) will be considered still hospitalized. Patients transferred to a non-acute ward or 
facility will be considered discharged. 
 
Secondary 
 Note that additional background information, rationale for selection, and details about 
specific functional status measures are given in Appendix 4. An interesting methodological issue 
is how to measure post-discharge outcomes. Physician and neuropsychological evaluations are 
considered the gold standard for the diagnosis of cognitive impairment. However such methods 
are unlikely to be feasible and likely to be associated with a high proportion of missing data in a 
population that resides in such a diverse geographic area as that participating in the 
Resuscitation Outcomes Consortium. For example, data from the ROC EMS structures serve 
demonstrates that participating EMS agencies (72% reporting) serve a total catchment area of 
78,521 square miles. If the pattern of missingness is informative (e.g. patients from rural areas 
with delayed resuscitation less likely to be interviewed), then the post-discharge outcome data 
are susceptible to bias. Therefore all post-discharge outcome assessments will be made by 
using measures validated for phone administration to increase the response rate. All 
assessments will be made by trained interviewers. 
 
Our criteria for choosing particular instruments to measure neurological status include 
prior data about reliability and reproducibility, availability of instruments suitable for a multicenter 
trial, and prior data in cardiac arrest survivors. The Modified Rankin Scale (MRS) has face 
validity and can be determined via review of the clinical record, in person or over the 
telephone.(72, 73) MRS has concurrent validity with other measures of neurological recovery 
after stroke and brain injury.(74, 75) MRS has prior use in a cohort of neurosurgical patients 
 42 
with in-hospital cardiac arrest(76) and in a cohort of survivors of out-of-hospital cardiac 
arrest.(77) 
 
 We are aware that CPC is less validated compared to some other measures that will be 
utilized in this study. CPC will be assessed by using a structured questionnaire via telephone 
administration (Appendix 4 of protocol). These latter questions were developed based on 
experience assessing outcomes after discharge in the OPALS study, PAD trial and ASPIRE 
trial.  However it should be recognized that these questions have not been validated in their 
current format. 
 
The Health Utilities Index (HUI) is a generic measure of health-related quality of life. 
(33) It has reliable interview, telephone, and proxy instruments with extensive validation in a 
multiple populations, including two cohort studies of survivors of cardiac arrest.(84, 85) HUI was 
positively correlated with bystander CPR, suggesting construct validity for measuring 
neurological injury incurred during cardiac arrest.(85)   
 
The Adult Lifestyle and Function (ALFI) version of the Mini-Mental Status Exam (MMSE) 
is a measure of cognitive status.(31, 32) ALFI-MMSE correlates with severity of cognitive 
impairment as measured by the Clinical Dementia Rating Scale class.(31) Compared to the 
brief neuropsychiatric screening test, which is a weighted score of the Trailmaking A,(86) Word 
Fluency,(87) Weschler Memory Scale-Mental Control and Logical Memory,(88) ALFI-MMSE had 
a sensitivity of 68% and specificity of 100% for mild cognitive impairment. The corresponding 
MMSE values were 67% and 100%.(31)   
 
  The telephone version of the Geriatric Depression Scale (T-GDS)(34) detects the 
presence or absence of depression. Using a cutoff of 10/11T-GDS has a sensitivity of 86% and 
specificity of 70% for detecting depression compared to a comprehensive assessment by a 
geriatric psychiatrist. 
 
Table 10:  Timing and Content of Secondary and Exploratory Outcome Measures 
 
 
Exploratory Outcome 
 
Consensus statements recommend use of the Cerebral Performance Category (CPC) 
to assess functional outcomes after resuscitation from cardiac arrest.(78, 79)  CPC is a five-
point scale that was adapted from the Glasgow Outcome Scale.(80, 81)  CPC had limited 
discrimination between mild and moderate brain injury, and only moderate correlation with a 
generic measure of health-related quality of life in a small study that was limited by a high rate 
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of loss to follow-up.(82)  However, CPC predicts long-term survival after resuscitation from 
cardiac arrest.(83)   
 
Method of Assessing Post Discharge Outcomes 
 
All post-discharge assessments will be performed by using instruments that will be made 
available in English and Spanish.  Study coordinators will be trained to administer these 
instruments prior to study implementation by using didactic instruction, standardized patients 
and mock interview of each other according to current standards.(89) Spanish-language 
translators will be used as required. Interviewers will be instructed to speak clearly and 
articulate distinctly; ascertain the interviewee’s ability to hear a spoken language at a 
conversational volume; try to ensure no one other than a proxy and the interviewee are present; 
if a precise answer is not given, probe for the correct response; exercise judgment about 
allowing sufficient time to answer a question before proceeding on to the next question; record 
the interviewee’s last response as their answer to each question. Only research staff that 
completed this training successfully will be allowed to perform post-discharge assessments.  
 
We are aware that some patients may be too impaired to complete an interview. 
Therefore, the ALFI-MMSE will be the instrument administered first during the three month 
interview. Patients who score >17 will be asked to complete the interview by self-report. 
Patients who score < 17 will be assessed further by interview of a proxy. We and others used a 
similar approach to assessment of post-discharge outcomes in the Public Access Defibrillation 
(PAD) trial. Contact details for the patient and their proxy will be identified at the time of 
notification of participation in hospital. Consent will be sought from the patient and their proxy for 
interview after discharge. 
 
In-Hospital Morbidity 
Number of hospital days and time interval from 911 call to patient death will be described 
for all hospitalized patients as measures of morbidity after resuscitation. 
 
Other Outcomes 
 Other surrogate outcomes will be collected for descriptive purposes: 
i) Return of Spontaneous Circulation: (ROSC) defined as the documented presence of a 
measurable pulse and blood pressure at any time after initiation of resuscitative efforts.  There 
is no minimum duration for this return of spontaneous circulation. 
ii) Admission to Hospital. 
iii) Survival to 24 Hours. 
iv) Process Outcomes: a) Number of Shocks Required: The total number of defibrillatory 
shocks; b) Duration of Pulselessness: The duration of pulselessness (from 911 to ROSC). 
 
Data Collection 
 
Data Forms 
Appendix 6 contains draft data forms for both protocols. 
 
Source of Data Collection 
Data will be collected prospectively as patient care progresses. This will include a review 
of all the EMS patient care report(s), EMS dispatch times, EMS/fire/first responder electronic 
ECGs, emergency and hospital records. No additional studies or patient contact (except for 
notification of study participation) will be required for collection of this data up to hospital 
discharge.  
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Data Common to Both Protocols 
Out-of-Hospital 
 Demographics, EMS response times (call receipt to arrival, arrival at patient side, etc.), 
witnessed arrest, bystander CPR, location of arrest, CPR process monitoring measures 
(ventilation rate, compression rate, CPR fraction), cause of arrest (cardiac vs. non cardiac), 
EMS therapies (drugs, shocks, advanced airway, hypothermia), first ECG rhythm, disposition, 
return of spontaneous circulation, potential adverse events. 
Emergency and Hospital  
 Major procedures, possible complications of intervention, admittance to the hospital, 
cause of arrest, ICU days, date of awakening, disposition at discharge, withdrawal of care (DNR 
status) as well as MRS and CPC at hospital discharge. 
Follow-up 
 Patients will be contacted by study personnel at 1 month after discharge and will have 
the ALFI-MMSE applied by telephone interview. They will be contacted by study personnel at 3 
months and 6 months to have the MRS, CPC, ALFI-MMSE, HUI and GDS applied by telephone 
interview. 
Initial ECG Rhythm 
 The initial ECG tracing will be analyzed off-line.  The individuals performing this analysis 
will be blind to the interpretation that was performed in real-time by the AED and/or rescuers.  
The entire tracing that is available for analysis will be provided, and three possible ECG rhythms 
will be defined. 
 Asystole will be defined as background electrical activity less than 0.2 mV in amplitude 
with <10 beats per minute average rate (e.g., a 6-second strip without ventricular complexes). 
 VF will be defined as irregular, disorganized ventricular electrical activity of variable 
amplitude exceeding 0.2 mV. 
 Pulseless electrical activity (PEA) will be defined as electrical activity with R-waves of 
any width at an average rate of >10 beats per minute (e.g., organized ventricular electrical 
activity with R waves of any width that occur more than once over a 6-second period).  The rate 
of PEA will be recorded as well. 
 
Items Specific to ITD Protocol 
 Items specific to the ITD protocol will generally deal with events surrounding the use of 
the device; approximate time ITD attached, vomit with ITD, attachment of ITD to bag-mask or 
advanced airway, adverse/unusual events (device fills with fluid twice, device failure, patient 
complications) and protocol adherence. 
 
Items Specific to Analyze Later Protocol 
 Items specific to the Analyze Later protocol will generally deal with events surrounding 
the compliance with the assigned cluster.  Each event will be reviewed to determine whether the 
assigned protocol was followed.   
 
Data Entry 
The DCC will provide web-based HTML forms to collect necessary information from the 
RCCs. Web entry forms will have dynamic features such as immediate checks on data and 
relationships within a form and between forms.  Details and clarification about data items will be 
provided using pop-up windows and links to appropriate sections of the on-line version of the 
Manual of Operations.  Data encryption and authentication methods will be used. The DCC will 
build additional features into the web entry forms including: forms transmission history, access 
to past forms, tracking of data corrections, and the capability to save and re-load incomplete 
forms. 
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Database Management 
The DCC will use a two-tiered database structure.  A front-end database serves the web 
entry needs, using a database management system well-suited to handling updates from 
multiple interactive users.  The data from this database will be transferred periodically (e.g. bi-
weekly) to a “warehouse” database, on which data queries for analyses and monitoring will be 
run.  Various versions of this database are kept as needed, e.g. for quarterly or DSMB reports.  
The “warehouse” database management system was selected for its ability to manage large 
quantities of data, to merge data from multiple databases as required, to handle complex and 
possibly changing relationships, and to produce analysis datasets that can be imported into a 
variety of statistical analysis packages. 
 
Training 
 
Overview 
The training objectives include the following (each detailed below): review of optimal 
CPR performance, scientific basis for and review of study protocols, practicum/”hands-on” 
session, and post-test.  It is anticipated that approximately 2 hours of didactic instruction and 1 
hour of practicum will be required. 
 
Optimal CPR Performance 
The purpose of this component is to provide training in optimal chest compression and 
ventilation skills for all participating EMS personnel and to standardize the performance of CPR 
across all ROC sites as much as possible.  This training component will be implemented either 
as part of the protocol training or as a separate training module prior to specific study training.  
Key concepts include: optimal chest compression rate (100/min) and depth (38-51 mm), correct 
hand position on the distal sternum, complete chest wall recoil with each compression, 
minimizing “hands-off” intervals, avoiding hyperventilation (target rate 10-12/min), and proper 
breath duration (<2 seconds for an unprotected airway and 1 second for a protected airway).  
Training will also emphasize maintaining a continuously tight facemask seal with the “E-C” hand 
technique (one airway rescuer) or two-handed technique (two airway rescuers) when using the 
ITD and the use of ventilation timing assist lights with advanced airways (e.g., Combitube, 
laryngeal mask airway [LMA], or endotracheal tube).   
 
Scientific Basis for ITD and Analyze Later Protocols 
Level-appropriate presentation of the scientific principles underlying the ITD and Analyze 
Early versus Analyze Later studies will increase provider investment and improve protocol 
adherence.  This should include presentation of prior work in both animals and humans and 
justification for a randomized clinical trial, including discussion as to why these approaches 
require further investigation prior to widespread implementation. 
 
Study Protocols 
This section will include the following: overall study design, inclusion and exclusion 
criteria, the process of exception to informed consent under emergency circumstances, and the 
study protocol.  While the overall factorial design makes the analytic methodology somewhat 
complex, the operational protocol has been simplified for the purposes of training and actual trial 
implementation.  From the provider perspective, there are only two arms to the study, as an ITD 
will be applied to all eligible patients but the group assignment (active or sham device) will be 
unknown to the providers.  This creates an Analyze Early arm and an Analyze Later arm, both 
with ITD application existing as part of the study protocol.  The training will mandate that one of 
the providers be designated the “compressor”; this designation should occur prior to the patient 
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encounter to avoid confusion about role assignments once an arrest is recognized.  The two 
study arms are then defined by the number of compressions delivered by the “compressor” 
before a pause for rhythm analysis and defibrillation attempts when indicated.  In the Analyze 
Later arm, a number of compressions equivalent to approximately 3 minutes (e.g. 300 if the 
local CPR protocol is 100 compressions per minute with ventilations interposed, 180 if the local 
protocol is a compression:ventilation ratio of 15:2) will be delivered, while in the Analyze Early 
arm a minimum of 50 compressions will be delivered (see schematics below).  The 
“compressor” should count the number of compressions out loud to alert the other providers as 
to the ongoing duration of chest compressions and to maintain an accurate count.  Visual 
reminders (such as a colored tag on the AED/defibrillator) designating “300” or “50” 
compressions will be used to enhance protocol compliance, especially with a crossover design.  
In addition, crews will be encouraged to review their designated number of compressions as 
part of the daily checklist.  The use of the term “compressor” should be encouraged, not only to 
enhance protocol compliance but also to underscore the importance of chest compressions 
during resuscitation.   
Training will define two tasks for the remaining provider(s): a) placement of the 
monitor/defibrillator pads and preparation for analysis/defibrillation, and b) proper application of 
the ITD/facemask, including maintenance of a continuously adequate seal during chest 
compressions and ventilations.  The first priority following initiation of chest compressions by the 
“compressor” is the rapid placement of defibrillator pads; the monitor/defibrillator should be 
“powered-up” immediately upon recognition of pulselessness or sooner.  The ITD and facemask 
should then be attached to the resuscitation bag and oxygen canister and a continuously tight 
seal maintained.  When additional personnel are available, the two tasks should be performed 
simultaneously.  Training will emphasize immediate use of the ITD with initial airway 
management and continued use throughout the resuscitation while chest compressions are 
being performed as well as dedication of a single individual to maintaining adequate mask seal 
using a two-handed facemask technique whenever possible.  Upon completion of rhythm 
analysis and defibrillation when indicated, standard ACLS procedure will ensue. Providers will 
receive specific training to transfer the ITD to the advanced airway and activate the ventilation 
assist timing lights on the ITD (both sham and active) once tube confirmation has occurred.  
Asynchronous ventilations should be performed using the assist timing lights as a guide.  The 
proper ITD “clearing” procedure, indications for discontinuation of the ITD, and completion of 
study protocol will also be covered, including turnover report to ED personnel and retrieval of 
the ITD. 
 
Figure 5:  Training Scheme 
 
50+
compressions
Apply AED
and turn on
Apply ITD
30-60 sec
Compressor Other Provider(s)
Analyze/shock
ACLS
  Analyze Early Schema    
 
 
300 
compressions
Apply AED
and turn on
Apply ITD
30-60 sec
Compressor Other Provider(s)
Analyze/shock
ACLS
3 min
      Analyze Later Schema
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Protocol Practicum 
 Providers will be given the opportunity to practice to proficiency each component 
of the protocol.  The number of providers used during these rehearsals should simulate 
actual clinical practice whenever possible.  The use of an AED or ALS defibrillator 
should also be dictated by clinical practice, using the identical brand and technology that 
will be available during the trial.  Various permutations of the study protocol should be 
presented, including each of the study arms as discussed above.  Specific assessment 
goals should emphasize inclusion/exclusion criteria, role assignment, correct number of 
compressions, maintenance of continuous tight facemask seal during CPR using “E-C” 
hand technique or two-handed technique, transfer of ITD to advanced airway and 
performance of optimal CPR (minimal “hands-off” time).  All EMS personnel need to 
demonstrate proficiency in adequately managing a factorial study cardiac arrest patient.  
See Appendix 7 for a list of training proficiency goals. 
 
Cognitive post-test 
 A cognitive post test will cover key enrollment procedures and may be completed 
online or as a written or verbal component of the training sessions.  A record of training 
completion will be maintained by each site or EMS agency  
 
Run-in Phase 
 After personnel have been formally trained, they will receive additional training 
through feedback during a run-in phase.  Compliance with the protocol and completion 
and submission of the data will be required before the DCC will notify the site that that 
agency is now in the active phase of the trial.  Compliance monitoring includes:  correct 
inclusion/exclusion criteria, adherence to study protocol, CPR process measures 
reported, and correct completion of data elements including reporting of adverse events. 
 
DSMB and Monitoring Strategy 
 
Data Safety and Monitoring Committee 
 An independent data safety and monitoring committee will help ensure the safety 
of the trial by monitoring adverse outcomes throughout the trial and by reviewing 
outcome data for possible harm. In addition, the committee will review the results of the 
interim analyses.  The committee must review and approve the protocol before the study 
can commence.  The DSMB will evaluate the rate of adverse events between the 
treatment and control arms at intervals to be determined by the DSMB, expected to be 
approximately semi-annually and anticipated to correspond roughly to patient enrollment 
of one-third and two-thirds of total enrollment. The DSMB will also monitor primary and 
secondary study outcomes between the treatment and control groups.  The DCC will 
forward DSMB reports to study investigators, the Institutions Research Board, the Food 
and Drug Administration, and the NIH in accordance with federal regulations 45 CFR 
Part 46 Subpart A and 21 CFR 312 and the IDE regulations, as well as appropriate 
Canadian oversight bodies. 
 
Safety and Data Monitoring  
 The plans for monitoring protocol implementation/compliance, and data 
collection/quality are detailed elsewhere. Clinical centers will report all potential adverse 
events to the DCC as soon as possible.  These will be collected in both a structured 
(standard form) and open (describing any difficulties encountered) form.  All potentially 
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serious adverse events will be reviewed by an events committee of ROC Investigators 
blinded as to treatment arm and further classified by:  a) Severity (life-threatening, 
serious, non-serious); and b) Expected vs. unexpected; and c) Relation to study device. 
For serious adverse events, the DCC will notify the DSMB as well as appropriate 
regulatory agencies, sites, and NIH promptly. 
The DCC will tabulate and report compliance, data quality, and non-serious 
adverse events on a regular basis. 
 
Proposed Interim Monitoring Plan 
 Each factor will be monitored independently by the DSMB and either study could 
be terminated, without terminating the other.  However, interactions will be evaluated.  
Interim analyses will be conducted after accrual of 1/3 and 2/3 of the sample size target 
(Appendix 8).   
 
Proposed Interaction and Extension Monitoring Plan 
 We are aware that some may believe that the ITD will be ineffective for patients 
who receive Analyze Early care.  Others may believe that this is not a realistic scenario.  
If it were true, it would require twice the duration to have the same power for observing 
the hypothesized effect in the Analyze Later cohort.  The outcome will be observed 
during the course of the study by the independent DSMB as described in Appendix 9. 
In the event that the Analyze Late vs Analyze Early (ALvE) intervention is 
terminated early due to demonstrated superiority of one rhythm analysis strategy over 
the other, the efficacy population for the ITD/sham device comparison will be restricted 
to those subjects treated under the rhythm analysis strategy found to be superior. The 
number of subjects accrued to the study will be increased to achieve the planned 
maximal sample size in the superior rhythm analysis strategy arm. 
In the event that the ITD/sham device intervention is terminated early, future 
patients will receive no device, and the efficacy population for the ALvE treatment 
comparison will be otherwise unchanged. 
 
Human Subjects 
 
Protection Against Risks 
In accordance with the FDA, we will develop an adverse event reporting system 
to identify and treat any potential adverse events.  We intend to closely monitor the 
clinical course of all patients enrolled in this trial to identify any expected or unexpected 
adverse events. Data regarding adverse events will be collected in both a structured 
(standard form) and open (describing any difficulties encountered) format.  In 
accordance with the regulations 21 CFR 312.32, we have outlined the expected serious 
and non-serious adverse events, our plans to identify these and the time line for 
reporting them to the FDA, IRB and DMSB and other overseeing agencies.  
An additional risk to subjects in this proposal pertains to the potential for a breach in 
patient confidentiality. All study personnel involved in data collection and analysis will be 
required to sign a confidentiality agreement as required by the institutional review board. In 
addition, subjects will be identified in the database by a study number and links to specific 
identifiers will be kept in a separate secure location. Database files will be maintained on a 
password protected computer in a secure location. 
 
Recruitment and Informed Consent 
This study qualifies for exception from informed consent required for emergency 
research as outlined in FDA regulation 21CFR50.24. The study intervention needs to be 
 49 
administered quickly following the onset of cardiac arrest. In this uncontrolled setting the 
patient is unconscious. As a result, the patient is unable to provide consent for study 
enrollment. Legal next-of-kin are often not immediately available at the scene, nor is it 
practical for the prehospital provider to explain the study and receive consent while caring for 
a patient in cardiac arrest. Taken together, these issues provide sufficient support for an 
exception from consent in order to evaluate an intervention that may have significant outcome 
benefits to this patient population. We have outlined below each criterion stipulated in the 
regulations for this exception and how our study design applies to these criteria. 
 
Sec. 50.24 Exception from informed consent requirements for emergency 
research 
(1) The human subjects are in a life-threatening situation, available treatments are 
unproven or unsatisfactory, and the collection of valid scientific evidence, which 
may include evidence obtained through randomized placebo-controlled 
investigations, is necessary to determine the safety and effectiveness of particular 
interventions. 
The proposed trial is a factorial trial of use of either an active of sham ITD 
supplemented by either of two resuscitation strategies (Analyze Later and Analyze Early) 
in patients with nontraumatic out-of-hospital cardiac arrest. These patients are in an 
immediate life-threatening situation with a mortality approaching 95%. The standard of 
care for prehospital management of these patients includes the timely provision of CPR 
and advanced life support including airway management. 
 As reviewed in this proposal, previous studies of ITD have suggested a short-
term survival advantage with this device but have not been definitive.  These studies 
attest to the safety of ITD in the cardiac arrest population and to the practicality of using 
them in the prehospital environment. The major limitations of previous studies are their 
lack of focus on the specific intervention and their lack of sufficient size to detect 
significant clinical differences in outcome.  Also, in contrast to the previous human 
studies, the present trial will evaluate the device in patients with unprotected airways in 
which case potentially harmful hyperventilation is less common.  Thus, critical evaluation 
of this intervention in humans has not been undertaken.   
 Animal and human data demonstrate the safety of Analyze Later.   Studies in 
animal models of cardiac arrest indicate that a period of artificial circulation prior to the 
initial rescue shock can increase the likelihood of successful defibrillation when VF and 
circulatory arrest lasts more than 3-4 minutes.  Small randomized trials in humans with 
cardiac arrest show that an initial period of CPR may or may not improve survival.  
However, the prior studies lacked concurrent control groups or were too small to detect 
meaningful differences in survival. Therefore, no study has adequately answered the 
question of whether an EMS provider, upon reaching a subject who has already 
developed cardiac arrest, should a) deploy a defibrillator and administer an immediate 
rescue shock or b) perform CPR for an interval prior to deploying the defibrillator and 
rescue shock.  
  We propose a large randomized trial focused on evaluation of these two 
interventions in the out-of-hospital cardiac arrest population, with sufficient statistical 
power to detect changes in outcome. Furthermore, an emphasis on the neurological 
outcome of resuscitated cardiac arrest patients will define the clinical utility of this 
resuscitation approach for these patients. 
 
(2) Obtaining informed consent is not feasible because: 
(i) The subjects will not be able to give their informed consent as a result of 
their medical condition; 
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(ii) The intervention under investigation must be administered before 
consent from the subjects' legally authorized representatives is feasible; 
and 
(iii) There is no reasonable way to identify prospectively the individuals 
likely to become eligible for participation in the clinical investigation. 
The study interventions need to be administered as an early intervention after the 
onset of cardiac arrest (see discussion of therapeutic window below). In this uncontrolled 
setting the patient is unconscious and unable to provide consent for study enrollment. 
Legal next-of-kin are often not immediately available at the scene, nor is it practical for 
the prehospital provider to explain the study and receive consent while caring for the 
cardiac arrest patient. Since we are studying out-of-hospital cardiac arrest, which is 
frequently the first manifestation of cardiovascular disease, there is no way to 
prospectively identify individuals who are likely to become eligible for this trial. 
 
(3) Participation in the research holds out the prospect of direct benefit to the 
subjects because: 
(i) Subjects are facing a life-threatening situation that necessitates 
intervention; 
(ii) Appropriate animal and other preclinical studies have been conducted, 
and the information derived from those studies and related evidence 
support the potential for the intervention to provide a direct benefit to the 
individual subjects; and 
(iii) Risks associated with the investigation are reasonable in relation to 
what is known about the medical condition of the potential class of 
subjects, the risks and benefits of standard therapy, if any, and what is 
known about the risks and benefits of the proposed intervention or activity. 
 
 (i) As defined, these patients with cardiac arrest are facing a life-threatening situation 
that requires immediate intervention. 
(ii) Previous animal and human studies have been conducted, and suggest the potential 
for a direct benefit to individual subjects in cardiac arrest via improved hemodynamics 
and short-term survival advantage. 
(iii) ITD administration has been tested in three previous clinical trials no serious adverse 
effects reported. Both Analyze Early and Analyze Late are currently used strategies.  
Three studies give inconsistent results, but no adverse effects have been noted. As 
discussed above, there are potential risks to subjects that may have not been observed 
in previous trials. We contend that these risks are reasonable in light of the potential 
benefits outlined in this proposal and the current poor outcome for patients with out-of-
hospital cardiac arrest. 
 
(4) The clinical investigation could not practicably be carried out without the 
waiver. 
 
This study could not be conducted without the waiver of consent due to the need 
to administer the interventions as early as possible after the onset of cardiac arrest. 
 
(5) The proposed investigational plan defines the length of the potential 
therapeutic window based on scientific evidence, and the investigator has 
committed to attempting to contact a legally authorized representative for each 
subject within that window of time and, if feasible, to asking the legally authorized 
representative contacted for consent within that window rather than proceeding 
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without consent. The investigator will summarize efforts made to contact legally 
authorized representatives and make this information available to the IRB at the 
time of continuing review. 
 
There have been three clinical studies of ITD use during standard manual CPR 
for the treatment of patients with out-of-hospital cardiac arrest.  These demonstrated a 
potential survival benefit for patients treated with ITD vs. standard CPR. Animal models 
of cardiac arrest suggest that the ITD may increase venous return during the 
decompression phase of CPR.  Based on these data, coupled with the previous clinical 
trials, the therapeutic window for this agent is for the time of initial resuscitation, which 
occurs when CPR is administered by prehospital care providers, up to hospital 
discharge. 
It is well established that the probability of rescue shock success declines quickly 
during cardiac arrest.(49, 90) The decay in the probability of rescue shock success 
occurs over minutes, and approaches zero by 10-12 minutes.  Therefore, the Analyze 
Early vs. Analyze Late intervention must be performed within the first few minutes of 
treatment in order to be meaningful.  
Since this is an immediately life-threatening situation, it will not be possible to 
contact legal representatives at the time of study entry. We will make every effort to 
contact legal representatives after admission to the hospital to notify them that the 
patient was enrolled in a randomized trial. Requiring consent to review a hospital chart to 
determine the presence or absence of serious adverse events is likely to be associated 
with a biased estimate of the safety and efficacy of the intervention. Therefore we 
propose to use exception from informed consent for emergency consent, public 
notification, community consultation, patient notification of enrollment, and waiver of 
documented informed consent to review clinical records.  
If legal representatives are not immediately available, research personnel will 
attempt to contact the subject’s legal representative as soon as feasible and a summary 
of these efforts will be documented in the patient’s chart. If the subject becomes 
competent during the study period then he/she will be approached by research 
personnel for notification of enrollment. 
 
(6) The IRB has reviewed and approved informed consent procedures and an 
informed consent document consistent with Sec. 50.25. These procedures and the 
informed consent document are to be used with subjects or their legally 
authorized representatives in situations where use of such procedures and 
documents is feasible. The IRB has reviewed and approved procedures and 
information to be used when providing an opportunity for a family member to 
object to a subject's participation in the clinical investigation consistent with 
paragraph (a)(7)(v) of this section. 
All procedures and consent forms will be approved by the Institutional Review 
Board (IRB) of the regional study site (or Research Ethics Boards (REBs) in Canada) 
prior to the onset of the trial. 
 
(7) Additional protections of the rights and welfare of the subjects will be 
provided, including, at least: 
(i) Consultation (including, where appropriate, consultation carried out by 
the IRB) with representatives of the communities in which the clinical 
investigation will be conducted and from which the subjects will be drawn; 
(ii) Public disclosure to the communities in which the clinical investigation 
will be conducted and from which the subjects will be drawn, prior to 
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initiation of the clinical investigation, of plans for the investigation and its 
risks and expected benefits; 
(iii) Public disclosure of sufficient information following completion of the 
clinical investigation to apprise the community and researchers of the 
study, including the demographic characteristics of the research 
population, and its results; 
(iv) Establishment of an independent data monitoring committee to 
exercise oversight of the clinical investigation; and 
(v) If obtaining informed consent is not feasible and a legally authorized 
representative is not reasonably available, the investigator has committed, 
if feasible, to attempting to contact within the therapeutic window the 
subject's family member who is not a legally authorized representative, and 
asking whether he or she objects to the subject's participation in the 
clinical investigation. The investigator will summarize efforts made to 
contact family members and make this Information available to the IRB at 
the time of continuing review 
 (i) In U.S, centers, community consultation as outlined by the local IRB will be 
undertaken prior to IRB approval.  Similarly, the Canadian centers will follow the 
requirements of their local REBs. Since the population eligible for enrollment includes all 
citizens in the study regions it will not be possible to target any particular small group. 
The community consultation plan for each study site will have to be individualized to fit 
the IRB requirements. Attached is an example of a proposed plan for community 
consultation, which has been used in a prior ITD trial (Appendix 10). Feedback from the 
community will be obtained by research personnel regarding any concerns they may 
have about potential enrollment. If requested, bracelets will be made available that could 
be worn by members of the community who do not want to participate. 
 (ii) & (iii) Public disclosures will be performed both prior to study enrollment and 
at the completion of the study in the form of multimedia press releases organized by the 
Resuscitation Outcomes Consortium. These will include plans for the study including 
potential risks and benefits and a summary of the results of the study upon completion. 
In the event that the press releases are not widely circulated, advertisements will also be 
placed in local papers describing the study. 
 (iv) An independent data monitoring committee will exercise oversight of the 
study as described below.  
 (v) We expect that all patients who meet the enrollment criteria will be 
unconscious. Any delay in medical care that would be required for the paramedic to 
attempt to obtain consent from the patient’s legal guardian would be life threatening. 
Thus it will not be feasible to attempt to obtain informed consent during the initial 
therapeutic window. 
Once enrolled in an emergency research trial, patients die in the field, die in the 
hospital or survive the event. Review of the clinical record is important to ascertain 
adverse events and important outcomes such as hospital discharge status.   This does 
not require further participation of the patient. 
The local ROC investigator will provide information about the emergency 
research study to the patient or their representative at the earliest feasible opportunity 
after administration of the intervention. Since in many cases this will be while the patient 
is still hospitalized, this will not include a request for consent for further 
participation/intervention, but will provide the patient/representative contact 
names/numbers for purposes of obtaining further information if desired.  Since only 
patients who survive several months after discharge will be asked for further 
participation (in the form of telephone administered functional status measures at 3 
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months and 6 months), the timing of the request for consent for this participation will be 
determined by the local IRBs.    However, we suggest that it should be during the first 
month after discharge so that patients who die before that time are not inconvenienced 
with a decision and so that those who have not died have had time to recover sufficiently 
to make a reasoned decision. 
In summary, we shall notify patients enrolled under waiver of consent for 
emergency research as quickly as feasible, and seek consent from those who survive to 
discharge for ongoing participation. 
 
Please see Appendix 10 for a sample Exception to Consent plan. 
 54 
References 
 
1. Niemann JT. Cardiopulmonary resuscitation. N Engl J Med. 1992 Oct 
8;327(15):1075-80. 
2. Eisenberg MS, Horwood BT, Cummins RO, Reynolds-Haertle R, Hearne TR. 
Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med. 1990 
Feb;19(2):179-86. 
3. Becker LB, Ostrander MP, Barrett J, Kondos GT. Outcomes of CPR in a Large 
Metropolitan Area- Where are the Survivors? Ann Emerg Med. 1991;20(4):355-
61. 
4. Nichol G, Stiell IG, Laupacis A, Pham B, De Maio V, Wells GA. A Cumulative 
Metaanalysis Of The Effectiveness of Defibrillator-Capable Emergency Medical 
Services For Victims Of Out-Of-Hospital Cardiac Arrest. Annals of Emergency 
Medicine. 1999;34(4):517-25. 
5. Lurie KG, Voelckel WG, Zielinski T, McKnite S, Lindstrom P, Peterson C, et al. 
Improving standard cardiopulmonary resuscitation with an inspiratory impedance 
threshold valve in a porcine model of cardiac arrest. Anesth Analg. 2001 
Sep;93(3):649-55. 
6. Lurie KG, Coffeen P, Shultz J, McKnite S, Detloff B, Mulligan K. Improving active 
compression-decompression cardiopulmonary resuscitation with an inspiratory 
impedance valve. Circulation. 1995 Mar 15;91(6):1629-32. 
7. Plaisance P, Lurie KG, Payen D. Inspiratory impedance during active 
compression-decompression cardiopulmonary resuscitation: a randomized 
evaluation in patients in cardiac arrest. Circulation. 2000 Mar 7;101(9):989-94. 
8. Aufderheide TP, Pirrallo RG, Yannopoulos D, Klein JP, von Briesen C, Sparks 
CW, et al. Incomplete chest wall decompression: a clinical evaluation of CPR 
performance by EMS personnel and assessment of alternative manual chest 
compression-decompression techniques. Resuscitation. 2005 Mar;64(3):353-62. 
9. Paradis NA, Martin GB, Rivers EP, Goetting MG, Appleton TJ, Feingold M, et al. 
Coronary perfusion pressure and the return of spontaneous circulation in human 
cardiopulmonary resuscitation. Jama. 1990 Feb 23;263(8):1106-13. 
10. Martin GB, Rivers EP, Paradis NA, Goetting MG, Morris DC, Nowak RM. 
Emergency department cardiopulmonary bypass in the treatment of human 
cardiac arrest. Chest. 1998 Mar;113(3):743-51. 
11. Sanders AB, Ogle M, Ewy GA. Coronary perfusion pressure during 
cardiopulmonary resuscitation. Am J Emerg Med. 1985 Jan;3(1):11-4. 
12. Kouwenhoven WB, Jude JR, Knickerbocker GG. Closed-chest cardiac massage. 
Jama. 1960 Jul 9;173:1064-7. 
13. Halperin HR, Guerci AD, Chandra N, Herskowitz A, Tsitlik JE, Niskanen RA, et 
al. Vest inflation without simultaneous ventilation during cardiac arrest in dogs: 
improved survival from prolonged cardiopulmonary resuscitation. Circulation. 
1986 Dec;74(6):1407-15. 
14. Halperin HR, Tsitlik JE, Gelfand M, Weisfeldt ML, Gruben KG, Levin HR, et al. A 
preliminary study of cardiopulmonary resuscitation by circumferential 
compression of the chest with use of a pneumatic vest. N Engl J Med. 1993 Sep 
9;329(11):762-8. 
15. Babbs CF, Tacker WA, Jr. Cardiopulmonary resuscitation with interposed 
abdominal compression. Circulation. 1986 Dec;74(6 Pt 2):IV37-41. 
16. Babbs CF, Sack JB, Kern KB. Interposed abdominal compression as an adjunct 
to cardiopulmonary resuscitation. Am Heart J. 1994 Feb;127(2):412-21. 
 55 
17. Sack J, Kesselbrenner M, Bregman D. Survival from in-hospital cardiac arrest 
with interposed abdominal counterpulsation during cardiopulmonary 
resuscitation. JAMA. 1992;267:p.379-85. 
18. Sack J, Kesselbrenner M, Jarrad A. Interposed abdominal compression-
Cardiopulmonary resuscitation and resuscitation outcome during asystole and 
electromechanical disassociation. Circulation. 1992;86:p.1692-700. 
19. Mateer JR, Stueven HA, Thompson BM, Aprahamian C, Darin JC. Pre-hospital 
IAC-CPR versus standard CPR: paramedic resuscitation of cardiac arrests. Am J 
Emerg Med. 1985 Mar;3(2):143-6. 
20. Tang W, Weil MH, Schock RB, Sato Y, Lucas J, Sun S, et al. Phased chest and 
abdominal compression-decompression. A new option for cardiopulmonary 
resuscitation. Circulation. 1997 Mar 4;95(5):1335-40. 
21. Lurie K, Shultz J, Callaham M, Schwab t, Gisch T, Rector T, et al. Evaluation of 
active compression-decompression CPR in victims of out-of-hospital  cardiac 
arrest. JAMA. 1994;271:p.1405-11. 
22. Lurie KG, Mulligan KA, McKnite S, Detloff B, Lindstrom P, Lindner KH. 
Optimizing standard cardiopulmonary resuscitation with an inspiratory impedance 
threshold valve. Chest. 1998 Apr;113(4):1084-90. 
23. Aufderheide T, Pirallo RG, Provo TA, Lurie KG. Clinical evaluation of an 
inspiratory impedance threshold device during standard cardiopulmonary 
resuscitation in patients with out-of-hospital cardiac arrest. Crit Care Med. 
2005;In Press. 
24. Pirrallo RG, Aufderheide TP, Provo TA, Lurie KG. Effect of an inspiratory 
impedance threshold device on hemodynamics during conventional manual 
cardiopulmonary resuscitation. Resuscitation. 2005;In Press. 
25. Thayne RC, Thomas DC, Neville JD, van Dellen A. Use of an impedance 
threshold device improves short-term outcomes following out-of-hospital cardiac 
arrest. Resuscitation. 2005;In Press. 
26. Aufderheide TP, Sigurdsson G, Pirrallo RG, Yannopoulos D, McKnite S, von 
Briesen C, et al. Hyperventilation-induced hypotension during cardiopulmonary 
resuscitation. Circulation. 2004 Apr 27;109(16):1960-5. 
27. Milander MM, Hiscok PS, Sanders AB, Kern KB, Berg RA, Ewy GA. Chest 
compression and ventilation rates during cardiopulmonary resuscitation: the 
effects of audible tone guidance. Acad Emerg Med. 1995 Aug;2(8):708-13. 
28. Abella BS, Alvarado JP, Myklebust H, Edelson DP, Barry A, O'Hearn N, et al. 
Quality of cardiopulmonary resuscitation during in-hospital cardiac arrest. Jama. 
2005 Jan 19;293(3):305-10. 
29. Wik L, Kramer-Johansen J, Myklebust H, Sorebo H, Svensson L, Fellows B, et 
al. Quality of cardiopulmonary resuscitation during out-of-hospital cardiac arrest. 
Jama. 2005 Jan 19;293(3):299-304. 
30. Wolcke BB, Mauer DK, Schoefmann MF, Teichmann H, Provo TA, Lindner KH, 
et al. Comparison of standard cardiopulmonary resuscitation versus the 
combination of active compression-decompression cardiopulmonary 
resuscitation and an inspiratory impedance threshold device for out-of-hospital 
cardiac arrest. Circulation. 2003 Nov 4;108(18):2201-5. 
31. Roccaforte WH, Burke WJ, Bayer BL, Wengel SP. Validation of a Telephone 
Version of the Mini-Mental State Examination. J Am Geriatric Soc. 1992;40:697-
702. 
32. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State:" a Practical Method 
for Grading the Cognitive State of Patients for the Clinician. J Psychiatr Res. 
1975;12:189-98. 
 56 
33. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, et al. 
Multiattribute and single-attribute utility functions for the health utilities index mark 
3 system. Med Care. 2002 Feb;40(2):113-28. 
34. Burke WJ, Roccaforte WH, Wengel SP, Conley DM, Potter JF. The reliability and 
validity of the Geriatric Depression Rating Scale administered by telephone. J 
Am Geriatr Soc. 1995 Jun;43(6):674-9. 
35. Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA. An analysis of 
physicians' reasons for prescribing long-term digitalis therapy in outpatients. J 
Chron Dis. 1985;38:733-9. 
36. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic 
patient in the emergency department have congestive heart failure? Jama. 2005 
Oct 19;294(15):1944-56. 
37. Dohi S. Postcardiopulmonary resuscitation pulmonary edema. Crit Care Med. 
1983 Jun;11(6):434-7. 
38. Huber PJ. The behaviour of maximum likelihood esimates under non-standard 
conditions.  Fifth Berkeley Symposium on Mathematical Statistics and 
Probability. Berkeley, CA: University of California Press; 1967. 
39. White H. Maximum likelihood estimation of misspecified models. Econometrica. 
1982;50:1-25. 
40. Pampallona S, Tsiatis AA. Group sequential designs for one-sided and two-sided 
hypothesis testing with provision for early stopping in favor of the null hypothesis. 
J Stat Planning and Inference. 1994;42:19-35. 
41. Lurie KG, Voelckel WG, Iskos DN, McKnite SH, Zielinski TM, Sugiyama A, et al. 
Combination drug therapy with vasopressin, adrenaline (epinephrine) and 
nitroglycerin improves vital organ blood flow in a porcine model of ventricular 
fibrillation. Resuscitation. 2002 Aug;54(2):187-94. 
42. Anonymous. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency 
Cardiovascular Care. International Consensus on Science. Circulation. 
2000;102(8 Suppl I):1-291. 
43. Weisfeldt ML, Kerber RE, McGoldrick RP, Moss AJ, Nichol G, Ornato JP, et al. Public 
Access Defibrillation.  A statement for health care professionals from the American Heart 
Association Task Force on Automatic External Defibrillation. Circulation. 
1995;92:2763. 
44. Caffrey SL, Willoughby PJ, Pepe PE, Becker LB. Public use of automated 
external defibrillators. N Engl J Med. 2002 Oct 17;347(16):1242-7. 
45. Valenzuela TD, Roe DJ, Nichol G, Clark LL, Spaite DW, Hardman RG. 
Outcomes of Rapid Defibrillation by Security Officers after Cardiac Arrest in 
Casinos. N Engl J Med. 2000;343(17):1206-9. 
46. Hallstrom AP, Ornato JP, Weisfeldt M, Travers A, Christenson J, McBurnie MA, 
et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. 
N Engl J Med. 2004 Aug 12;351(7):637-46. 
47. Myerburg RJ, Fenster J, Velez M, Rosenberg D, Lai S, Kurlansky P, et al. Impact 
of community-wide police car deployment of automated external defibrillators on 
survival from out-of-hospital cardiac arrest. Circulation. 2002 Aug 
27;106(9):1058-64. 
48. Mosesso VN, Davis EA, Auble TE, Paris PM, Yealy DM. Use of Automated 
External Defibrillators by Police Officers for Treatment of Out of Hospital Cardiac 
Arrest. Ann Emerg Med. 1998;32:200-7. 
49. Stiell IG, Wells GA, Field BJ, Spaite DW, De Maio VJ, Ward R, et al. Improved 
out-of-hospital cardiac arrest survival through the inexpensive optimization of an 
 57 
existing defibrillation program: OPALS study phase II. Ontario Prehospital 
Advanced Life Support. JAMA. 1999;281(13):1175-81. 
50. Weisfeldt ML, Becker LB. Resuscitation after cardiac arrest: a 3-phase time-
sensitive model. Jama. 2002 Dec 18;288(23):3035-8. 
51. Niemann JT, Stratton SJ, Cruz B, Lewis RJ. Outcome of out-of-hospital 
postcountershock asystole and pulseless electrical activity versus primary 
asystole and pulseless electrical activity. Crit Care Med. 2001 Dec;29(12):2366-
70. 
52. Yakaitis RW, Ewy GA, Otto CW, Taren DL, Moon TE. Influence of time and 
therapy on ventricular defibrillation in dogs. Crit Care Med. 1980 Mar;8(3):157-
63. 
53. Niemann JT, Cruz B, Garner D, Lewis RJ. Immediate countershock versus 
cardiopulmonary resuscitation before countershock in a 5-minute swine model of 
ventricular fibrillation arrest. Ann Emerg Med. 2000 Dec;36(6):543-6. 
54. Menegazzi JJ, Seaberg DC, Yealy DM, Davis EA, MacLeod BA. Combination 
pharmacotherapy with delayed countershock vs standard advanced cardiac life 
support after prolonged ventricular fibrillation. Prehosp Emerg Care. 2000 Jan-
Mar;4(1):31-7. 
55. Menegazzi JJ, Davis EA, Yealy DM, Molner RL, Nicklas KA, Hosack GM, et al. 
An experimental algorithm versus standard advanced cardiac life support in a 
swine model of out-of-hospital cardiac arrest. Ann Emerg Med. 1993 
Feb;22(2):235-9. 
56. Lightfoot CB, Nremt P, Callaway CW, Hsieh M, Fertig KC, Sherman LD, et al. 
Dynamic nature of electrocardiographic waveform predicts rescue shock 
outcome in porcine ventricular fibrillation. Ann Emerg Med. 2003 Aug;42(2):230-
41. 
57. Berg RA, Hilwig RW, Kern KB, Ewy GA. Precountershock cardiopulmonary 
resuscitation improves ventricular fibrillation median frequency and myocardial 
readiness for successful defibrillation from prolonged ventricular fibrillation: a 
randomized, controlled swine study. Ann Emerg Med. 2002 Dec;40(6):563-70. 
58. Callaway CW, Sherman LD, Mosesso VN, Jr., Dietrich TJ, Holt E, Clarkson MC. 
Scaling exponent predicts defibrillation success for out-of-hospital ventricular 
fibrillation cardiac arrest. Circulation. 2001 Mar 27;103(12):1656-61. 
59. Jekova I, Dushanova J, Popivanov D. Method for ventricular fibrillation detection 
in the external electrocardiogram using nonlinear prediction. Physiol Meas. 2002 
May;23(2):337-45. 
60. Eftestol T, Sunde K, Steen PA. Effects of interrupting precordial compressions on 
the calculated probability of defibrillation success during out-of-hospital cardiac 
arrest. Circulation. 2002 May 14;105(19):2270-3. 
61. Berg RA, Hilwig RW, Kern KB, Sanders AB, Xavier LC, Ewy GA. Automated 
external defibrillation versus manual defibrillation for prolonged ventricular 
fibrillation: lethal delays of chest compressions before and after countershocks. 
Ann Emerg Med. 2003 Oct;42(4):458-67. 
62. Koster RW. Limiting 'hands-off' periods during resuscitation. Resuscitation. 2003 
Sep;58(3):275-6. 
63. Cobb LA, Fahrenbruch CE, Walsh TR, Copass MK, Olsufka M, Breskin M, et al. 
Influence of cardiopulmonary resuscitation prior to defibrillation in patients with 
out-of-hospital ventricular fibrillation. Jama. 1999;281:1182-8. 
64. Wik L, Hansen TB, Fylling F, Steen T, Vaagenes P, Auestad BH, et al. Delaying 
defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-
 58 
hospital ventricular fibrillation: a randomized trial. Jama. 2003 Mar 
19;289(11):1389-95. 
65. Jacobs IG, Finn JC, Oxer HF, Jelinek GA. CPR before defibrillation in out-of-
hospital cardiac arrest: a randomized trial. Emerg Med Australas. 2005 
Feb;17(1):39-45. 
66. Stiell IG, Wells GA, Field B, Spaite DW, Nesbitt LP, De Maio VJ, et al. Advanced 
cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004 Aug 
12;351(7):647-56. 
67. van der Hoeven J, de Koning J, can der Weyden P, Meinders A. Improved 
outcome for patients with a cardiac arrest by supervision of the emergency 
medical services system. Netherlands J of Med. 1995;46:p.123-30. 
68. Abella BS, Sandbo N, Vassilatos P, Alvarado JP, O'Hearn N, Wigder HN, et al. 
Chest compression rates during cardiopulmonary resuscitation are suboptimal: a 
prospective study during in-hospital cardiac arrest. Circulation. 2005 Feb 
1;111(4):428-34. 
69. Kim DW. Detection of physiological events by impedance. Yonsei Med J. 
1989;30(1):1-11. 
70. Allison RD, Holmes EL, Nyboer J. Volumetric Dynamics of Respiration as 
Measured by Electrical Impedance Plethysmography. J Appl Physiol. 1964 
Jan;19:166-73. 
71. Aase SO, Myklebust H. Compression depth estimation for CPR quality 
assessment using DSP on accelerometer signals. IEEE Trans Biomed Eng. 2002 
Mar;49(3):263-8. 
72. Newcommon NJ, Green TL, Haley E, Cooke T, Hill MD. Improving the 
assessment of outcomes in stroke: use of a structured interview to assign grades 
on the modified Rankin Scale. Stroke. 2003 Feb;34(2):377-8; author reply -8. 
73. Merino JG, Lattimore SU, Warach S. Telephone assessment of stroke outcome 
is reliable. Stroke. 2005 Feb;36(2):232-3. 
74. Weimar C, Kurth T, Kraywinkel K, Wagner M, Busse O, Haberl RL, et al. 
Assessment of functioning and disability after ischemic stroke. Stroke. 2002 
Aug;33(8):2053-9. 
75. Hop JW, Rinkel GJ, Algra A, van Gijn J. Changes in functional outcome and 
quality of life in patients and caregivers after aneurysmal subarachnoid 
hemorrhage. J Neurosurg. 2001 Dec;95(6):957-63. 
76. Rabinstein AA, McClelland RL, Wijdicks EF, Manno EM, Atkinson JL. 
Cardiopulmonary resuscitation in critically ill neurologic-neurosurgical patients. 
Mayo Clin Proc. 2004 Nov;79(11):1391-5. 
77. van Alem AP, de Vos R, Schmand B, Koster RW. Cognitive impairment in 
survivors of out-of-hospital cardiac arrest. Am Heart J. 2004 Sep;148(3):416-21. 
78. Cummins RO, Chamberlain DA, Abramson NS, Allen M, Baskett PJ, Becker L, et 
al. Recommended guidelines for uniform reporting of data from out-of-hospital 
cardiac arrest: the Utstein style. Circulation. 1991;84(2):960-75. 
79. Jacobs I, Nadkarni V, Bahr J, Berg RA, Billi JE, Bossaert L, et al. Cardiac arrest 
and cardiopulmonary resuscitation outcome reports: update and simplification of 
the Utstein templates for resuscitation registries: a statement for healthcare 
professionals from a task force of the International Liaison Committee on 
Resuscitation (American Heart Association, European Resuscitation Council, 
Australian Resuscitation Council, New Zealand Resuscitation Council, Heart and 
Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation 
Councils of Southern Africa). Circulation. 2004 Nov 23;110(21):3385-97. 
 59 
80. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 
1975;1(7905):480-4. 
81. Anonymous. A randomized clinical trial of calcium entry blocker administration to 
comatose survivors of cardiac arrest. Design, methods, and patient 
characteristics. The Brain Resuscitation Clinical Trial II Study Group. Control Clin 
Trials. 1991 Aug;12(4):525-45. 
82. Hsu JWY, Callaham M, Madsen CD. Quality-of-Life and Formal Functional 
Testing of Survivors of Out-of-Hospital Cardiac Arrest Correlates Poorly with 
Traditional Neurological Outcome Scales. Ann Emerg Med. 1996;28:597-605. 
83. Herlitz J, Ekstrom L, Wennerblom B, Axelsson A, Bang A, Holmberg S. 
Prognosis Among Survivors of  Prehospital Cardiac Arrest. Ann Emerg Med. 
1995;25:58-63. 
84. Nichol G, Stiell IG, Hebert P, Wells G, Vandemheen K, Laupacis A. What is the 
Quality of Life of Survivors of Cardiac Arrest?  A Prospective Study. Acad Emerg 
Med. 1999;6:95-102. 
85. Stiell I, Nichol G, Wells G, De Maio V, Nesbitt L, Blackburn J, et al. Health-related 
quality of life is better for cardiac arrest survivors who received citizen 
cardiopulmonary resuscitation. Circulation. 2003 Oct 21;108(16):1939-44. 
86. Armitage SG. An analysis of certain psychological tests used for the evaluation of 
brain injury. Psychol Monogr. 1946;60:1-48. 
87. Thurston LL, Thurston TG. Examiner Manual for the SRA Primary Mental 
Abilities Test. Chicago, IL: Science Research Associates; 1949. 
88. Weschler D, Stone CP. Manual: Weschler Memory Scale. New York: 
Psychological Corporation; 1983. 
89. American Educational Research Association, American Psychological 
Association, National Council on Measurement in Education. Standards for 
Educational and Psychological Testing. Washington, DC; 1999. 
90. Valenzuela T, Roe DJ, Cretin S, Spaite DW, Larsen MP. Estimating effectiveness 
of cardiac arrest interventions: A logistic regression survival model. Circulation. 
1997;96:3308-13. 
 
 
IDE G980125/S52  Page 1 of 21 
PROTOCOL AMENDMENT #1 (DRAFT 061227) 
PROTOCOL AMENDMENT  
IDE G980125/S52 
Resuscitation Outcomes Consortium 
Prehospital Resuscitation using an 
IMpedance valve and Early vs Delayed 
analysis (ROC PRIMED) Trial 
 
   This protocol amendment  
 clarifies the conditions under which patients who are initially treated by 
emergency medical services (EMS) providers from an agency that is not 
participating in the Resuscitation Outcomes Consortium would be considered 
eligible for enrollment in the trial, 
 clarifies when the impedance threshold device (ITD) can be used with other 
resuscitation devices in light of a recent study of the ITD in an animal model of 
cardiac arrest, and 
 clarifies the partial factorial nature of the clinical trial and explicitly describes the 
participation of the Seattle Medic One EMS agency in the ITD/sham device 
intervention, but not the Analyze Later/Analyze Early intervention.. 
   This amendment has been approved by all study investigators and will take effect 
immediately upon initiation of patient enrollment.  This amendment will be submitted to 
Health Canada as well as all IRBs (U.S.) and REBs (Canada) that provide local oversight 
for this trial. 
 
1. Section 1 – Factorial Study Summary-Background (pg. 3): 
Change: 
 “… propose a large clinical trial, using a factorial design, to test two strategies …” 
to  
“… propose a large clinical trial, using a partial factorial design, to test two strategies … 
 
Rationale: To emphasize the partial factorial (as opposed to full factorial) nature of the clinical 
trial design. 
 
2. Section 1 – Factorial Study Summary-Rationale (pg. 3): 
Change:  
“… rationale for the factorial design is based on …”  
to  
“…rationale for the partial factorial design is based on … 
 
Rationale: To emphasize the partial factorial (as opposed to full factorial) nature of the clinical 
trial design. 
 
  
IDE G980125/S52  Page 2 of 21 
PROTOCOL AMENDMENT #1 (DRAFT 061227) 
3. Section 1 – Factorial Study Summary-Rationale (pg. 3): 
Add: 
• “A partial factorial design, as opposed to a full factorial design, is necessary 
because eligibility criteria for the two interventions are not identical. Current 
medical standards would dictate that the Analyze Later strategy is inappropriate 
for patients whose cardiac arrest was witnessed by EMS, but some such patients 
might have an ITD or sham device applied during their resuscitation. Similarly, 
some patients on either the Analyze Later or Analyze Early arm might achieve 
resumption of spontaneous circulation (ROSC) prior to the application of the ITD 
or sham device. Further, because a greater sample size if required to achieve the 
desired statistical power to detect the anticipated effect of the ITD than that 
required to detect the effect of the Analyze Later strategy, the ROC investigators 
have allowed for the inclusion of one agency (Seattle Medic One) that would 
participate only in the ITD/sham comparison and not the Analyze Later vs 
Analyze Early comparison. We anticipate that of all cardiac arrests treated by 
participating ROC agencies during the course of the study, approximately 85% 
will be judged evaluable for both the ITD/sham and Analyze Later/Analyze Early 
comparisons.“  
 
Rationale: To emphasize the reasons for a partial factorial (as opposed to full factorial) nature of 
the clinical trial design and to explicitly note the participation of the Seattle Medic One EMS in 
the ITD/sham device intervention, but not the Analyze Later/Analyze Early intervention. 
 
4. Section 1 – Factorial Study Summary-Challenges (pg. 4): 
Change:  
“The factorial design poses three challenges: …”  
to  
“The partial factorial design poses three challenges:” 
 
Rationale: To emphasize the partial factorial (as opposed to full factorial) nature of the clinical 
trial design. 
 
5. Section 1 – Factorial Study Summary-Design (pg. 5): 
Change:  
“The trial will be factorial with: …”  
to  
“The trial will be partial factorial with:” 
 
Rationale: To emphasize the partial factorial (as opposed to full factorial) nature of the clinical 
trial design. 
 
6. Section 1 – Factorial Study Summary-Remainder of This Protocol (pg. 6): 
Change:  
“and/or specific to the factorial design of the study: …”  
to  
“and/or specific to the partial factorial design of the study:” 
 
Rationale: To emphasize the partial factorial (as opposed to full factorial) nature of the clinical 
trial design. 
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7. Section 2 – Impedance Threshold Device Trial-Study Summary-Sample Size (pg. 
7): 
Change:  
“…to discharge rate of 5.32% with standard CPR and sham ITD, and two interim 
analyses, a maximum of 14,742 evaluable patients are needed to detect a 6.68% 
absolute survival: …”  
to  
“…to discharge rate of 5.33% with standard CPR and sham ITD, and two interim 
analyses, a maximum of 14,742 evaluable patients are needed to detect a 6.69% 
absolute survival…” 
 
Rationale: To reflect aspects of the sample size calculations that change due to the Seattle agency 
participating only in the ITD/sham device intervention and not in the Analyze Later/Analyze 
Early intervention. A slight change in weighting of the strata resulted in a change in the third 
significant digit for the hypothesized response probabilities. 
 
8. Section 2 – Impedance Threshold Device Trial-Research Design and Methods-
Exclusion Criteria (pg. 13): 
Change: 
–  “CPR performed with the mechanical compression “Autopulse” device”  
to  
– “CPR performed with any mechanical compression device (e.g. Autopulse, LUCAS, 
Thumper)  
– Ventilated with a mechanical device (e.g. automated transport ventilator) Note: a 
bag-mask is not considered a mechanical ventilation device.” 
 
Rationale: Dr. Jim Menegazzi of the University of Pittsburgh and colleagues recently completed a 
controlled study of the use of the Impedance Threshold Device in an animal model of cardiac 
arrest. He observed a significantly greater mortality in the animals that were treated with cardiac 
arrest compared to those that were not. A subcommittee of ROC investigators supplemented by 
two independent experts in animal models of cardiac arrest reviewed these unpublished data as 
well as published controlled studies of ITD in animals models of cardiac arrest or humans in 
cardiac arrest. A summary of the methods and results of this review process is attached to this 
amendment. In brief, we concluded that that there were a variety of plausible explanations for Dr. 
Menegazzi’s results. After weighing the totality of animal and human evidence, the subcommittee 
recommended that the ROC PRIMED trial proceed as planned. In doing so, we recognized that 
the Menegazzi experiment used a mechanical compression device as well as a mechanical 
ventilator whereas the Milwaukee pilot study of ITD use in out of hospital cardiac arrest did not. 
We shall continue to monitor ongoing animal and human research that evaluates the ITD, and will 
advise the ROC DSMB and FDA if we believe the ROC PRIMED design should be altered. 
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9. Section 2 – Impedance Threshold Device Trial-Research Design and Methods-
Exclusion Criteria (pg. 13): 
Change: 
–  “Non-ROC EMS agency/provider began CPR or placed pads”  
to  
– “A non-ROC EMS agency/provider, for whom time call received at dispatch cannot 
be obtained, began CPR or placed pads.”  
 
Rationale: We need to be able to determine the time interval from 911 call to arrival of EMS 
providers in order to determine whether the patient should be included in efficacy analysis of 
ITD. The geographic coverage area of some ROC EMS agencies overlaps with that of some other 
agencies that are not participating in ROC. It is not feasible to train, equip and monitor all EMS 
providers within a fixed geographic area.  Nor is it possible to obtain response time interval data 
from all non-ROC EMS agencies. Hence we are focusing on training, equipping and monitoring 
ROC EMS providers, as well as enrolling patients treated by these individuals. We shall exclude 
patients who are initially treated by non-ROC EMS providers in the event that we are unable to 
determine whether the patients are eligible for enrollment in the trial. 
 
10.  Section 2-Impedance Threshold Device Trial-Research Design and Methods-
Efficacy Population (pg. 13): 
 Change:  
“arrival of EMS providers at scene”  
to  
“arrival of ROC EMS providers at scene”. 
 
Rationale: The efficacy analysis will focus on patients who are promptly treated by ROC EMS 
providers, as delay in care could attenuate any possible treatment effect. 
 
11. Section 2. Impedance Threshold Device Trial- Prespecified Subgroup Analyses 
(pg. 15): 
Change: 
“initiation of CPR by EMS”  
to  
“initiation of  CPR by ROC EMS”  
 
Rationale: The subroup analysis will focus on patients who are promptly treated by ROC EMS 
providers, as delay in care could attenuate any possible treatment effect. 
 
12. Section 2 – Impedance Threshold Device Trial-Outcome Measures-Prespecified 
Subgroup Analyses (pg. 15): 
Change:  
“Analyze Early vs. Analyze Later cohorts”  
to  
“Analyze Early vs. Analyze Later vs. not participating in ALvE cohorts” 
 
Rationale: To clarify partial factorial nature of design and its impact on the subgroup analyses. 
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13. Section 2 – Impedance Threshold Device Trial-Analyses-Sample Size and Study 
Duration (pg. 21): 
Change:  
“…will be randomized (by cluster) in a 1:1 ratio to the AE or AL strategies, the expected 
distribution of patients to the various treatment strategies…”  
to  
“…will be randomized (by cluster) in a 1:1 ratio to the AE or AL strategies at all 
participating agencies except Seattle Medic One (which is projected to accrue 
approximately 2.7% of all patients—see Table 9), the expected distribution of patients to 
the various treatment strategies…” 
 
Rationale: To explicitly note the decision by the Seattle Medic One agency to participate only in 
the ITD/sham device intervention and not the Analyze Later/Analyze Early intervention. 
 
14. Section 2 – Impedance Threshold Device Trial-Analyses-Sample Size and Study 
Duration (pg. 21): 
Change:  
Table 2: Proportion of all EMS treated OOHCA patients randomized to treatment combinations 
according to presenting rhythm and EMS Witness status 
 
EMS Witnessed CA 
(AL vs. AE Ineligible) Analyze Early Analyze Late 
Total 
ITD/Sham 
Randomized Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD Sham ITD 
Asystole 0.000 0.012 0.012 0.000 0.119 0.119 0.119 0.119 0.250 0.250 
PEA 0.000 0.014 0.014 0.000 0.056 0.056 0.056 0.056 0.125 0.125 
VT/VF 0.015 0.017 0.017 0.030 0.035 0.035 0.050 0.050 0.103 0.103 
TOTAL 0.015 0.043 0.043 0.030 0.210 0.210 0.225 0.225 0.478 0.478 
to  
Table 2: Proportion of all EMS treated OOHCA patients randomized to treatment combinations 
according to presenting rhythm and EMS Witness status 
 
EMS Witnessed CA or 
Seattle Medic One 
(AL vs. AE Ineligible) 
Analyze Early Analyze Late 
Total 
ITD/Sham 
Randomized Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD Sham ITD 
Asystole 0.000 0.018 0.018 0.000 0.116 0.116 0.116 0.116 0.250 0.250 
PEA 0.000 0.017 0.017 0.000 0.054 0.054 0.054 0.054 0.125 0.125 
VT/VF 0.015 0.020 0.020 0.029 0.034 0.034 0.049 0.049 0.103 0.103 
TOTAL 0.015 0.055 0.055 0.029 0.204 0.204 0.219 0.219 0.478 0.478 
 
Rationale: To explicitly note the impact on the sample size calculations of the decision by the 
Seattle Medic One agency to participate only in the ITD/sham device intervention and not the 
Analyze Later/Analyze Early intervention. This did not affect the proportion of subjects 
randomized to the ITD/sham device intervention, but did affect the relative size of the strata 
defined by Analyze Early, Analyze Late, or ALvE ineligible. 
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15. Section 2 – Impedance Threshold Device Trial-Analyses-Sample Size and Study 
Duration (pg. 21): 
Change:  
 “survival to hospital discharge of 0.0599 when treated under the AE strategy with a 
sham valve. We assume that 88.9% of such survivors would have acceptable 
neurological status (MRS ≤ 3) based on a combination of observed rates from the 
ASPIRE and PAD trials where 35 of 45 and 42 of 45 survivors had CPC scores < 2. 
Therefore we estimate a rate of 0.0532 for neurologically intact”  
to  
“survival to hospital discharge of 0.0600 when treated under the AE strategy with a sham 
valve. We assume that 88.9% of such survivors would have acceptable neurological 
status (MRS ≤ 3) based on a combination of observed rates from the ASPIRE and PAD 
trials where 35 of 45 and 42 of 45 survivors had CPC scores < 2. Therefore we estimate 
a rate of 0.0533 for neurologically intact” 
 
Rationale: To explicitly note the impact on the sample size calculations of the decision by the 
Seattle Medic One agency to participate only in the ITD/sham device intervention and not the 
Analyze Later/Analyze Early intervention. The consequent slight change in weighting of the 
strata resulted in a change in the third significant digit for the hypothesized response probabilities. 
 
16. Section 2 – Impedance Threshold Device Trial-Analyses-Sample Size and Study 
Duration (pg. 22): 
Change:  
 “… estimated probability of survival to hospital discharge of 0.0751 for patients treated 
with an ITD under the AE strategy, with a corresponding hypothesized rate of 0.0668 for”  
to  
“… estimated probability of survival to hospital discharge of 0.0753 for patients treated 
with an ITD under the AE strategy, with a corresponding hypothesized rate of 0.0669 for” 
 
Rationale: To explicitly note the impact on the sample size calculations of the decision by the 
Seattle Medic One agency to participate only in the ITD/sham device intervention and not the 
Analyze Later/Analyze Early intervention. A slight change in weighting of the strata resulted in a 
change in the third significant digit for the hypothesized response probabilities. 
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17. Section 2 – Impedance Threshold Device Trial-Analyses-Sample Size and Study 
Duration (pg. 22): 
Change:  
“Table 3: Estimated proportions of all EMS treated OOHCA patients surviving to discharge and 
surviving to discharge with MRS ≤ 3 by ITD/sham treatment arm and presenting rhythm. 
 
Presenting Rhythm Stratum Weight 
Sham Device 
Probability of 
Survival to 
Discharge 
ITD / Sham 
Relative 
Benefit 
ITD Probability 
of Survival to 
Discharge 
Asystole 0.5235 0.0105 1.40 0.0147 
PEA 0.2618 0.0420 1.40 0.0588 
VT/VF 0.2147 0.2020 1.20 0.2424 
 
Probability of Survival to Discharge 
(weighted average) 
 0.0599  0.0751 
 
Probability of Neurologically Intact 
Survival to Discharge 
(88.9% of patients surviving to 
hospital discharge) 
 0.0532  0.0668 
 
The number of patients to be accrued to the ITD vs. sham device comparison is 
based on the ability of a one-sided level 0.025 test to reject a null hypothesis that the 
probability of neurologically intact survival to hospital discharge is 0.0532 on both 
treatment arms. Sample size computations are based on a two-sample test of binomial 
proportions using Pearson’s chi squared statistic. The test should have approximately 
90% statistical power to reject the null hypothesis when the ITD treatment arm would 
have a 0.0668 probability of neurologically intact survival.” 
to  
“Table 3: Estimated proportions of all EMS treated OOHCA patients surviving to discharge and 
surviving to discharge with MRS ≤ 3 by ITD/sham treatment arm and presenting rhythm. 
 
Presenting Rhythm Stratum Weight 
Sham Device 
Probability of 
Survival to 
Discharge 
ITD / Sham 
Relative 
Benefit 
ITD Probability 
of Survival to 
Discharge 
Asystole 0.5231 0.0105 1.40 0.0147 
PEA 0.2616 0.0420 1.40 0.0588 
VT/VF 0.2153 0.2020 1.20 0.2424 
 
Probability of Survival to Discharge 
(weighted average) 
 0.0600  0.0753 
 
Probability of Neurologically Intact 
Survival to Discharge 
(88.9% of patients surviving to 
hospital discharge) 
 0.0533  0.0669 
 
The number of patients to be accrued to the ITD vs. sham device comparison is 
based on the ability of a one-sided level 0.025 test to reject a null hypothesis that the 
probability of neurologically intact survival to hospital discharge is 0.0533 on both 
treatment arms. Sample size computations are based on a two-sample test of binomial 
proportions using Pearson’s chi squared statistic. The test should have approximately 
90% statistical power to reject the null hypothesis when the ITD treatment arm would 
have a 0.0669 probability of neurologically intact survival.” 
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Rationale: To explicitly note the impact on the sample size calculations of the decision by the 
Seattle Medic One agency to participate only in the ITD/sham device intervention and not the 
Analyze Later/Analyze Early intervention. A slight change in weighting of the strata resulted in a 
change in the third significant digit for the hypothesized response probabilities. 
 
18. Section 2 – Impedance Threshold Device Trial-Analyses-Sample Size and Study 
Duration (pg. 22): 
Change:  
 “The 11 participating ROC sites are estimated to have approximately 10,000 OOHCA 
treatable by EMS each year, so it is estimated that accrual of 15,742 patients (up to 
1,000 during the run-in phase, 14,742 during the actual trial) will require 18 months.” 
to  
“The 11 participating ROC sites are estimated to have approximately 10,000 OOHCA 
treatable by EMS each year, so it is estimated that accrual of 16,542 patients (up to 
1,800 during the run-in phase, 14,742 during the actual trial) will require 20 months.” 
 
Rationale: To correct the protocol to reflect the 1,800 run-in patients approved by the FDA. 
 
19. Section 2 – Impedance Threshold Device Trial-Human Subjects-Risk to 
Subjects-Population (pg. 23): 
Change:  
 “study will enroll approximately 15,742 adult patients” 
to  
“study will enroll approximately 16,542 adult patients” 
 
Rationale: To correct the protocol to reflect the 1,800 run-in patients approved by the FDA. 
 
20. Section 3 – Analyze Later versus Analyze Early-Study Summary-Setting (pg. 
25): 
Change:  
 “EMS systems participating in the Resuscitation Outcomes Consortium.” 
to  
“EMS systems participating in the Resuscitation Outcomes Consortium and agreeing to 
cluster randomization to the Analyze Later/Analyze Early intervention in a crossover 
fashion.” 
 
Rationale: To explicitly note the decision by the Seattle Medic One agency to participate only in 
the ITD/sham device intervention and not the Analyze Later/Analyze Early intervention. 
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21. Section 3 – Analyze Later versus Analyze Early-Study Summary-Sample Size 
(pg. 25): 
Change:  
 “Based on a two-sided significance level of 0.05, p=0.99, a survival to discharge with 
modified Rankin score < 3 rate of 5.41% after Analyze Early, and two interim analyses, a 
maximum of 13,560 evaluable patients are needed to detect a 7.45% absolute survival 
to discharge with modified Rankin score < 3 after Analyze Later.” 
to  
“Based on a two-sided significance level of 0.05, a maximum of 13,239 evaluable 
patients will allow statistical power of 0.996 to detect an improvement in the probability of  
survival to discharge with modified Rankin score < 3 rate from 5.41% after Analyze Early 
to 7.45% after Analyze Later.” 
 
Rationale: To explicitly note the impact on the ALvE sample size of the decision by the Seattle 
Medic One agency to participate only in the ITD/sham device intervention and not the Analyze 
Later/Analyze Early intervention. The projected net loss of 321 evaluable subjects in the ALvE 
comparison had negligible impact on the statistical power (now reported to 3 significant digits). 
 
22. Section 3 – Analyze Later versus Analyze Early-Specific Aims-Prespecified 
Subgroup Analyses (pg. 25): 
Change:  
“Response time from 911 call to arrival at patient’s side <4 minutes and > 4 minutes.” 
to  
“Response time from 911 call to initiation of EMS CPR <4 minutes and > 4 minutes.” 
 
Rationale: EMS agencies routinely obtain the time of initiation of EMS CPR whereas few 
agencies collect the time of arrival at patient’s side. 
 
23. Section 3 – Analyze Later versus Analyze Early-Research Design and Methods-
Study Design Overview (pg. 29): 
Change:  
“…within the Resuscitation Outcomes Consortium.  Outcomes will be assessed in the 
field and at the receiving hospitals.” 
to  
“… within the Resuscitation Outcomes Consortium and served by an EMS agency 
participating in the Analyze Later/Analyze Early intervention (the Seattle Medic One 
EMS agency is participating only in the ITD/sham device intervention of the partial 
factorial ROC PRIMED study).  Outcomes will be assessed in the field and at the 
receiving hospitals.” 
 
Rationale: To explicitly note the decision by the Seattle Medic One agency to participate only in 
the ITD/sham device intervention and not the Analyze Later/Analyze Early intervention. 
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24. Section 3 – Analyze Later versus Analyze Early-Research Design and Methods-
Study Population-Exclusion Criteria (pg. 29): 
Change:  
“Non-ROC EMS agency/provider 
to  
“Non-ROC EMS agency/provider on scene and CPR begun or pads placed.” 
 
Rationale: We need to exclude patients who have already received CPR or rhythm analysis by 
EMS prior to arrival of participating ROC EMS providers from our assessment of whether early 
rhythm analysis or late analysis (i.e. CPR before rhythm analysis) by EMS is effective. Failure to 
exclude patients with such concurrent intervention would attenuate any possible treatment effect. 
 
25.  Section 3-Analyze Later versus Analyze Early- Primary Comparison 
Populations-Safety Population (pg. 30): 
Add: 
“This will include patients who were defibrillated by ROC EMS providers but did not 
receive CPR from ROC EMS providers.” 
 
Rationale: We need to include all patients who received the study intervention in our assessment 
of its safety. 
 
26. Section 3 – Impedance Threshold Device Trial-Analyses Methods-Sample Size 
and Study Duration (pg. 36): 
Change:  
Table 6: Proportion of all EMS treated OOHCA patients randomized to treatment combinations 
according to presenting rhythm and EMS Witness status 
EMS Witnessed CA 
(AL vs. AE Ineligible) Analyze Early Analyze Late 
Total  
AE vs AL 
Randomized Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD AE AL 
Asystole 0.000 0.012 0.012 0.000 0.119 0.119 0.119 0.119 0.250 0.250 
PEA 0.000 0.014 0.014 0.000 0.056 0.056 0.056 0.056 0.125 0.125 
VT/VF 0.015 0.017 0.017 0.030 0.035 0.035 0.050 0.050 0.103 0.103 
TOTAL 0.015 0.043 0.043 0.030 0.210 0.210 0.225 0.225 0.478 0.478 
to  
Table 6: Proportion of all EMS treated OOHCA patients randomized to treatment combinations 
according to presenting rhythm and EMS Witness status 
EMS Witnessed CA or 
Seattle Medic One 
(AL vs. AE Ineligible) 
Analyze Early Analyze Late 
Total  
AE vs AL 
Randomized Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD AE AL 
Asystole 0.000 0.018 0.018 0.000 0.116 0.116 0.116 0.116 0.232 0.232 
PEA 0.000 0.017 0.017 0.000 0.054 0.054 0.054 0.054 0.109 0.109 
VT/VF 0.015 0.020 0.020 0.029 0.034 0.034 0.049 0.049 0.097 0.097 
TOTAL 0.015 0.055 0.055 0.029 0.204 0.204 0.219 0.219 0.438 0.438 
 
Rationale: To explicitly note the impact on the sample size calculations of the decision by the 
Seattle Medic One agency to participate only in the ITD/sham device intervention and not the 
Analyze Later/Analyze Early intervention. Note: In the previous protocol there had been an error 
in the proportions given in Table 6 for the total randomized. This error has also been corrected in 
this amendment. 
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27. Section 3 – Analyze Later versus Analyze Early-Analyses Methods-Sample Size 
and Study Duration (pg. 37): 
Change:  
 “In the process of accruing 14,154 evaluable patients to the ITD/sham device 
intervention, it is estimated that approximately 15,436 patients with OOHCA will be 
treated by EMS at one of the participating ROC sites, with approximately 13,893 of these 
patients (90%)  not having EMS witnessed arrest and therefore receiving Analyze Late 
or Analyze Early. Estimating that 98% of these patients will be judged evaluable, 13,560 
patients will be used for the comparison of Analyze Late versus Analyze Early strategies. 
We therefore consider the ability of a two-sided level 0.05 test with 13,560 subjects…” 
to  
“In the process of accruing 14,154 evaluable patients to the ITD/sham device 
intervention, it is estimated that approximately 15,423 patients with OOHCA will be 
treated by EMS at one of the participating ROC sites, with approximately 13,509 of these 
patients eligible to participate in the Analyze Late or Analyze Early interventions. 
Estimating that 98% of these patients will be judged evaluable, 13,239 patients will be 
used for the comparison of Analyze Late versus Analyze Early strategies. We therefore 
consider the ability of a two-sided level 0.05 test with 13,239 subjects…” 
 
Rationale: To explicitly note the impact on the sample size calculations of the decision by the 
Seattle Medic One agency to participate only in the ITD/sham device intervention and not the 
Analyze Later/Analyze Early intervention. This decreases the number of evaluable patients by 
321. 
 
28. Section 3 – Analyze Later versus Analyze Early-Analyses Methods-Sample Size 
and Study Duration (pg. 37): 
Change:  
 “Using that stopping rule, a sample size of 13,560 evaluable patients will provide 
approximately 99% power to reject the null hypothesis under the conjectured treatment 
effect.  
The 11 participating ROC sites are estimated to have approximately 10,000 
OOHCA treatable by EMS each year, so it is estimated that accrual of 13,560 evaluable 
patients for the Analyze Late versus Analyze Early comparison will require 16-18 
months.” 
to  
“Using that stopping rule, a sample size of 13,239 evaluable patients will provide 
approximately 99.6% power to reject the null hypothesis under the conjectured treatment 
effect.  
The 11 participating ROC sites are estimated to have approximately 10,000 
OOHCA treatable by EMS each year, so it is estimated that accrual of 13,239 evaluable 
patients for the Analyze Late versus Analyze Early comparison will require 20 months.” 
 
Rationale: To explicitly note the impact on the sample size calculations of the decision by the 
Seattle Medic One agency to participate only in the ITD/sham device intervention and not the 
Analyze Later/Analyze Early intervention. 
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29. Section 3 – Analyze Later versus Analyze Early-Analyses Methods-Effect of 
Clustering and Crossover on Required Sample Size (pg. 38, Table 8): 
Change:  
 
Seattle/King Co 1,763,000 888 agency, geographic 23 
…     
Totals 20,537,108 12,437  1441 
 
to  
Seattle/King Co 1,191,204 555 agency, geographic 31 
…     
Totals 19,965,312 12,104  1449 
 
Rationale: To explicitly note the impact on the sample size calculations of the decision by the 
Seattle Medic One agency to participate only in the ITD/sham device intervention and not the 
Analyze Later/Analyze Early intervention, as well as to update the clustering plan for King 
County. Seattle Medic One is projected to provide 333 or the 888 OOHCA treated annually in 
Seattle/King County. 
 
30. Section 4 – Factorial Implementation of Both Protocols-Study Population (pg. 
40): 
Change:  
Common Exclusion Criteria 
– Do not attempt resuscitation (DNAR) orders; 
– Blunt, penetrating, or burn-related injury; 
– Patients with exsanguinations; 
– Known prisoners; 
– Known pregnancy. 
– Non-ROC EMS agency/provider 
 
ITD Exclusion Criteria 
– Tracheostomy present; 
– CPR performed with the mechanical compression “Autopulse” device; 
 
Analyze Later Exclusion Criteria 
– EMS witnessed arrests; 
– Non-EMS rhythm analysis (AED placed by police or lay responder); 
 
to  
Common Exclusion Criteria 
– Do not attempt resuscitation (DNAR) orders; 
– Blunt, penetrating, or burn-related injury; 
– Patients with exsanguinations; 
– Known prisoners; 
– Known pregnancy. 
 
ITD Exclusion Criteria 
– Tracheostomy present; 
– CPR performed with any mechanical compression device (e.g. AutoPulse, 
Thumper, ACD-CPR). 
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– Ventilated with a mechanical device (e.g. automated transport ventilator).  
Note: a bag-mask is not considered a mechanical ventilator device. 
– A non-ROC EMS agency/provider, for whom time call received at dispatch 
cannot be obtained, began CPR or placed pads. 
 
Analyze Later Exclusion Criteria 
– EMS witnessed arrests; 
– Non-EMS rhythm analysis (AED placed by police or lay responder); 
– Non-ROC EMS agency/provider on scene and began CPR or placed pads. 
 
Rationale: Criteria for exclusion of patients treated by non-ROC EMS agency/provider 
differ slightly between factors. Also to reflect changes to exclusion criteria related to 
mechanical compression devices and mechanical ventilation devices. 
. 
31. Appendix 8 – Interim Monitoring Plan – Impedance Threshold Device Factor: 
Change: 
itdDesign <- seqDesign( 
 prob.model = "proportions",  
 arms = 2,  
 test.type = "greater", 
 nbr.analyses = 3,  
 alpha = c(0.1, 0.025), beta = c(0.975, 0.9),  
 P = c(1.2, 0.8), R= c(0,0), A= c(0,0), 
 null.hypothesis = 0.0532, alt.hypothesis = 0.0668, 
 variance = “alternative”, 
 sample.size=14154, 
 power= “calculate”) 
to  
itdDesign <- seqDesign( 
 prob.model = "proportions",  
 arms = 2,  
 test.type = "greater", 
 nbr.analyses = 3,  
 alpha = c(0.1, 0.025), beta = c(0.975, 0.9),  
 P = c(1.2, 0.8), R= c(0,0), A= c(0,0), 
 null.hypothesis = 0.0533, alt.hypothesis = 0.0669, 
 variance = “alternative”, 
 sample.size=14154, 
 power= “calculate”) 
 
Rationale: To update code for stopping rule to reflect changes due to Seattle Medic One’s 
participation in only the ITD/sham device comparison. The consequent slight change in 
weighting of the strata resulted in a change in the third significant digit for the hypothesized 
response probabilities. 
. 
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32. Appendix 8 – Interim Monitoring Plan – Impedance Threshold Device Factor: 
Change: 
“…rate of 5.32% on the sham device arm, a sample size of 14,154 evaluable patients 
(7,077 patients on each of the sham device and ITD treatment arms) will provide 
approximately 90% power to detect an improvement to a 6.68% rate of neurologically 
intact survival on the active ITD treatment arm (corresponding to a relative improvement 
of 25.0% in neurologically intact survival…” 
to  
“…rate of 5.33% on the sham device arm, a sample size of 14,154 evaluable patients 
(7,077 patients on each of the sham device and ITD treatment arms) will provide 
approximately 90% power to detect an improvement to a 6.69% rate of neurologically 
intact survival on the active ITD treatment arm (corresponding to a relative improvement 
of 25.5% in neurologically intact survival…” 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison. A slight change in weighting of the strata resulted in a change in the third 
significant digit for the hypothesized response probabilities. Similar changes from 5.32% to 
5.33% and from 6.68% to 6.69% were made throughout this section of the Appendix 8. These 
changes had no impact on the tables of statistical power or statistical inference. 
. 
33. Appendix 8 – Interim Monitoring Plan – Analyze Early versus Analyze Late 
Factor: 
Change: 
alveDesign <- seqDesign( 
 prob.model = "proportions",  
 arms = 2,  
 test.type = "two.sided", early.stopping=”alternative”, 
 nbr.analyses = 3,  
 size = 0.05,  
 P = 1, R= 0, A= 0, 
 null.hypothesis = 0.0541,  alt.hypothesis = 0.0745, 
 variance = “alternative”, 
 sample.size= c(1,3,6)/6*13560*0.95, 
 power= “calculate”) 
to  
alveDesign <- seqDesign( 
 prob.model = "proportions",  
 arms = 2,  
 test.type = "two.sided", early.stopping=”alternative”, 
 nbr.analyses = 3,  
 size = 0.05,  
 P = 1, R= 0, A= 0, 
 null.hypothesis = 0.0541,  alt.hypothesis = 0.0745, 
 variance = “alternative”, 
 sample.size= c(1,3,6)/6*13239*0.95, 
 power= “calculate”) 
 
Rationale: To update code for stopping rule to reflect changes due to Seattle Medic One’s 
participation in only the ITD/sham device comparison. This change resulted in a projected net 
decrease of 321 evaluable patients in the ALvE comparison. 
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. 
34. Appendix 8 – Interim Monitoring Plan – Analyze Early versus Analyze Late 
Factor: 
Change: 
“…rate of 5.41% on the Analyze Early arm, a sample size of 13,560 evaluable patients 
(6,780 patients on each of the Analyze Late and Analyze Early treatment arms) will 
provide approximately 99.7% power to detect an improvement to a 7.45% rate of 
neurologically intact survival on the Analyze Late treatment arm (corresponding to a 
relative improvement of 25.0% in neurologically intact survival to discharge). A more …” 
to  
“…rate of 5.41% on the Analyze Early arm, a sample size of 13,239 evaluable patients 
(6,620 patients on each of the Analyze Late and Analyze Early treatment arms) will 
provide approximately 99.6% power to detect an improvement to a 7.45% rate of 
neurologically intact survival on the Analyze Late treatment arm (corresponding to a 
relative improvement of 37.7% in neurologically intact survival to discharge). A more …” 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison, as well as to correct one typographical error in the original protocol. This 
change resulted in a projected net decrease of 321 evaluable patients in the ALvE comparison, but 
had only negligible effects on the statistical power or precision of inference. 
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35. Appendix 8 – Interim Monitoring Plan – Analyze Early versus Analyze Late 
Factor: 
Change: 
 
Table 4: Alternatives for which a sample size of 13,560 subjects provides the specified power as a 
function of Analyze Early arm rates of neurologically intact (MRS ≤ 3) survival to hospital discharge 
 
0.0475 AE Neuro Intact Surv 
to Hosp Discharge 
0.0541 AE Neuro Intact Surv 
to Hosp Discharge 
0.0606 AE Neuro Intact Surv 
to Hosp Discharge 
 
 
Power 
AL 
Neur 
Intact 
Surv to 
Hosp 
D/C 
 
Abs 
Diff 
 
Rel Diff 
AL 
Neuro 
Intact 
Surv to 
Hosp 
D/C 
AL 
Neur 
Intact 
Surv to 
Hosp 
D/C 
 
Abs 
Diff 
 
Rel Diff 
 
Abs 
Diff 
AL 
Neur 
Intact 
Surv to 
Hosp 
D/C 
80% .0584 .0109 22.9% 80% .0584 .0109 22.9% 80% .0584 
90% .0602 .0127 26.7% 90% .0602 .0127 26.7% 90% .0602 
95% .0617 .0142 29.9% 95% .0617 .0142 29.9% 95% .0617 
97.5% .0631 .0156 32.7% 97.5% .0631 .0156 32.7% 97.5% .0631 
99% .0646 .0171 36.1% 99% .0646 .0171 36.1% 99% .0646 
 
to  
 
Table 4: Alternatives for which a sample size of 13,239 subjects provides the specified power as a 
function of Analyze Early arm rates of neurologically intact (MRS ≤ 3) survival to hospital discharge 
 
0.0475 AE Neuro Intact Surv 
to Hosp Discharge 
0.0541 AE Neuro Intact Surv 
to Hosp Discharge 
0.0606 AE Neuro Intact Surv 
to Hosp Discharge 
 
 
Power 
AL 
Neur 
Intact 
Surv to 
Hosp 
D/C 
 
Abs 
Diff 
 
Rel Diff 
AL 
Neuro 
Intact 
Surv to 
Hosp 
D/C 
 
Abs 
Diff 
 
Rel Diff 
AL 
Neuro 
Intact 
Surv to 
Hosp 
D/C 
 
Abs 
Diff 
 
Rel Diff 
80% .0584 .0109 22.9% .0656 .0115 21.3% .0727 .0121 20.0% 
90% .0602 .0127 26.7% .0675 .0134 24.9% .0747 .0141 23.3% 
95% .0617 .0142 29.9% .0691 .0150 27.8% .0764 .0158 26.1% 
97.5% .0631 .0156 32.7% .0706 .0165 30.4% .0779 .0173 28.5% 
99% .0646 .0171 36.1% .0722 .0181 33.5% .0796 .0190 31.4% 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison. Note that this table had multiple formatting errors in the original protocol. 
These have been corrected as well. This change resulted in a projected net decrease of 321 
evaluable patients in the ALvE comparison, but had only negligible effects on the statistical 
power or precision of inference. 
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36. Appendix 8 – Interim Monitoring Plan – Analyze Early versus Analyze Late 
Factor: 
Change: 
 
“Table 5: Stopping boundaries for a level α=.05 two-sided group sequential design in the unified 
family (Kittelson and Emerson 1999) to detect a two-sided alternative, early stopping only to declare 
superiority or inferiority of the AL strategy, boundary shape parameters corresponding to O’Brien-
Fleming boundaries, three analyses after accrual of 33%, 67%, and 100% of the maximal sample size 
of 13,560 evaluable subjects, and a rate of neurologically intact survival to hospital discharge of 
approximately 0.0643 on both treatment arms combined (e.g., 0.0541 on the Analyze Early arm and 
0.0745 on the Analyze Late arm) 
 
Inferiority (lower) stopping 
boundary 
Superiority (upper) stopping 
boundary  
 
Analysis 
Sample 
Size 
 
Prop of 
Max Stat 
Info Abs Diff 
 
Z 
statistic 
Fixed P 
(lower) 
 
Abs Diff 
 
Z 
statistic 
Fixed P 
(lower) 
1 4520 0.17 -.0512 -4.844 1.0000 .0512 4.844 .0000 
2 9040 0.50 -.0171 -2.797 .9974 .0171 2.797 .0026 
3 13560 1.00 -.0085 -1.977 .9760 .0085 1.977 .0240 
 
 
Thus, according to the above table, if the rate of neurologically intact survival to hospital 
discharge on the combined treatment arms is 6.43%, an absolute difference of 5.12% or 
more (e.g., 3.87% on the AE arm and 8.99% on the AL arm) when 4,520 evaluable 
subjects have been accrued to the study (2,260 subjects on each arm), the stopping rule 
would suggest that the study be terminated early with a decision that treatment with the 
Analyze Late strategy results in a statistically significant improvement in neurologically 
intact survival to hospital discharge. On the other hand, if at that first analysis the results 
were reversed (e.g., 8.99% on the AE arm and 3.87% on the AL arm), the stopping…” 
 
 to  
 
“Table 5: Stopping boundaries for a level α=.05 two-sided group sequential design in the unified 
family (Kittelson and Emerson 1999) to detect a two-sided alternative, early stopping only to declare 
superiority or inferiority of the AL strategy, boundary shape parameters corresponding to O’Brien-
Fleming boundaries, three analyses after accrual of 33%, 67%, and 100% of the maximal sample size 
of 13,239 evaluable subjects, and a rate of neurologically intact survival to hospital discharge of 
approximately 0.0643 on both treatment arms combined (e.g., 0.0541 on the Analyze Early arm and 
0.0745 on the Analyze Late arm) 
 
Inferiority (lower) stopping 
boundary 
Superiority (upper) stopping 
boundary  
 
Analysis 
Sample 
Size 
 
Prop of 
Max Stat 
Info Abs Diff 
 
Z 
statistic 
Fixed P 
(lower) 
 
Abs Diff 
 
Z 
statistic 
Fixed P 
(lower) 
1 4413 0.17 -.0519 -4.844 1.0000 .0519 4.844 .0000 
2 8826 0.50 -.0173 -2.797 .9974 .0173 2.797 .0026 
3 13236 1.00 -.0086 -1.977 .9760 .0086 1.977 .0240 
 
 
Thus, according to the above table, if the rate of neurologically intact survival to hospital 
discharge on the combined treatment arms is 6.43%, an absolute difference of 5.19% or 
more (e.g., 3.84% on the AE arm and 9.03% on the AL arm) when 4,413 evaluable 
subjects have been accrued to the study (2,206 subjects on each arm), the stopping rule 
would suggest that the study be terminated early with a decision that treatment with the 
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Analyze Late strategy results in a statistically significant improvement in neurologically 
intact survival to hospital discharge. On the other hand, if at that first analysis the results 
were reversed (e.g., 9.03% on the AE arm and 3.84% on the AL arm), the stopping…” 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison. This change resulted in a projected net decrease of 321 evaluable patients in 
the ALvE comparison, but had only negligible effects on the statistical power or precision of 
inference. 
 
37. Appendix 8 – Interim Monitoring Plan – Analyze Early versus Analyze Late 
Factor: 
Change: 
 
Table 6: Statistical inference regarding the effect of the Analyze Late strategy on rates of 
neurologically intact survival to hospital discharge (measured as the absolute difference in favorable 
outcome rates between the AL and AE arms) which would be reported if observed results 
corresponded exactly to the stopping boundaries for a level 0.05 two-sided group sequential design 
as presented in Table 5 
 
AL Inferiority (lower) stopping boundary AL Superiority  (upper) stopping boundary 
 
 
Analysis 
 
Proportion of 
Maximal 
Statistical 
Information 
Adjusted 
estimate 
Exact 
95% conf intvl 
Adjusted 
Two-sided
P value 
Adjusted 
estimate 
Exact 
95% conf intvl 
Adjusted 
Two-sided
P value  
1 0.17 -4.85% (-6.19%,-3.05%) 0.000 4.85% (3.05%,6.19%) 0.000 
2 0.50 -1.59% (-2.47%,-0.50%) 0.003 1.59% (0.50%,2.47%) 0.003 
3 1.00 -0.81% (-1.70%,0.00%) 0.025 0.81% (0.00%,1.70%) 0.025 
 
to  
 
Table 6: Statistical inference regarding the effect of the Analyze Late strategy on rates of 
neurologically intact survival to hospital discharge (measured as the absolute difference in favorable 
outcome rates between the AL and AE arms) which would be reported if observed results 
corresponded exactly to the stopping boundaries for a level 0.05 two-sided group sequential design 
as presented in Table 5 
 
AL Inferiority (lower) stopping boundary AL Superiority  (upper) stopping boundary 
 
 
Analysis 
 
Proportion of 
Maximal 
Statistical 
Information 
Adjusted 
estimate 
Exact 
95% conf intvl 
Adjusted 
Two-sided
P value 
Adjusted 
estimate 
Exact 
95% conf intvl 
Adjusted 
Two-sided
P value  
1 0.17 -4.91% (-6.26%,-3.08%) 0.000 4.91% (3.08%,6.26%) 0.000 
2 0.50 -1.61% (-2.50%,-0.51%) 0.003 1.61% (0.51%,2.50%) 0.003 
3 1.00 -0.82% (-1.72%,0.00%) 0.025 0.82% (0.00%,1.72%) 0.025 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison. This change resulted in a projected net decrease of 321 evaluable patients in 
the ALvE comparison, but had only negligible effects on the statistical power or precision of 
inference. 
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38. Appendix 9 – Interaction and Extension Monitoring Plan: 
Change: 
“14,154 evaluable patients for the comparison of the ITD to the sham device and 13,560 
evaluable patients for the comparison of the Analyze Late to the Analyze Early strategy. 
The following table details regarding the distribution of those 15,436 patients according 
to presenting rhythm and randomized treatment group. 
 
Table 1: Estimated distribution of 15,436 potentially eligible EMS treated OOHCA patients by 
presenting rhythm and randomization group. 
EMS Witnessed CA 
(AL vs AE Ineligible) Analyze Early Analyze Late Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD 
Asystole 0 179 179 0 1840 1840 1840 1840 
PEA 0 209 209 0 860 860 860 860 
VT/VF 231 269 269 463 541 541 772 772 
TOTAL 231 656 656 463 3241 3241 3473 3473 
 
to  
“14,154 evaluable patients for the comparison of the ITD to the sham device and 13,239 
evaluable patients for the comparison of the Analyze Late to the Analyze Early strategy. 
The following table details regarding the distribution of those 15,436 patients according 
to presenting rhythm and randomized treatment group. 
 
Table 1: Estimated distribution of 15,436 potentially eligible EMS treated OOHCA patients by 
presenting rhythm and randomization group. 
EMS Witnessed CA 
(AL vs AE Ineligible) Analyze Early Analyze Late Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD 
Asystole 0 277 277 0 1789 1789 1789 1789 
PEA 0 254 254 0 837 837 837 837 
VT/VF 231 310 310 451 526 526 751 751 
TOTAL 231 842 842 451 3152 3152 3377 3377 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison. This change resulted in a projected net decrease of 321 evaluable patients in 
the ALvE comparison. 
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39. Appendix 9 – Interaction and Extension Monitoring Plan: 
Change: 
 
Table 3: Estimated maximal sample size of 13,286 evaluable patients available for safety analyses 
related to treatment combinations. 
Analyze Early Analyze Late 
Initial Rhythm No 
Device Sham ITD Sham ITD 
Asystole 0 1767 1767 1767 1767 
PEA 0 826 826 826 826 
VT/VF 445 519 519 742 742 
TOTAL 445 3112 3112 3335 3335 
 
to  
 
Table 3: Estimated maximal sample size of 12,970 evaluable patients available for safety analyses 
related to treatment combinations. 
Analyze Early Analyze Late 
Initial Rhythm No 
Device Sham ITD Sham ITD 
Asystole 0 1718 1718 1718 1718 
PEA 0 803 803 803 803 
VT/VF 433 505 505 721 721 
TOTAL 433 3026 3026 3243 3243 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison. This change resulted in a projected net decrease of 316 evaluable patients in 
analyses related to interactions. 
 
40. Appendix 9 – Interaction and Extension Monitoring Plan: 
Change: 
 
“…intervals for the difference in the proportion with favorable response between any two 
treatment combinations will be approximately ±0.047, ±0.023, and ±0.012. Issues …” 
to  
 
“…intervals for the difference in the proportion with favorable response between any two 
treatment combinations will be approximately ±0.047, ±0.024, and ±0.012. Issues …” 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison. This change resulted in a projected net decrease of 316 evaluable patients in 
analyses related to interactions, but had only negligible effects on the statistical power or 
precision of inference. 
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41. Appendix 9 – Interaction and Extension Monitoring Plan: 
Change: 
 
“…the estimated precision of the repeated confidence intervals for the difference in the 
ITD treatment effect in the Analyze Late stratum and the ITD treatment effect in the 
Analyze Early stratum will be approximately ±0.066, ±0.033, and ±0.016 …” 
to  
 
“…the estimated precision of the repeated confidence intervals for the difference in the 
ITD treatment effect in the Analyze Late stratum and the ITD treatment effect in the 
Analyze Early stratum will be approximately ±0.067, ±0.034, and ±0.017 …” 
 
Rationale: To reflect changes due to Seattle Medic One’s participation in only the ITD/sham 
device comparison. This change resulted in a projected net decrease of 316 evaluable patients in 
analyses related to interactions, but had only negligible effects on the statistical power or 
precision of inference. 
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1. Factorial Study Summary 
 
Background 
 Little is known about how to optimize resuscitation for patients with out-of-
hospital cardiac arrest.  This is evident from the very low survival rates that are currently 
reported.  The advent of automatic external defibrillators (AEDs) and their potential for 
wide-spread use by less highly trained emergency medical service (EMS) providers and 
lay persons has not resulted in the substantial increased survival rates anticipated.  This 
has led to speculation that more and sooner circulation of oxygenated blood to the brain 
and heart may be important.  Resuscitation Outcomes Consortium (ROC) Investigators 
propose a large clinical trial, using a partial factorial design, to test two strategies to 
increase blood flow.  One strategy involves the impedance threshold device (ITD), which 
enhances venous return and cardiac output by increasing the degree of negative 
intrathoracic pressure during decompression.  The second involves initiating 
resuscitation with a period of manual compressions and ventilations (Analyze Later), 
rather than attempting defibrillation immediately (Analyze Early). 
 
Rationale 
The rationale for the partial factorial design is based on several arguments. 
• Most importantly, both interventions are worthy of study in their own right.  Both 
interventions were proposed by several of the participating ROC sites in their 
initial applications. 
• A number of ROC EMS agencies currently use cardiopulmonary resuscitation 
(CPR) first (i.e., Analyze Later) as their standard protocol, whereas others 
analyze the rhythm and shock as required before initiating CPR (i.e. Analyze 
Early.)  Thus, if the ITD intervention were to be studied alone, we would be faced 
with an uncontrolled heterogeneity of practice, possibly changing during the 
course of the trial.  This would necessitate, at a minimum, stratifying by the EMS 
protocol. 
• We anticipate no substantial interactive effect between these two interventions.  
One relates to when assisted circulation takes place, compared with when the 
defibrillatory attempt takes place.  The other has to do with the quantity of flow 
during assisted circulation.  Both include some blood flow prior to any 
defibrillation attempt. 
• The infrastructures to conduct the two trials are virtually identical, thus assuring 
substantial efficiencies in costs, and virtually cutting in half the number of patients 
and the time needed to study the two interventions sequentially, providing there 
are no interactions between the interventions. 
• A partial factorial design, as opposed to a full factorial design, is necessary 
because eligibility criteria for the two interventions are not identical. Current 
medical standards would dictate that the Analyze Later strategy is inappropriate 
for patients whose cardiac arrest was witnessed by EMS, but some such patients 
might have an ITD or sham device applied during their resuscitation. Similarly, 
some patients on either the Analyze Later or Analyze Early arm might achieve 
resumption of spontaneous circulation (ROSC) prior to the application of the ITD 
or sham device. Further, because a greater sample size is required to achieve 
the desired statistical power to detect the anticipated effect of the ITD than that 
required to detect the effect of the Analyze Later strategy, the ROC investigators 
have allowed for the inclusion of one agency (Seattle Medic One) that would 
participate only in the ITD/sham comparison and not the Analyze Later vs 
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Analyze Early comparison. We anticipate that of all cardiac arrests treated by 
participating ROC agencies during the course of the study, approximately 85% 
will be judged evaluable for both the ITD/sham and Analyze Later/Analyze Early 
comparisons.   
 
Challenges 
The partial factorial design poses three challenges: 
• Implementation of two interventions may be difficult for the persons who must 
conduct these interventions; the emergency medical technicians and 
paramedics, who must perform their efforts under the duress of life-threatening 
emergent conditions.  This potential challenge has been mitigated by adopting 
cluster randomization for the Analyze Later protocol, whereby each cluster will 
be randomized to either always doing CPR first (Analyze Later) or always doing 
rhythm analysis first (Analyze Early).  These clusters will consist of geographic 
areas or monitor/defibrillators within the EMS agencies. EMS personnel will 
place an active or sham ITD on all patients meeting criteria.  Hence, EMS 
providers will always follow the same procedures:  a) place an active or sham 
ITD on all patients, and b) analyze the rhythm either early or later consistently 
according to cluster randomization.  No on-the-spot decisions regarding 
randomization will be required for use of either intervention. 
• The cluster randomization will require that all out-of-hospital cardiac arrest 
events be accounted for.  This requirement is actually beneficial, in that it 
provides additional motivation for the implementation of a comprehensive 
epidemiologic database of all life-threatening out-of-hospital events (what we 
have termed the ROC Registry).  Whether the trial benefits from the Registry or 
the Registry benefits from the trial is unclear at this point and will depend in part 
upon the timing of various funding mechanisms. 
• When a factorial design is used, there is an almost irresistible temptation to test 
for an interactive effect (i.e., risk difference for one factor depends on the level 
of the other factor).  While a factorial design is the only reasonably efficient way 
of testing for an interaction between several interventions, to power the trial for 
the specific interaction effect generally requires a substantially increased sample 
size.  As noted previously, we do not anticipate any substantial interaction 
between these two therapies.  Nonetheless, potential interactions will be 
assessed by the DSMB at interim analyses and the sample size adjusted 
accordingly.   
 
Potential Advantage 
 It should be noted that the intervention of Analyze Later probably cannot be 
appropriately compared by randomizing individual episodes.  The issues with 
compliance caused by the confusion of having an EMS provider alternate between the 
basic concept of aggressively doing CPR initially versus assiduously assessing rhythm 
and defibrillating initially can be easily appreciated.  The choice of the cluster will vary 
depending upon the realities of training and the fluidity of personnel within an agency.  
All clusters will be encouraged, and large clusters will be required, to switch from 
Analyze Later to Analyze Early or vice versa at midpoint, or more often through the trial, 
thus serving as their own control. 
 
Outcomes 
 The trials share a common primary outcome, namely survival to hospital 
discharge with modified Rankin score <3, and common secondary outcomes, namely 
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survival to discharge as well as functional status at discharge and at 1, 3 and 6 months 
after discharge as well as depression at 3 and 6 months. 
 
Design 
 The trial will be partial factorial with one intervention based on a double-blind 
randomization of individuals through the use of an active versus a sham ITD (identical to 
the user), and the other intervention based on non-blinded randomized clusters. 
 
Setting 
 The trial will be conducted in all EMS agencies participating in the Resuscitation 
Outcomes Consortium. 
 
Sample Size and Analysis 
 Since we are not testing for an interaction, sample size for each intervention will 
be based on the traditional significance levels of .05 for two-sided and .025 for one-sided 
and a power of 0.9.  Each will require approximately 16-18 months of enrollment.  The 
specific inclusion criteria, sample size, and analytic techniques are defined with each of 
the specific interventions. 
 
CPR Performance 
 Critical to understanding both interventions is the monitoring of CPR 
performance.  All sites will implement procedures to attempt to collect 100% of data 
sources needed to assess CPR performance.  Three performance measures will be 
abstracted:  the ventilation rate, the compression rate, and the CPR fraction as defined 
in Appendix 2.  It is known, based on the longstanding effort in Seattle, as well as more 
recent efforts in Chicago and Norway, that the data sources will be missing or 
incomplete in approximately 25% of episodes.  Details for the CPR performance 
monitoring are dealt with in Section 4, since the process is applicable to both 
interventions. 
 
Run-in Phase 
 After personnel have been trained in use of the ITD and the methods for 
Analyze Later vs. Analyze Early according to their cluster randomization, they will initiate 
a run-in phase.  Evidence of compliance with the protocol and completion and 
submission of the data will be required before the site can enroll in the active phase of 
the trial.   
 
Anticipated Clinical Impact 
If the ITD demonstrates the hypothesized improvement in survival, we estimate 
that the premature death of approximately 2,700 victims of cardiac arrest1 per year 
would be averted in North America compared to standard CPR.  If the Analyze Later 
approach demonstrates the hypothesized improvement in survival, we estimate 
approximately 4,000 lives will be saved per year in North America.  By implementing a 
factorial study design, these benefits to clinical practice can be achieved more efficiently 
and faster than otherwise would be the case. 
                                                 
1 Number of treatable cardiac arrests  X Proportion of cases with non VF initial rhythm or VF that 
does not respond to initial shock X Absolute difference in survival i.e. (US population 295,483,056 
X 0.53 per 1000 population (52)  + Canadian population 31,127,234 X 0.57 per 1000 population 
(53)) X Absolute difference 
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Remainder of This Protocol 
The remainder of this protocol is split into three parts. The second section contains the 
materials specific to the ITD intervention. The third section contains the materials 
specific to the Analyze Later intervention. The fourth section contains materials common 
to both interventions and/or specific to the partial factorial design of the study.
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2. Impedance Threshold Device Trial 
 
Comparison of Standard CPR Plus Active Impedance Threshold Device Versus Standard 
CPR Plus Sham Impedance Threshold Device In Patients With Out-Of-Hospital Cardiac 
Arrest 
 
Study Summary 
 
Background: Most patients with out-of-hospital cardiac arrest do not survive to hospital 
discharge. Survival after cardiac arrest is correlated with the time from its onset to the circulation 
of oxygenated blood to the brain and heart. Compression of the chest during cardiopulmonary 
resuscitation (CPR) increases intrathoracic pressure and compresses the heart. Decompression 
of the chest results in negative intrathoracic pressure, which enhances venous return and 
cardiac output. Collectively these actions circulate blood to the brain and heart. The impedance 
threshold device (ITD) is a novel respiratory device intended to increase the degree of negative 
intrathoracic pressure during decompression. Studies in animal models of cardiac arrest or 
small randomized trials in humans demonstrate that the ITD improves hemodynamics and 
short-term outcomes but it remains unclear whether ITD improves survival to discharge or 
neurological outcome. Therefore we propose a large clinical trial to test whether standard CPR 
supplemented by active ITD is effective compared to standard CPR supplemented by sham 
ITD.  
 
Aims: The primary aim of the trial is to compare survival to hospital discharge with modified 
Rankin score <3 between standard CPR plus active ITD versus standard CPR plus sham ITD in 
patients with out-of-hospital cardiac arrest. The secondary aims of the trial are to compare 
survival to discharge, functional status at discharge and at 1, 3 and 6 months as well as 
depression at 3 and 6 months. 
 
Hypotheses: The null hypothesis is that survival to hospital discharge with modified Rankin 
score <3 is identically distributed with use of standard CPR plus active ITD versus standard 
CPR plus sham ITD in patients with cardiac arrest. The secondary null hypotheses are that 
survival to discharge, functional status at discharge and at 1, 3 and 6 months after discharge as 
well as depression at 3 and 6 months will be identically distributed with use of standard CPR 
plus active ITD versus standard CPR plus sham ITD in patients with cardiac arrest. 
 
Design: Double-blind randomized controlled trial. 
 
Population: Patients with non-traumatic out-of-hospital cardiac arrest, presumed to be local 
age of consent or greater and treated by EMS providers. 
 
Setting: EMS systems participating in the Resuscitation Outcomes Consortium. 
 
Sample Size:  Based on a one-sided significance level of 0.025, power = 0.90, a survival with 
modified Rankin score < 3 to discharge rate of 5.33% with standard CPR and sham ITD, and 
two interim analyses, a maximum of 14,742 evaluable patients are needed to detect a 6.69% 
absolute survival with modified Rankin score < 3 to discharge with standard CPR and active 
ITD.  
 
Anticipated Clinical Impact: If this trial demonstrates a significant improvement in survival with 
use of the ITD, we estimate that the premature deaths of approximately 2,700 victims of cardiac 
arrest per year would be averted annually in North America alone. 
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Specific Aims 
 
Primary Aim:  The primary aim of the trial is to compare survival to hospital discharge with 
modified Rankin score <3 between standard CPR plus active ITD versus standard CPR plus 
sham ITD in patients with out-of-hospital cardiac arrest. 
 
Hypothesis:  The null hypothesis is that survival to hospital discharge with modified Rankin 
score <3 is identically distributed with use of standard CPR plus active ITD versus standard 
CPR plus sham ITD in patients with cardiac arrest. 
 
Secondary Aims: The secondary aims of this trial are to compare survival to discharge, 
functional status scores at discharge and at 1, 3 and 6 months as well as depression at 3 and 6 
months between standard CPR plus active ITD versus standard CPR plus sham ITD in patients 
with out-of-hospital cardiac arrest. 
 
Hypotheses:  The null hypotheses are that survival to discharge, functional status scores at 
discharge and at 1, 3 and 6 months as well as depression score at 3 and 6 months are 
identically distributed with use of standard CPR plus active ITD versus standard CPR plus sham 
ITD in patients with cardiac arrest. 
 
Prespecified Subgroup Analyses:  These include assessment of treatment effect by:  
a) First recorded cardiac arrest rhythm before application of the ITD. 
b) Observational status of an arrest (e.g., witnessed versus unwitnessed). 
c) EMS response time interval of <10 minutes and >10 minutes from 911 call to 
initiation of CPR by EMS. 
 
Background and Significance 
 
Conceptual Framework for ITD 
Despite the widespread availability of basic and advanced life support for patients with 
out-of-hospital cardiac arrest, few survive to hospital discharge.(1-3) In the most efficient EMS 
systems, less than 15% of all patients with out-of-hospital cardiac arrest are discharged from the 
hospital with intact neurological function.(1-3) Furthermore, the median published survival to 
hospital discharge after out-of-hospital cardiac arrest is only 6.4%.(4) 
While there are many variables that impact on the potential for a patient in cardiac arrest 
to survive, the timely circulation of oxygenated blood to the heart and brain is considered 
critical.(2)  An airway device such as a facemask or an endotracheal tube is commonly used to 
assist in oxygenating and ventilating the patient.  However, the inherent mechanical 
inefficiencies of standard CPR limit the ability to circulate blood by even the most highly skilled 
rescuers.(5) 
The purpose of CPR is to pump blood from the chest to the vital organs. Blood flow to 
the vital organs is highly dependent on the amount of blood return to the chest after each 
compression phase.(6, 7)  During standard CPR, chest compression results in an elevation of 
intrathoracic pressure and direct cardiac compression. Both of these mechanisms result in 
forward blood flow out of the chest to perfuse the brain and other vital organs. When the chest 
recoils, intrathoracic pressures decrease relative to extrathoracic pressures, enhancing venous 
return to the right heart. Blood flow back to the chest is highly dependent on the degree of chest 
wall recoil.(8) 
Blood flows through the coronary arteries predominantly during the chest decompression 
phase.  The pressure gradient generated between the aorta and the right atrium during the 
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decompression phase of CPR has been termed the coronary perfusion pressure.(9) The 
pressure gradient between the aorta and left ventricular cavity is also a fundamental 
determinant of blood flow to the heart during CPR. During standard CPR, the coronary perfusion 
pressures are only marginally adequate, resulting in inadequate venous return during the chest 
wall recoil phase.(10, 11) 
Since the description of standard CPR by Kouwenhoven and colleagues in 1960,(12) 
several new CPR techniques have been described. These include circumferential vest CPR,(13, 
14) interposed abdominal counterpulsation CPR, (15-19) and phased abdominal counter-
pulsation CPR.(20) These techniques are not widely applied as they have not been shown to 
significantly improve survival to discharge or other long-term outcomes compared with standard 
CPR in patients with out-of-hospital cardiac arrest. 
This trial is focused on evaluating the ITD (see Appendix 1 for detailed information 
regarding the ITD). This novel device is designed to increase the coronary perfusion pressure 
during the decompression phase of CPR, thereby enhancing delivery of oxygenated blood to 
the heart.  The concept of the ITD was discovered while evaluating the mechanism of another 
new method of CPR termed active compression decompression (ACD) CPR.(21) ACD CPR is 
performed with a hand-held suction device.  When measuring intrathoracic pressures in patients 
undergoing ACD CPR, investigators realized that if the endotracheal tube was transiently 
occluded during the active decompression phase, intrathoracic pressures became markedly 
more negative. This led to the concept of impeding inspiratory gas exchange during the chest 
wall decompression phase of CPR to create a greater pressure differential between the thorax 
and the rest of the body, thereby enhancing venous return to the heart. As such, the impedance 
valve harnesses the kinetic energy of the chest wall recoil, thereby augmenting the “bellows-
like” action of the chest with each compression-decompression cycle.(22) 
The ITD is based on the principle that this impedance leads to a greater negative 
intrathoracic pressure, creating a small vacuum within the thorax relative to the rest of the body, 
leading to increased venous blood return to the heart and increased cardiac output. This 
concept has been evaluated in animals undergoing standard CPR (22) or active compression 
decompression (ACD) CPR,(6) as well as in human patients with prolonged cardiac arrest 
undergoing standard manual CPR (23-25) and ACD CPR.(7) 
 
Preliminary Studies 
 Initial studies to test the impedance valve concept were performed in a pig model of 
cardiac arrest.(6) Two positive end expiratory valves (PEEP) were coupled together and placed 
in reverse in the respiratory circuit. These were designed to prevent respiratory gases from 
entering the lungs during the chest decompression phase of CPR. The pigs were ventilated by 
overcoming the 40 cm H20 resistance of the PEEP valves. After four minutes of cardiac arrest, 
the combination of this impedance valve combined with ACD CPR significantly improved vital 
organ blood flow compared with ACD CPR alone (p < 0.05).  Brain blood flow increased to 
greater than baseline values (normal = 0.35 ml/min/gm) (p <0.05) and blood flow to the heart 
increased to greater than 50% of baseline values (normal = 1.2ml/min/gm) (p <0.05).(6) This 
enhanced myocardial perfusion was associated with lower energy requirements to defibrillate 
the animals at the end of that study. Use of the active ITD resulted in a marked improvement in 
coronary perfusion pressures compared to sham valve.  These studies led to the development 
of the current ITD. 
The first controlled animal studies of the ITD with standard CPR utilized a four-minute 
period of cardiac arrest followed by standard CPR with an automated compression device.(22) 
Standard CPR was performed with and without the ITD in an alternating fashion. Each time the 
ITD was removed from the respiratory circuit, the coronary perfusion pressures and vital organ 
perfusion decreased; and each time the ITD was added back, perfusion pressures stabilized or 
increased.  A similar study evaluated active ITD versus sham ITD for 11 minutes after a six-
 10 
minute period of cardiac arrest without CPR.(5) A sham ITD was used in the control group and 
an active ITD in the other.  
After 6 minutes of cardiac arrest and 6 minutes of standard CPR, radiolabeled 
microspheres were injected to measure vital organ blood flow. The active ITD increased left 
ventricular flow by 100%, and nearly normalized blood flow to the brain compared to the sham 
ITD (Figures 1 and 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After a total of 17 minutes of ventricular fibrillation and 11 minutes of CPR, 3/11 pigs in the 
sham ITD group and 6/11 pigs in the active ITD group were resuscitated by direct current shock. 
In many ways, this six-minute arrest time prior to start of CPR more closely resembles clinical 
field experience where the time from arrest to the start of CPR in the United States ranges 
between 4-8 minutes in cities with highly efficient emergency medical services systems.  
The Milwaukee ROC investigators recently randomized 230 adults who had protected 
airways after out-of-hospital cardiac arrest to receive standard CPR and sham ITD versus 
standard CPR and active ITD.(23, 24) The primary outcome of this study was admittance to 
ICU. Femoral arterial blood pressures were also evaluated by the research team during 
standard CPR at the scene of cardiac arrest in 22 other patients using the same protocol.  
  ICU admissions for all patients were not significantly different with use of the active ITD 
versus sham ITD (25% vs. 17%, respectively, P=NS). However, there was significantly 
increased ICU admissions in patients presenting in pulseless electrical activity (PEA) with use of 
active ITD, 19% (5 of 26) vs. 52% (14 of 27) (P = 0.02; not significant when corrected for 
comparisons in three rhythm groups-.05/3=.017) (Figure 3). In the hemodynamic study, systolic 
blood pressure was significantly increased with the active ITD versus the sham ITD: 85.1 ± 28.9 
mmHg (n = 10) versus 42.9 ± 15.1 mmHg  (n = 12), respectively; P < 0.001. Collectively these 
findings imply that by increasing venous return, and thus cardiac output, the ITD provides a 
novel means to increase circulation during standard CPR and cardiac arrest.  
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Figure 3: Outcomes Presenting in Patients with PEA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a secondary analysis of the same study, the Milwaukee ROC investigators found that 
paramedics and EMTs ventilated patients in cardiac arrest an average of 30 ± 3 breaths per 
minute, nearly twice that recommended by the American Heart Association.(26) Subsequent 
studies in pigs demonstrated that excessive ventilation rates (similar to that observed in the 
clinical setting) significantly decreased coronary perfusion pressures and survival rates.(26) Two 
other studies demonstrated excessive ventilation rates delivered by healthcare professionals 
during in-hospital cardiac arrest.(27, 28) However a recent study demonstrated ventilation at the 
recommended rate during resuscitation by paramedics or nurse anesthetists in a different out-
of-hospital setting.(29) Most chest compressions were too shallow and nearly half the time, 
chest compressions were not delivered at all.  
In another analysis of the Milwaukee pilot study, rescuers were observed to maintain 
some residual and continuous pressure on the chest wall during the decompression phase of 
CPR, preventing full chest wall recoil.(8) Airway pressures were consistently positive during 
those periods. When this incomplete chest wall decompression was reproduced in a porcine 
model of ventricular fibrillation cardiac arrest, it was associated with significantly increased 
intrathoracic pressure and significantly decreased coronary and cerebral perfusion pressures.  
When monitoring CPR performance of professional EMS rescuers using a recording manikin, 
only 16.3% of decompressions were associated with complete recoil. A slight modification in the 
technique of manual CPR increased the frequency of complete chest recoil to 95.0% (OR: 
129.0; CI: 43.4-382.0, P < 0.0001).(8) 
The ITD in combination with conventional manual CPR was evaluated in a case-control 
study in large EMS system in Staffordshire, England.  Survival to emergency department 
admittance was significantly greater among patients with any initial rhythm who received the ITD 
(61/181 [34%]) compared with historical controls (180/808 [22%]) (p<0.01).  No device-related 
adverse effects were observed.(25) 
ROSC = Return of Spontaneous 
Circulation
1 HrS  = 1-Hour Survival
ICU  = ICU Admission Rate 
24 Hrs = 24-Hour Survival
* 
** 
***
* P = 0.010
** P = 0.02
***P =0.036
      
 = ICU Admission Rate 
  
***
  
0   
10   
20   
30   
40   
50   
60   
ROSC    ICU
Admin
24 Hr
STD CPR
STD CPR + ITD
Admission
I Hr  
Admission      
 12 
In summary, these studies demonstrate that the ITD improves hemodynamics and short-
term outcomes but may be associated with poor performance of other components of CPR. In-
field monitoring facilitates identification of such poor performance and provides opportunities for 
corrective feedback to EMS personnel. 
 
Choice of Intervention  
The investigators chose to evaluate the ITD alone rather than in combination with ACD 
CPR for several reasons.  While the results with simultaneous use of ACD CPR and the ITD are 
promising,(6, 7, 30) use of the ACD CPR device requires more energy than standard CPR to 
perform it correctly.(6, 7, 30)  Also, the sample size required to assess the effect of ACD CPR, 
ITD, combined therapy or standard CPR upon survival to discharge is impractical. Furthermore, 
a double-blind trial of ACD-CPR with or without ITD is not feasible, so the treatment effect from 
such a trial would be susceptible to bias. Therefore we propose a large clinical trial to assess 
the effect of standard CPR plus active ITD versus standard CPR plus sham ITD.  
 
Summary of Rationale 
Survival after out-of-hospital cardiac arrest is poor.  Studies in animal models of cardiac 
arrest demonstrate enhanced myocardial perfusion and vital organ blood flow when using the 
ITD.  Studies in humans with out-of-hospital cardiac arrest demonstrated that the ITD increased 
systolic blood pressure and tended to improve short-term clinical outcomes without any adverse 
effects. A large trial is required to demonstrate whether ITD significantly improves survival and 
functional status. Evaluation of the effect of ITD requires monitoring whether CPR process is 
consistent with currently recommended methods of resuscitation. 
 
Research Design and Methods 
 
Experimental Design 
 
This randomized trial will evaluate manual CPR with either an active or sham ITD in 
adult patients with out-of-hospital cardiac arrest.  Randomization will occur through use of a 
study ITD that is constructed such that the sham and active valves are indistinguishable.  The 
intervention will be implemented by the first qualified provider to arrive at the scene of cardiac 
arrest and continued by subsequent providers in all ROC sites. The first qualified providers will 
most often be EMT-certified responders but will also include responders able to mechanically 
ventilate the patient using either a bag-mask or an advanced airway.  Ventilation rates will be 
consistent with AHA guidelines. 
 
Study Episodes 
Episodes attended by EMS will be included if a study device was taken from its sealed 
container. All such episodes will be followed for purposes of safety evaluation. 
 
Study Population 
 
Inclusion Criteria 
 Persons aged 18 years or more (or local age of consent) who suffer non-traumatic 
cardiopulmonary arrest outside of the hospital in the study communities who receive 
defibrillation and/or chest compressions by EMS providers dispatched to the scene and do not 
meet any of the exclusion criteria below.  Note: The etiology will be presumed to be non-
traumatic in origin unless the apparent cause is due to trauma, drowning, strangulation, 
electrocution, or exsanguination. 
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Exclusion Criteria 
– Do not attempt resuscitation (DNAR) orders; 
– Blunt, penetrating, or burn-related injury; 
– Patients with exsanguinations; 
– Known prisoners; 
– Known pregnancy; 
– Tracheostomy present; 
– CPR performed with any mechanical compression device (e.g. AutoPulse, LUCAS, 
Thumper).  
– Ventilated with a mechanical device (e.g. automated transport ventilator) Note: a bag-mask 
is not considered a mechanical ventilation device. 
–   A non-ROC EMS agency/provider, for whom time call received at dispatch cannot be  
     obtained, began CPR or placed pads. 
 
 
Primary Comparison Population 
The ITD is conjectured to provide an improvement in the rate of neurologically intact 
(MRS ≤ 3) survival to hospital discharge in those patients experiencing OOHCA of cardiac origin 
and treated by EMS within 15 minutes of initial call to 911. There is, however, no 
contraindication to the use of the ITD in the relatively few patients whom experience OOHCA 
due to such noncardiac events as strangulation, drowning, or electrocution. In the emergency 
setting, unnecessarily introducing a need for EMS providers to evaluate eligibility criteria could 
potentially delay the institution of appropriate life saving treatments. Furthermore, if the ITD is 
proven effective and adopted widely, the eventual use of the device may include patients for 
whom the cardiac origin of OOHCA could not be accurately determined. Hence, this study 
protocol allows for the evaluation of the safety of the ITD device in some patients for whom the 
indication of the ITD could not be firmly established in the emergency setting. On the other 
hand, efficacy of the device will be analyzed in only those patients who are determined to meet 
the criteria defining the pre-hospital conditions for which the use of ITD is conjectured to be of 
benefit.  
Efficacy Population: Analysis of primary and secondary efficacy outcomes will be 
conducted on a modified intent-to-treat basis. In order to be included in the efficacy analyses, 
patients must meet the inclusion/exclusion criteria for the ITD/sham device intervention. 
Furthermore, they must also meet the following criteria 
 Not have experienced cardiac arrest secondary to drowning, electrocution, or 
strangulation; 
 Have a response time (time from 911 call to time of arrival of ROC EMS 
providers at scene) less than 15 minutes, and 
 Have the device actually applied. 
With the exception of the criterion regarding actual application of the device, 
determination of whether patients meet these criteria or not will be made on the basis of data 
available prior to randomization (i.e., available prior to opening of the bag containing the 
device). In every case, the determination of whether a patient belongs in the efficacy population 
will be made in a blinded fashion (without knowledge of whether the device bag opened was an 
active ITD or a sham device). Within the efficacy population, analyses will be conducted on an 
intent-to-treat basis. Hence in the rare event that first and second responders in a tiered 
response system might both open a bag containing a device, the patient will be analyzed 
according to the treatment arm corresponding to the first arriving vehicle. 
In the event that the Analyze Late vs Analyze Early (ALvE) intervention is terminated 
early due to demonstrated superiority of one rhythm analysis strategy over the other, the 
efficacy population for the ITD/sham device comparison will be restricted to those subjects 
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treated under the rhythm analysis strategy found to be superior. The number of subjects 
accrued to the study will be increased to achieve the planned maximal sample size in the 
superior rhythm analysis strategy arm. 
 Safety Population: Evaluation of the safety of the ITD will be made using all data from 
patients who were treated with a device, regardless of whether they are a member of the 
efficacy population or not.  
In the event that the Analyze Late vs Analyze Early (ALvE) intervention is terminated 
early due to demonstrated superiority of one rhythm analysis strategy over the other, the safety 
of the ITD will also be evaluated separately in subgroups defined by the rhythm analysis 
strategy arm (AL or AE). 
 
 
Intervention 
Upon arrival of EMS providers at a patient with cardiac arrest, CPR will be initiated. 
Defibrillation will be performed consistent with local practice and cluster assignment.  For 
subjects who are being ventilated with bag-mask or advanced airway (e.g., Combitube, 
laryngeal mask airway [LMA], or endotracheal tube) and receiving chest compressions, EMS 
providers will insert a study valve between the bag and the mask/airway, whichever is available. 
Training will target use of the ITD with initial management of the airway to assure the earliest 
placement of the ITD during CPR.  To assure correct ventilation rate, the rescuers will turn on 
the ventilation timing assist lights on the device once an advanced airway has been established. 
The providers will be instructed to immediately remove the valve if the patient has return of 
spontaneous circulation or is breathing spontaneously, to facilitate rapid elimination of 
inspiratory impedance in a resuscitated patient. (The ITD has a safety check valve that opens if 
the pressure in the airway is <16 cm H2O in the event the rescuer does not recognize that the 
patient is able to breathe on their own).  The providers will be instructed to immediately reapply 
the mask if such a patient ceases to have spontaneous circulation or to breath spontaneously 
(i.e., has recurrent cardiac arrest).   
The EMS providers will be instructed to remove the ITD from the advanced airway if the 
valve fills with fluid; removing this fluid by forcing air through the device with the ventilation bag, 
suctioning the patient, and reapplying the ITD. If the device fills with fluid a second time, EMS 
personnel will be instructed to remove the ITD completely and continue resuscitative efforts 
without use of the device. 
Use of the ITD will be discontinued on arrival to the hospital.   
All other resuscitative measures will follow common guidelines (Appendix 3). 
 
Random Allocation  
 
Study devices will be randomly allocated in a proportion of 1:1 active vs. sham, with 
distribution determined by the CTC based on permuted blocks of concealed size within strata 
defined by participating site and within site by participating agency or subagency. Devices will 
be packaged with a flexible connector to facilitate adjunct equipment such as CO2 monitoring.  
A mask will also be provided to facilitate achievement of a good seal between the patient’s face 
and the ventilatory circuit so as to maintain the intrathoracic pressure. These will be placed at 
each base station where they can be retrieved by the medic. One device will be kept on each 
EMS vehicle. Study site personnel will keep inventory records for each EMS site and conduct 
EMS site visits to confirm inventory status. When a base station has less than three ITDs 
remaining, an additional set will be distributed. Each ITD package will have several stickers 
denoting its number. These will be placed on the medic report and emergency care record. 
Each site must establish a notification process with their EMS system and emergency 
department to notify study personnel of patient enrollment. In this manner, the subjects, 
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investigators, study coordinators and all persons caring for the patient will be blinded to the 
treatment assignment. Note that active and sham devices will not be distinguishable visually 
even when removed from the opaque packaging. Patients will be considered to have been 
randomized as soon as the ITD package has been opened. In the event that two bags are 
opened for the same patient during the same arrest episode, the patient will be assigned to the 
treatment group of the device used by the first-arriving vehicle. 
 
Intervention–Compliance 
 
The location and number of devices supplied to each EMS rig and station for appropriate 
distribution will vary with the structure of the system.   When an ITD is used, ambulance 
personnel will document the unique number of the device on their run report by using pull-off 
labels located within the packaging of the device. Following use, EMS providers will be 
encouraged to place the used device at a predetermined location and replace the used device 
with a new valve. After each use, the research team will be notified and will replace the used 
device.  The coordinating center will maintain a record of where each device is distributed, and 
track their use. 
 
Outcome Measures 
 
Primary  
The primary outcome is survival to hospital discharge with MRS < 3. Patients who are 
transferred to another acute care facility (e.g., to undergo ICD placement) will be considered to 
be still hospitalized. Patients transferred to a non-acute ward or facility will be considered 
discharged.  
 
Secondary  
The secondary outcomes are survival to discharge; MRS at 3 and 6 months following 
hospital discharge; Adult Lifestyle and Function (ALFI) version of the Mini-Mental Status Exam 
(MMSE) at 1, 3 and 6 months;(31, 32) as well as Health Utilities Index III (HUI3) score(33) and 
Geriatric Depression Scale (T-GDS)(34) score at 3 and 6 months (details in Section 4 and 
Appendix 4). 
 
Exploratory 
Cerebral Performance Category (CPC) will be assessed at discharge, 3 and 6 months 
following hospital discharge. 
 
   
In-Hospital Morbidity 
Number of hospital days and time interval from 911 call to patient death will be described 
for all hospitalized patients as measures of morbidity after resuscitation. 
 
Prespecified Subgroup Analyses 
 
a) First recorded cardiac arrest rhythm prior to valve application (VF/VT vs. PEA vs. 
asystole vs. not obtained before device implementation); 
b) Observational status of arrest (Witnessed by EMS vs. witnessed by bystanders vs. 
unwitnessed); 
c) In witnessed cardiac arrests, response time interval from call to initiation of CPR by 
ROC EMS (<10 vs. ≥ 10 minutes);(30) 
d) Analyze Early vs. Analyze Later vs. not participating in ALvE cohorts. 
 16 
 
 
Expected Adverse Events 
 
The following will be considered major adverse events if they occur during the resuscitative 
effort or the hospital stay: 
 
Pulmonary Edema- The presence of pulmonary edema in patients who survive long enough to 
receive a hospital-based chest x-ray (first emergency department or ICU chest x-ray). This will 
be defined as formal radiographic interpretation as consistent with the presence on x-ray of 
alveolar pulmonary edema, interstitial pulmonary edema, bilateral pleural effusions, 
cardiomegaly (cardiothoracic ratio > 0.5 on posteroanterior projection), or pulmonary venous 
congestion (upper-zone flow redistribution on posteroanterior projection).(35, 36) This will be 
monitored because failure to remove the ITD immediately following successful resuscitation will 
require the patient to generate more than 16 cm of H2O negative intrathoracic pressure before 
initiating inhalation. This may result in increased work of respiratory effort during the initial 
stages of successful resuscitation. This may result in secondary respiratory failure or pulmonary 
edema and the need for continuing to support the patient’s respiration.  Similarly, in the out-of-
hospital setting, if the valve fills with fluid twice (indicating possibly significant pulmonary 
edema), its use will be discontinued.   
 
All incidences where the valve fills with fluid will be reported to the DSMB.  Additionally, all 
cases of pulmonary edema who did not survive, will have the field report individually reviewed 
for evidence of failure to remove the ITD valve and these cases will be presented to the DSMB. 
 
Pulmonary edema is commonly observed after resuscitation from cardiac arrest.((37) and 
Unpublished Data, ASPIRE Investigators)  However device-related pulmonary edema has not 
been observed in previous published studies of ITD. We anticipate that pulmonary edema 
associated with use of the ITD would be unlikely except if the device were left on a patient who 
is breathing spontaneously. Since the rate of pulmonary edema in the control group is unknown, 
we shall monitor the incidence of pulmonary edema in sham and active ITD groups and assess 
whether there is a significant difference between treatment groups. 
 
Device Failure-  Mechanical failure (i.e., the device breaks). Malfunctions are unlikely due to 
the simple construction and durable materials of the device. There have been no instances of 
the ITD breaking in the Milwaukee feasibility study, ongoing European studies or during clinical 
use in Europe. 
 
Other- The following are commonly observed in patients who experience cardiac arrest or 
resuscitative efforts after its onset, and may or may not be attributable to specific resuscitation 
therapies. These will be monitored and reported but not classified as major adverse events. 
Vomiting During CPR. Vomiting during CPR is a common and anticipated complication of any 
method of CPR. Immediate clearing of the airway is necessary to prevent complications from 
aspiration. Rescuers are experienced in handling this type of complication and have portable 
and stationary suction available to them. The occurrence of vomiting during the application of 
the ITD will be recorded from the prehospital clinical record. Clinical diagnoses of cerebral 
bleeding, stroke, seizures, bleeding requiring transfusion or surgical intervention, rearrest, 
pulmonary edema, serious rib fractures, sternal fractures, internal thoracic or abdominal injuries 
as well as any other major medical or surgical outcomes will be recorded as noted in the 
hospital discharge summary. Since the treating physicians will be blinded as to whether the 
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patient received active or sham ITD, there is unlikely to be a treatment-related bias in identifying 
these events. 
 
Unexpected Adverse Device Events (UADE) 
These will be defined as any serious unexpected adverse effect on health or safety or 
any unexpected life-threatening problem caused by, or associated with, a device, if that effect or 
problem was not previously identified in nature, severity, or degree of incidence in the 
investigation plan or application (including a supplementary plan or application), or any other 
unexpected serious problem associated with a device that relates to the rights, safety or welfare 
of subjects. The death or neurological impairment of an individual patient is not considered an 
adverse event in this study. 
  
Analyses 
 
Primary Efficacy Analysis 
 
The primary analysis of treatment efficacy will be based on a comparison across 
treatment arms active and sham ITD of the observed proportion of patients in the efficacy 
population (see page 12 for definition of efficacy population) with neurologically intact (MRS ≤ 3) 
survival to hospital discharge. We assume that ITD would not be implemented if it were 
associated with worse neurologically-intact survival to discharge. A one-sided level 0.025 
hypothesis test will be used to test the null hypothesis of equal rates of such favorable events 
(H0: πITD = πSHAM) versus the alternative hypothesis that patients on the active ITD arm have a 
higher probability of neurologically intact survival to hospital discharge than do patients on the 
sham device arm (H1: πITD > πSHAM). The test statistic comparing those proportions will be a one-
sided version of Pearson’s chi squared statistic: the Z statistic defined as the difference of the 
proportions (ITD arm minus sham device arm) divided by its estimated standard error computed 
assuming the null hypothesis of equality of proportions.  ( )
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The fixed sample P value corresponding to that Z statistic will be compared to the 
boundaries of the protocol defined group sequential stopping rule when expressed on the fixed 
sample P value scale. At the end of the study, analysis results will be summarized using point 
estimates of the difference in probability of favorable events, 95% confidence intervals, and P 
values adjusted for the true sampling distribution imposed by the group sequential stopping rule. 
(See the discussion of the group sequential monitoring plan below.) 
This analytic approach assumes unbiased random allocation of patients to treatment 
group and relies on the sample size being large enough for asymptotic theory to provide good 
distributional approximations.  With the exception of the inclusion criterion regarding actual 
application of the device, determination of whether patients meet study criteria or not will be 
made on the basis of data available prior to randomization (i.e., available prior to opening of the 
bag containing the device) (see p. 12 for more detail). 
 
 
Secondary Efficacy Analyses 
 
All secondary analyses of efficacy endpoints are directed toward finding supporting evidence for 
the findings of the primary efficacy analysis. As such, they will not be used as the primary basis 
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for establishing benefit of the ITD relative to the sham device, nor will they be used as the 
primary basis for obtaining regulatory approval of the ITD. Hence, there is no plan to make any 
statistical adjustment for the multiple comparisons inherent in the secondary efficacy analyses, 
which include: 
 
Modified Rankin Score (MRS) at hospital discharge. The mean MRS at hospital discharge will 
be compared across treatment groups using the t test which allows for unequal variances 
across groups. For the purposes of this analysis, patients dying before admission to the hospital 
will be treated the same as admitted patients dying before hospital discharge and will be 
assigned an MRS of 6. 
 
Survival to hospital discharge.  This secondary analysis of treatment efficacy will be based on a 
comparison across treatment arms of the observed proportion of patients in the efficacy 
population with survival to hospital discharge. This analysis shall proceed in a manner entirely 
analogous to that for the primary efficacy endpoint. The test statistic comparing those 
proportions will be a one-sided version of Pearson’s chi squared statistic: the Z statistic as 
defined for the primary analysis. 
 
Neurologically intact survival to hospital discharge adjusted for prognostic variables. A 
secondary analysis of the primary endpoint will adjust for those pre-randomization variables 
which might reasonably be expected to be predictive of favorable outcomes. Generalized linear 
models will be used to model the proportion of subjects with neurologically intact (MRS ≤ 3) 
survival to hospital discharge by ITD/sham device group adjusted for site (dummy variables 
modeling the 11 ROC sites), patient sex, patient age (continuous variable), witness status 
(dummy variables modeling the three categories of unwitnessed arrest, non-EMS witnessed 
arrest, and EMS witnessed arrest), location of arrest (public versus non-public), time or 
response (continuous variable modeling minutes between call to 911 and arrival of EMS 
providers on scene), presenting rhythm (dummy variables modeling asystole, PEA, VT/VF, or 
unknown), and treatment assignment in the Analyze Late vs. Analyze Early intervention. The 
test statistic used to assess any benefit of the ITD relative to the sham device will be computed 
as the generalized linear model regression coefficient divided by the estimated “robust” 
standard error based on the Huber-White sandwich estimator(38, 39) in order to account for 
within group variability which might depart from the classical assumptions. Statistical inference 
will be based on one-sided P values and 95% confidence intervals which adjust for the stopping 
rule used for the primary analysis. 
 
Post-discharge neurological function, quality of life, and depression. Surviving patients will be 
contacted post-discharge to obtain consent for additional follow-up via telephone with 
consenting patients or their proxies regarding cognition, quality of life, and depression.  
Analyses of each of these outcomes at each time point will be compared across treatment 
groups by using the t test which allows for unequal variances.  Analyses will first be conducted 
conditional on survival to the relevant time point by using only data from those patients offering 
consent, as well as using data imputed from discharge data for those surviving patients refusing 
consent. The data missing due to lack of consent for follow-up will be multiply imputed using 
measurements of patient age, sex, length of hospital stay, incidence of major adverse outcomes 
during hospitalization, MRS at hospital discharge, and whether the patient was discharged to 
home or a nursing facility. Additional analyses of neurological function and quality of life will then 
incorporate measurements for patients dying prior to hospital admission, during hospitalization, 
or within 3 or 6 months post discharge. Dead patients will be assigned the worse category of 
neurological function and quality of life for each measurement. 
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Morbidity. As a measure of morbidity during hospitalization, the number of days hospitalized 
conditional upon survival to discharge will be compared across treatment groups using the t test 
which allows unequal variances. A similar analysis will also be conducted comparing the days of 
hospitalization for patients admitted to the hospital, but dying prior to hospital discharge. Finally, 
treatment groups will also be compared with respect to the number of days alive post hospital 
discharge during the first 6 months post OOHCA in order to incorporate information about both 
dead and surviving patients. In this analysis, data missing due to lack of consent for follow-up 
will be multiply imputed using data available at hospital discharge, and patients dying before 
hospital admittance or prior to hospital discharge will be scored as 0. 
 
Safety Analyses 
 
The incidence of adverse events will be recorded for all patients in the safety population 
and presented by treatment arm (ITD vs. sham device) to the DSMB for their review during the 
conduct of the study, as well as summarized and compared across treatment arms in the final 
report of study results. Assessment of the statistical significance of differences in the incidence 
of safety endpoints plays a lesser role, due to the need to be cautious in the introduction of new 
treatments in a human population. Hence, emphasis is placed on the presentation of results, 
with statistical tests provided for guidance on the precision of estimates as indicated. Specific 
measures that may reflect the safety of the ITD include: 
 
Delay of treatment. The process of opening and applying the device could delay treatment 
and/or potentially cause harm in patients other than those for whom the device is conjectured to 
provide benefit, as well as in the evaluable patient population. The distribution of time from EMS 
arrival to initiation of CPR will be described using mean, standard deviation, minimum, 25th, 
50th, and 75th percentiles, and maximum. When indicated, statistical tests comparing the 
distribution of times to initiation of CPR will be effected using the t test which allows for unequal 
variances. Similar analyses will be conducted for the time between EMS arrival and first 
assessment for defibrillation, stratified within Analyze Late vs. Analyze Early clusters. 
 
Complications of treatment. The incidence of vomiting during CPR, device filling with fluid, 
mechanical failure of the device, and any UADE will be reported by treatment arm and 
compared as indicated using Pearson’s chi squared statistic. 
 
Serious adverse events. The incidence of each serious adverse event, along with other major 
adverse medical or surgical outcomes identified during review of hospital records, will be 
tabulated by treatment arm and compared when indicated using Pearson’s chi squared test. In 
order to facilitate the identification of differences in rates of such events that might be due to 
greater survival to hospital admission and/or hospital discharge on one of the treatment arms, 
the incidence of any of the above specific events and/or death (either prehospital or during 
hospitalization) will be reported in a combined fashion and compared as indicated by using 
Pearson’s chi squared statistic. 
 
Subgroup Analyses 
 
Analyses will be performed in each subgroup, along with tests for statistically significant 
interactions. However, it is recognized that the study is not powered adequately to detect 
interactions, and thus all subgroup analyses are judged exploratory. 
 
Exploratory Analyses 
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Data from the clinical trial will also be used to explore two hypotheses unrelated to the treatment 
effect of ITD on neurologically intact survival post OOHCA.  
 
Correlation between MRS and other measures of cognition and quality of life. Analyses will 
evaluate the correlation between simultaneous measures using the MRS,  ALFI-MMSE, HUI or 
GDS at 3 and 6 months using linear regression analyses and standard errors computed using 
the Huber-White sandwich estimator. Additional analyses will evaluate the value of MRS at 
hospital discharge as a surrogate variable for the ALFI-MMSE and HUI at 6 months post 
hospital discharge. In this latter analysis, the effect of treatment with ITD vs. sham device on the 
6 month cognitive function and quality of life measures will be analyzed both without and with 
adjustment for MRS at hospital discharge. A descriptive measure of the usefulness of the MRS 
at hospital discharge as a surrogate for the later validated measures will be based on the 
difference in the estimates of treatment effect between the unadjusted and adjusted analyses.  
 
Cerebral Performance Category To assess the validity of the Cerebral Performance Category 
for use in future studies, CPC scores at discharge as well as three and six months after 
discharge will be analysed in a manner similar to the analyses of post-discharge neurologic 
function described above in the secondary efficacy analyses. However the results of any 
analysis of CPC scores will not be used to make labeling claims for ITD. 
 
Association between use of hypothermia and neurologically intact survival. Some patients may 
be treated with hypothermia according to local standards of best medical care. Data will be 
collected on both the pre-hospital and in-hospital use of hypothermia. In order to explore any 
association between the use of hypothermia and the probability of survival to hospital discharge 
proportional hazards regression models will be fit using use of hypothermia as a binary time-
varying covariate, adjusted for treatment with ITD vs. sham device. Test statistics will be based 
on the estimated hazard ratio for the hypothermia covariate and the Wald statistic computed 
from the regression parameter divided by the “robust” standard error computed using the Huber-
White sandwich estimator. Comparisons of neurologic function will use measures derived from 
the MRS, ALFI-MMSE, HUI and GDS over time in a generalized estimating equation (GEE) 
analysis restricted to patients surviving to hospital discharge and incorporating the multiple 
measurements made on each patient. Test statistics will be based on the Wald test using the 
regression parameter estimate for the hypothermia covariate and its “robust” standard error 
computed using the Huber-White sandwich estimator. 
 
Sample Size and Study Duration 
 
The sample size for the factorial trial is driven by the power analysis for the ITD 
intervention. These calculations are based on the estimated probability of survival to hospital 
discharge averaged over the participating ROC sites, which is then adjusted to reflect the 
estimated probability of survival to hospital discharge with acceptable neurological status (MRS 
≤ 3). 
Patients with OOHCA who are treated by participating agencies and subagencies and 
who meet the inclusion/exclusion criteria will be randomized to the ITD or sham device, unless 
resuscitated prior to the placement of such a device. This latter possibility may tend to occur 
with patients who present in VT/VF and who initially achieve ROSC following a first, early 
defibrillation as might be applied under the AE strategy. Thus, in computing sample sizes for the 
ITD intervention, we must consider the distribution of patients by presenting rhythm and their 
assignment to the AE or AL treatment strategies. We also must consider the number of patients 
who have EMS witnessed CA, because all such patients will be treated using an AE strategy, 
regardless of the cluster randomization of the responding unit to the AL vs. AE intervention.  
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It is estimated that approximately 50% of patients accrued to the factorial study will 
present in asystole, 25% of patients will present with pulseless electrical activity (PEA), and the 
remaining 25% will present in VT/VF. It is also estimated that approximately 10% of all EMS 
treated OOHCA will involve EMS witnessed arrest. In the ASPIRE trial, the presenting rhythm of 
EMS witnessed arrest occurred in the ratio of 2.20 asystole: 2.57 PEA : 4.74 VT/VF.  
The anticipated distribution of patients by presenting rhythm and whether CA was EMS 
witnessed or not was estimated based on these assumptions (Table 1). 
 
Table 1: Proportion of all EMS treated OOHCA patients according to presenting rhythm and EMS Witness 
status 
 
Presenting Rhythm EMS Witnessed EMS Unwitnessed Total 
Asystole 0.0231 0.4769 0.500 
Pulseless Electrical Activity (PEA) 0.0270 0.2230 0.250 
VT/VF 0.0499 0.2001 0.250 
TOTAL 0.1000 0.9000 1.000 
 
Eligibility criteria for the ITD intervention excludes subjects for whom no device (ITD or 
sham) was used, and it is anticipated that approximately 30% of the patients presenting in 
VT/VF will not have a device placed when treated under the AE strategy, On the other hand, it is 
anticipated that all such patients would have a device placed when treated under the Analyze 
Later (AL) strategy. Taking into account that patients with OOHCA that is not witnessed by EMS 
will be randomized (by cluster) in a 1:1 ratio to the AE or AL strategies at all participating 
agencies except Seattle Medic One (which is projected to accrue approximately 2.7% of all 
patients—see Table 9), the expected distribution of patients to the various treatment strategies 
by presenting rhythm was estimated (Table 2). 
 
Table 2: Proportion of all EMS treated OOHCA patients randomized to treatment combinations according to 
presenting rhythm and EMS Witness status 
 
EMS Witnessed CA or 
Seattle Medic One 
(AL vs. AE Ineligible) 
Analyze Early Analyze Late Total ITD/Sham Randomized Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD Sham ITD 
Asystole 0.000 0.018 0.018 0.000 0.116 0.116 0.116 0.116 0.250 0.250 
PEA 0.000 0.017 0.017 0.000 0.054 0.054 0.054 0.054 0.125 0.125 
VT/VF 0.015 0.020 0.020 0.029 0.034 0.034 0.049 0.049 0.103 0.103 
TOTAL 0.015 0.055 0.055 0.029 0.204 0.204 0.219 0.219 0.478 0.478 
 
Based on ranges of estimates in published data and results of the ASPIRE trial, and 
allowing for 1-5% improvement due to better CPR process in the clinical trial setting, It is 
estimated that in the absence of an ITD and when managed according to the Analyze Early 
(AE) strategy, the probability of survival to hospital discharge would be 1.05% for patients 
presenting with asystole, 4.02% for patients presenting with PEA, and 20.2% for VT/VF. These 
assumptions lead to an estimated probability of survival to hospital discharge of 0.0600 when 
treated under the AE strategy with a sham valve. We assume that 88.9% of such survivors 
would have acceptable neurological status (MRS ≤ 3) based on a combination of observed rates 
from the ASPIRE and PAD trials where 35 of 45 and 42 of 45 survivors had CPC scores < 2. 
Therefore we estimate a rate of 0.0533 for neurologically intact survival to hospital discharge 
under treatment with the AE strategy and a sham valve.  
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Under the alternative hypothesis used for sample size calculations, the effect of the ITD 
on neurologically intact survival is presumed to vary by presenting rhythm. Because a more 
substantial relative benefit is presumed for those patients receiving CPR for a longer period of 
time, neurologically intact survival is presumed to be 1.4 fold higher for patients treated with the 
ITD if their presenting rhythm was asystole or PEA. For patients presenting in VT/VF a relative 
benefit of 1.20 is hypothesized to account for a lesser benefit for those patients who would 
respond well to early defibrillation.  Applying these hypothesized effects to the numbers given 
above results in an estimated probability of survival to hospital discharge of 0.0753 for patients 
treated with an ITD under the AE strategy, with a corresponding hypothesized rate of 0.0669 for 
neurologically intact survival to discharge. Details of these calculations are provided below 
(Table 3). 
 
Table 3: Estimated proportions of all EMS treated OOHCA patients surviving to discharge and surviving to 
discharge with MRS ≤ 3 by ITD/sham treatment arm and presenting rhythm. 
 
Presenting Rhythm Stratum Weight 
Sham Device 
Probability of 
Survival to 
Discharge 
ITD / Sham 
Relative 
Benefit 
ITD Probability of 
Survival to 
Discharge 
Asystole 0.5231 0.0105 1.40 0.0147 
PEA 0.2616 0.0420 1.40 0.0588 
VT/VF 0.2153 0.2020 1.20 0.2424 
 
Probability of Survival to Discharge 
(weighted average) 
 0.0600  0.0753 
 
Probability of Neurologically Intact 
Survival to Discharge 
(88.9% of patients surviving to hospital 
discharge) 
 0.0533  0.0669 
 
The number of patients to be accrued to the ITD vs. sham device comparison is based 
on the ability of a one-sided level 0.025 test to reject a null hypothesis that the probability of 
neurologically intact survival to hospital discharge is 0.0533 on both treatment arms. Sample 
size computations are based on a two-sample test of binomial proportions using Pearson’s chi 
squared statistic. The test should have approximately 90% statistical power to reject the null 
hypothesis when the ITD treatment arm would have a 0.0669 probability of neurologically intact 
survival. 
 
The clinical trial will be conducted using a group sequential stopping rule based on up to 
three evenly spaced analyses (two interim analyses and the final analysis). The stopping rule 
corresponds to a Pampallona and Tsiatis design(40) as described in more detail under the 
monitoring plan. Using that stopping rule, a sample size of 14,154 evaluable patients will 
provide 90% power to reject the null hypothesis under the conjectured treatment effect. 
However, it is anticipated that approximately 4% of accrued patients will be judged 
nonevaluable due to non-cardiac origin of cardiac arrest or response time in excess of 15 
minutes. Hence, a maximum of 14,742 patients will be potentially treated with the ITD or sham 
device in order to obtain 14,154 evaluable patients for testing the effect of ITD on the primary 
endpoint of neurologically intact survival to hospital discharge.  
 
The 11 participating ROC sites are estimated to have approximately 10,000 OOHCA 
treatable by EMS each year, so it is estimated that accrual of 16,542 patients (up to 1,800 
during the run-in phase, 14,742 during the actual trial) will require 20 months. 
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In the event that the Analyze Late vs. Analyze Early (ALvE) intervention is terminated 
early due to demonstrated superiority of one rhythm analysis strategy over the other, the 
number of subjects accrued to the study will be increased to achieve the planned maximal 
sample size in the superior rhythm analysis strategy arm. The primary analyses of the 
effectiveness of the ITD will then be evaluated in just those patients who were treated with the 
rhythm analysis strategy deemed to be superior. The stopping rule will be applied to the data in 
the efficacy population restricted to that superior ALvE treatment arm.  
 
 
Human Subjects 
 
Risks to Subjects 
 
Population 
This study will enroll approximately 16,542 adult patients who have sustained a nontraumatic 
out-of-hospital cardiac arrest and are known or presumed to be at the local age of consent.  
 
Potential Risks 
ITD administration during standard manual CPR has been tested in three animal 
studies(5, 22, 41) and three human studies(23-25) with no serious device-related adverse 
effects reported. ITD increases negative intrathoracic pressure and coronary perfusion 
pressure, which has raised a concern for potential increased pulmonary edema. However 
previous studies have not observed device-related adverse events. 
Other potential concerns are mechanical failure of the device. We will report any 
evidence of pulmonary edema, or device failure as a serious adverse event.  If failure of the 
device or pulmonary edema occurs (the device fills with fluid twice) in the out-of-hospital setting, 
application of the device will be immediately stopped and appropriate clinical management 
undertaken. As part of the training of the prehospital providers for the study, potential signs and 
symptoms of serious adverse events will be clearly described. 
 
Potential Benefits to Subjects and Society 
There are several potential benefits to subjects who receive an active ITD. These 
include increased venous return, coronary perfusion pressure, cardiac output and admittance to 
intensive care with the use of the ITD during standard CPR in humans. We contend that use of 
the ITD may significantly increase survival to hospital discharge. The efficacy of this device can 
only be assessed by performing clinical studies such as the one proposed in this application. 
 
Inclusion of Women or Minorities 
There will be no exclusion on the basis of gender, race or ethnicity. Known pregnant 
women and prisoners will be excluded. Since this is the first large human trial using the ITD with 
standard CPR, there is no available evidence to determine whether or not there is a clinically 
important sex/gender and/or race/ethnicity difference with its use.  Investigators will compare 
primary and secondary study outcomes between the treatment and control groups broken down 
by sex/gender and race/ethnicity categories.  
 
Inclusion of Children 
The ITD has not been applied during standard CPR in humans < 21 years of age.  For 
this reason, clinical equipoise has not been established in the pediatric population.  Therefore 
the ROC Investigators believe that it is inappropriate to first use the ITD during standard CPR in 
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children in a randomized trial such as that proposed in this protocol.  Accordingly, victims of 
cardiac arrest less than the local age of consent (which varies from 17 to 21 years in ROC sites) 
will not be entered in the study. 
 
 
 
3. Analyze Later versus Analyze Early 
 
Analyze Later Trial - Comparison of a Strategy of Analyze Later Combined with CPR Early 
Versus a Strategy of Analyze Early Combined with CPR Later in Patients With Out-Of-
Hospital Cardiac Arrest  
 
Study Summary 
 
Background: While patients with the shockable rhythms of VF and pulseless VT (PVT) have 
the best chance of survival of amongst out-of-hospital cardiac arrest victims, the vast majority of 
such patients do not survive to hospital discharge. The traditional approach to these patients 
has been to analyze the cardiac rhythm and deliver defibrillatory shocks as quickly as possible 
with the onset of CPR delayed. Recent thinking suggests three phases for VF cardiac arrest: a) 
an early “electrical” phase where rapid defibrillation is effective, b) an intermediate phase where 
“priming” the heart with CPR enhances the effectiveness of defibrillation, and c) a late phase 
where defibrillation is rarely effective. Some now advocate delaying electrical shocks and 
providing early CPR in cases of VF where defibrillation cannot be carried out immediately. 
Three clinical studies have each attempted to evaluate this hypothesis of early CPR and 
delayed analysis. While two studies supported early CPR and one did not, none were definitive 
and all had important limitations. We believe there is an urgent need for a large and definitive 
clinical trial to determine the optimal strategy for rhythm analysis and CPR in patients with out-
of-hospital cardiac arrest. 
 
Aims: The primary aim of the trial is to compare survival to hospital discharge with modified 
Rankin score < 3 between a strategy of Analyze Later consisting of CPR first followed by rhythm 
analysis versus a strategy of Analyze Early consisting of early rhythm analysis in patients with 
out-of-hospital cardiac arrest. The secondary aims of the trial are to compare survival to 
discharge, functional status at discharge and at 1, 3 months and 6 months as well as 
depression at 3 and 6 months. 
 
Hypotheses: The null hypothesis is that survival to hospital discharge with modified Rankin 
score < 3 is identically distributed between Analyze Later versus Analyze Early in patients with 
cardiac arrest. The secondary null hypotheses are that survival to discharge, functional status at 
discharge and at 1, 3 months and 6 months as well as depression at 3 and 6 months will be 
identically distributed between Analyze Later versus Analyze Early in patients with cardiac 
arrest. 
 
Design: Cluster randomized trial with cluster units defined by geographic region, or 
monitor/defibrillator machine. 
 
Population: Patients with non-traumatic out-of-hospital cardiac arrest, known or presumed to 
be local age of consent or greater and treated by EMS providers. 
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Setting: EMS systems participating in the Resuscitation Outcomes Consortium and agreeing to 
cluster randomization to the Analyze Later/Analyze Early intervention in a crossover fashion. 
 
Sample Size:  Based on a two-sided significance level of 0.05, a maximum of 13,239 evaluable 
patients will allow statistical power of 0.996 to detect an improvement in the probability of  
survival to discharge with modified Rankin score < 3 rate from 5.41% after Analyze Early to 
7.45% after Analyze Later.   
 
Anticipated Clinical Impact: If this trial demonstrates a significant improvement in survival with 
a strategy of Analyze Later, we estimate that the premature death of 4,000 victims of cardiac 
arrest per year would be averted annually in North America alone. 
 
Specific Aims 
 
Primary Aim:  The primary aim of this study is to compare survival to hospital discharge with 
modified Rankin score <3 in a variety of communities in patients with out-of-hospital cardiac 
arrest between a protocol of compressions equivalent to approximately 3 minutes prior to 
cardiac rhythm analysis (Analyze Later) compared with cardiac rhythm analysis as soon as 
possible after 50 compressions (Analyze Early). 
 
Hypothesis:  The null hypothesis is that survival to hospital discharge with modified Rankin 
score <3 is identically distributed with use of Analyze Later versus Analyze Early in patients with 
cardiac arrest. 
 
Secondary Aims: The secondary aims of this trial are to compare survival to discharge, 
functional status scores at discharge and at 1, 3 and 6 months as well as depression at 3 and 6 
months between Analyze Later versus Analyze Early in patients with out-of-hospital cardiac 
arrest. 
 
Hypotheses:  The null hypotheses are that survival to discharge, functional status at discharge 
and at 1, 3 and 6 months as well as depression at 3 and 6 months are identically distributed with 
use of Analyze Later versus Analyze Early in patients with cardiac arrest. 
 
Prespecified Subgroup Analyses: These include assessment of treatment effect by:  
a) Rhythm immediately post electrode placement: VF/VT, PEA, asystole, and not obtained. 
b) Response time from 911 call to initiation of EMS CPR <4 minutes and > 4 minutes. 
c) CPR being performed by bystanders. 
 
Background and Significance 
 
Conceptual Framework for Analyze Later 
Our current paradigm of cardiac arrest defines VF as “shockable,” with the optimal 
therapeutic approach being immediate direct countershock.(42) Integral to this approach is the 
concept that defibrillation attempts should occur without delay upon recognition of VF, either by 
prehospital personnel or the analysis software contained within AEDs, which can then be 
applied by first responders with limited training or even laypersons.(43) This approach has 
defined current Advanced Cardiac Life Support (ACLS) algorithms and shaped the development 
of EMS systems, with prehospital providers that can rapidly respond to victims of cardiac arrest, 
and the placement of AEDs in public areas for use by non-medical personnel. (44-48) The 
ability to provide early defibrillation has resulted in improved survival for cardiac arrest victims 
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with an initial rhythm of VF in some EMS systems and has defined the current standard of care. 
(4, 49) 
One of the major limitations to this cardiac arrest paradigm is its consideration of VF as 
homogenous, without regard for variability in VF morphology or elapsed time since the arrest.  
In contrast, experimental models of VF arrest support three distinct phases, each with a different 
optimal therapeutic approach.(50) The early moments following arrest define an “electrical 
phase” during which little ischemic injury has occurred and rapid defibrillation attempts appear 
to be most efficacious.  After some time period, probably around 3-4 min, the optimal 
therapeutic approach no longer appears to be immediate countershock but instead includes a 
period of chest compressions prior to defibrillation attempts.  It is unclear whether this is related 
to a “priming” effect with the delivery of substrate necessary for successful return of 
spontaneous circulation (ROSC) or the removal of toxic metabolites that have accumulated 
during the ischemic period.  Effective chest compressions, traditionally held to provide 
approximately 30% of normal cardiac output during the first several minutes of CPR, may 
provide sufficient myocardial perfusion and improve the metabolic state of those myocytes in 
patients with ventricular fibrillation.  Immediate defibrillation attempts during the circulatory 
phase may be unsuccessful due to persistent or recurrent VF or may result in terminal PEA or 
asystole.  Interestingly, outcomes in patients”shocked” into PEA or asystole are significantly 
worse than when these are the presenting rhythms. (51) 
After some additional elapsed time period, even chest compressions prior to defibrillation 
attempts do not appear to change outcome.  This may be due to the initiation of irreversible 
ischemic changes that ultimately lead to substantial myocyte and neuronal cell death.  This 
“metabolic phase” is thought to start after about 10 min of total arrest duration, with no currently 
available therapies demonstrating efficacy once this phase is reached. 
 
Preliminary Studies 
 The effect of early rhythm analysis versus later rhythm analysis has been evaluated in 
animal and human studies. Animal models demonstrate improved ROSC and neurological 
outcomes with delayed countershock following a period of chest compressions in VF of 
moderate duration.(52-55) Several investigators have utilized this period of chest compressions 
as a therapeutic window in which to deliver various pharmacological agents designed to 
increase the likelihood of successful ROSC and improve neurological outcomes.  Yakaitis et al 
compared immediate countershock to delayed defibrillation following administration of 
epinephrine and 5 min of chest compressions in a dog model of VF.(52) Immediate defibrillation 
was superior with VF of 1- or 3-min duration, while the delayed approach was optimal with VF of 
5- or 9-min duration.  Niemann et al observed improved outcomes with delayed countershock 
following administration of epinephrine and 5 min of chest compressions alone with a VF 
duration of 7.5 min but not 5 min in a swine model.(53) Menegazzi et al observed substantially 
higher ROSC and better neurological outcomes with administration of a pharmacologic 
“cocktail” followed by chest compressions alone prior to defibrillation attempts versus immediate 
countershock in a swine model of VF of 8-min duration.(54, 55)  
Other parameters besides duration of ischemia may better indicate the likelihood of 
successful defibrillation in VF arrest victims.  Various VF morphologic features have been 
identified as potentially useful in predicting successful defibrillation in animal models of VF.(56-
58) Limited human data exist to support morphological analysis of VF/PVT as a predictor of 
successful ROSC.(58-60) In addition, animal and human data suggest that chest compressions 
alone can modulate these morphological features to a more favorable configuration for 
successful ROSC. (57-59) Berg et al used a swine model of VF to demonstrate that CPR alone 
can modulate VF median frequency to a value predictive of successful defibrillation; 
improvements in ROSC and cardiac function at 1 hour were also observed with CPR prior to 
defibrillation attempts.(57)  Eftestol et al demonstrated improvements in spectral flatness 
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measure, centroid frequency, and amplitude spectrum relationship. Improvement in ROSC was 
also observed in patients with at least 3 min of chest compressions prior to countershock.  None 
of these morphological features have demonstrated adequate predictive value to justify their 
clinical use; however, these data further support the therapeutic value of chest compressions 
prior to defibrillation in VF of moderate duration.  Finally, the duration between cessation of 
chest compressions and direct countershock appears to influence success of ROSC and 
ultimate survival.(61, 62) This suggests that prehospital providers should attempt to minimize 
delays after chest compressions due to rhythm analysis or ventilation prior to defibrillation 
attempts. 
 
Clinical Studies 
 Three clinical studies have compared outcomes from out-of-hospital cardiac arrest due 
to VF when a period of CPR has or has not been prescribed prior to the first attempts at 
defibrillation.(63-65) 
 Cobb et al. conducted an observational, population-based study(63) of 639 patients 
treated for out-of-hospital VF at a time when AED application and use was given the highest 
priority compared with 478 patients for whom 90 seconds of chest compressions and ventilation 
(CPR) were mandated before AED application and use.  An a priori hypothesis was that the 
survival benefit would be most evident in those cases with the greater delay from collapse to 
delivery of the first shock.  Survival to hospital discharge and favorable neurological status at 
discharge (defined as full or nearly full neurological recovery, or requiring some but not 
complete dependence upon others for assistance in activities of daily living) were the primary 
outcomes of the study.   
 Survival to hospital discharge was greater during the intervention period (mandated CPR 
prior to shock) than in the preintervention period (high priority for AED use):  30% vs. 24% 
(p=0.04).  There was a non-significant trend toward a more favorable neurological outcome 
observed during the intervention period (79% of patients with mandated CPR versus 71% of 
patients in whom AED use was prioritized, p=0.11).  A significant interaction also described a 
relatively greater survival benefit for CPR before defibrillation as the response interval of the first 
arriving unit increased, particularly in cases in which the response interval of the first arriving 
unit was 4 minutes or longer (p=0.04) (Figure 4). 
 
Figure 4: Survival versus Response Time Interval With and Without Initial CPR 
 
 
 
 Although its hypotheses were prospectively defined, this study was observational, and 
hence subject to the influence of factors, including the potential biases inherent in non-
randomized studies that tend to overestimate treatment effects.  For example, a change in the 
sequence of CPR could have been accompanied by an unconscious change in emphasis of 
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CPR over shock or even over other interventions during resuscitation.  As the authors 
themselves stated, their “observations represent an encouraging pilot study and that the 
development of randomized clinical trials be considered to evaluate further the influence of CPR 
before the delivery of a shock for patients who have a significant delay prior to treatment”. 
 Wik et al. (64) conducted a randomized trial of 200 patients with out-of-hospital cardiac 
arrest due to VF to compare standard care with immediate defibrillation (n=96) or 3 minutes of 
basic CPR prior to defibrillation (n=104).  In both treatment groups, if three sequential 
defibrillations were unsuccessful, 1 minute of CPR was given for VF/VT or three minutes for 
other rhythms before a new rhythm analysis.  Based on the report by Cobb et al that was 
published  subsequent to the start of the study but before analysis of outcomes, the authors 
hypothesized that survival benefit would be most evident in cases with longer response 
intervals, and analyzed subgroups with response times either up to or longer than 5 minutes.  
 The primary outcome of survival rate to hospital discharge did not differ significantly 
between the two treatment arms of the study (22% in those randomized to CPR-first versus 
15% in the standard group, p=0.17).  Nor were there significant differences in ROSC, 1 year 
survival, “good neurological recovery” at hospital discharge or 1 year after cardiac arrest 
between treatment groups. For those with a response time interval (time from dispatch to arrival 
of first EMS provider) of 5 minutes or less, there were no significant differences in ROSC, 
survival to hospital discharge, 1 year survival, or neurological outcome of survivors.  Among 119 
patients with response times longer than 5 minutes, more patients in the CPR first than in the 
standard group achieved ROSC (58% vs. 38%, p=0.04), survived to hospital discharge (22% vs. 
4%, p=0.006) and survived to 1 year (20% vs. 4% p=0.01). 
 However the criterion for statistical significance in this trial (p<0.05) was not adjusted for 
sequential monitoring performed at six, 18 and 30 months, nor for subgroup analysis.  The 
reported confidence intervals surrounding the estimated benefit were also wide.  Hence the 
findings of this study have to be interpreted with caution, and the observed results not 
interpreted as definitive of benefit from a CPR first strategy.  Moreover, this study had a long 
interval from collapse to EMS arrival (approximately 12 minutes), limiting the generalizability of 
the conclusions. 
 Jacobs et al. conducted a prospective prehospital randomized trial performed in 
Western Australia which randomized 256 patients to a strategy of 90 seconds of CPR before 
defibrillation versus immediate defibrillation.(65) Survival to hospital discharge was not 
significantly different in the CPR first group, 4.2%, compared with 5.1% in the immediate 
defibrillation group.  There was no significant difference in survival to hospital discharge among 
patients with a response interval of <5 versus >5 minutes (12% in the CPR first group, 
compared with 0% in the immediate defibrillation group among patients with a response interval 
<5 minutes (p= 0.24); and 3.5% vs. 4.9%, respectively, among patients with a response interval 
of >5 minutes (p=0.7).  Unfortunately this trial was underpowered due to failure to recruit a total 
sample size of 390 patients, lower than expected baseline survival rates, and exclusion of 41 
eligible cases.  Notably, the overall low survival rate and longer response intervals observed in 
this trial should have favored a greater benefit from CPR before defibrillation if the interactions 
observed by Wik and Cobb et al. between survival and benefit from CPR hold true.   
 
Summary of Rationale 
  
 Survival after cardiac arrest is poor.  The most treatable arrhythmias immediately 
following cardiac arrest are VF and PVT.  Current ACLS algorithms emphasize the importance 
of immediate defibrillation attempts in these patients.  While it has been recognized for many 
years that chest compressions on OOH-CA patients who received “bystander CPR” result in 
positive outcomes,(66) this impact has been relegated to a secondary or even tertiary role in 
resuscitation sequencing.  Small randomized or observational studies suggest that CPR before 
 29 
defibrillation may increase survival but the results to date are inconclusive. Although there is 
some evidence that favors immediate defibrillation in cases where the response time is < 2 
minutes, such response times are rare and the frequent delay in recognition of the OOH-CA and 
calling 911, as well as the complexity of the resuscitation protocol, convince us that response 
time should not be used as an intervention modifier. We believe that there is clinical equipoise 
with regard to the competing strategies of Analyze Early vs. Analyze Later. A large, randomized 
clinical trial is needed to examine the impact of delayed defibrillation on survival to hospital 
discharge in patients who are presumed to be without circulation for several minutes. Since the 
only cost of the intervention is training or retraining providers, the proposed study has the 
potential to have substantial impact upon prevention of premature cardiac death at 
comparatively little cost. 
 
Research Design and Methods 
 
Study Design Overview 
 
 This protocol will be a single-blinded (i.e. blinded to data management team) cluster 
randomized crossover controlled trial with two intervention groups: a) an Analyze Early group, 
and b) Analyze Later group. Subjects in the Analyze Early group will be assigned to receive 50 
(or more) compressions of CPR prior to early ECG analysis and defibrillation shocks if indicated 
and those in the Analyze Later group will receive compressions equivalent to approximately 3 
minutes of CPR prior to ECG analysis and rescue defibrillation.  The intervention will be 
implemented by the first qualified provider to arrive at the scene of cardiac arrest and continued 
by subsequent providers in all ROC sites.  Qualified providers are defibrillation-capable first-
responders, emergency medical technicians (EMTs), and paramedics. 
We will include all out-of-hospital locations within the participating study communities 
within the Resuscitation Outcomes Consortium and served by an EMS agency participating in 
the Analyze Later/Analyze Early intervention (the Seattle Medic One EMS agency is 
participating only in the ITD/sham device intervention of the partial factorial ROC PRIMED 
study).  Outcomes will be assessed in the field and at the receiving hospitals. 
 
Study Population 
 
Inclusion Criteria 
 All persons of local age of consent or older who suffer non-traumatic cardiopulmonary 
arrest outside of the hospital in the study communities with defibrillation and/or delivery of chest 
compressions provided by defibrillation equipped EMS providers dispatched to the scene and 
do not meet any of the exclusion criteria below. 
 
Exclusion Criteria 
– Do not attempt resuscitation (DNAR) orders; 
– Blunt, penetrating, or burn-related injury; 
– Patients with exsanguinations; 
– Known prisoners; 
– Known pregnancy; 
– EMS-witnessed arrests; 
– Non-EMS rhythm analysis (AED placed by police or lay responder is an exclusion but CPR by 
lay or other non-EMS responders is not); 
– Non-ROC EMS agency/provider on scene and CPR begun or pads placed. 
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EMS responders will generally provide CPR according to the cluster randomization even 
for patients with exclusions.  Those with a clear exclusion will not be included in the primary 
analysis.  However, all eligible patients are considered enrolled into the Analyze Later protocol 
regardless of how they are treated and will be included in the primary analysis. 
 
Primary Comparison Populations 
 
The Analyze Late treatment strategy is conjectured to provide an improvement in the 
rate of neurologically intact (MRS ≤ 3) survival to hospital discharge in those patients 
experiencing OOHCA of cardiac origin unwitnessed by EMS and not previously defibrillated. 
EMS witnessed OOHCA should be treated by an Analyze Early strategy. There is, however, no 
contraindication to the use of either Analyze Late or Analyze Early in the relatively few patients 
experiencing OOHCA due to such noncardiac events as strangulation, drowning, or 
electrocution. In the emergency setting, unnecessarily introducing a need for EMS providers to 
evaluate eligibility criteria and randomize individual patients could potentially delay the institution 
of appropriate life saving treatments. Furthermore, if either the Analyze Late or Analyze Early 
strategy is proven superior to the other and therefore adopted widely, the eventual use of the 
superior treatment strategy would likely be applied to all OOHCA unwitnessed by EMS. Hence, 
this study protocol uses cluster randomization and allows for the evaluation of the safety of the 
treatment strategies in some patients for whom there is no conjecture of clear benefit. On the 
other hand, efficacy of the treatment strategies will be analyzed in only those patients who are 
determined to meet the criteria defining the pre-hospital conditions for which the Analyze Late 
strategy is conjectured to be of benefit.  
Efficacy Population: Analysis of primary and secondary efficacy outcomes will be 
conducted on a modified intent-to-treat basis. In order to be included in the efficacy analyses, 
patients must meet the inclusion/exclusion criteria for the Analyze Late vs. Analyze Early 
intervention. In particular, they must not have DNAR orders, have blunt or penetrating traumatic 
injury or burns, be visibly pregnant, a prisoner, a minor, or have had OOHCA witnessed by 
EMS. Furthermore, in order to be evaluable, they must also have not have experienced cardiac 
arrest secondary to drowning, electrocution, or strangulation.  
Safety Population: Evaluation of the safety of the Analyze Late versus Analyze Early 
strategies will be made using all data from patients who were treated, regardless of whether 
they are a member of the efficacy population or not.  This will include patients who were 
defibrillated by ROC EMS providers but did not receive CPR from ROC EMS providers. 
 
Random Allocation 
 
 The intervention will be randomly allocated according to the cluster assignment (i.e., 
Analyze Later or Analyze Early). Each ROC site has been subdivided into multiple clusters (see 
Sample Size section below) by various means. We believe that randomization by event or by 
individual patient is not feasible because the intervention is a psychomotor skill and there would 
be a significant risk of carryover effect from event to event. In addition, randomization by event 
would add unacceptable complexity for EMS providers who already must deal with 
randomization of the ITD protocol. Each RCC will be subdivided into a goal of at least 20 
clusters by the following means: a) according to EMS agency or geographical boundaries, or b) 
according to individual defibrillator devices, rig, or station.  
 The randomization of clusters will be stratified by site. Within each site, clusters will be 
organized in blocks of varying size (hidden from investigators) according to the number of 
patients expected to be treated over the course of the study in that cluster. Within each block, 
clusters will be assigned in equal numbers to order of treatment. All clusters will crossover 
between intervention assignments at least once (i.e. have at least two distinct treatment 
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periods).  Some clusters will crossover more than once (e.g. have four or more distinct 
treatment periods). There will always be an even number of treatment periods.  Among clusters 
having a single crossover, equal numbers will be assigned to Analyze Late first and Analyze 
Early second as are assigned to Analyze Early first and Analyze Late second. Among clusters 
having four treatment periods, equal numbers within each block will be assigned to each of the 
following four orders of treatment: Late-Early-Late-Early, Late-Early-Early-Late, Early-Late-Late-
Early, and Early-Late-Early-Late. Randomization assignment will be performed at the Data 
Coordinating Center prior to the start of the study. Clusters will not be informed as to which 
group they are assigned until it is time to crossover to another intervention. Responders will, 
however, know that each intervention will be tested in the first two periods, and each 
intervention will be tested in the last two periods in each cluster. 
 
 
Intervention 
 
 Detailed descriptions and algorithms demonstrating the sequence of action for Analyze 
Early versus Analyze Later with use of an ITD are presented in Section 4. For those clusters 
allocated to Analyze Later, defibrillator analysis will not be initiated until after delivery of 
compressions equivalent to approximately 3 minutes of CPR, after which a rescue shock will be 
administered, if indicated. For those clusters allocated to Analyze Early, defibrillator analysis will 
not be initiated until the chest compression count reaches 50 (e.g., 30-60 seconds), or as soon 
thereafter as possible, after which a rescue shock will be administered if indicated. 
 
Both Early and Later Arms 
Chest Compressions: Initiation of chest compressions will not be delayed.  Recognition that a 
patient is in cardiac arrest will immediately prompt one rescuer to initiate and count chest 
compressions.  If the scene is first attended by two EMS rescuers, chest compressions will be 
performed by one while the second will set up the monitor/defibrillator and place the defibrillator 
pads.  Then ventilation with the ITD will proceed.  If three rescuers are present, ventilation and 
defibrillation readiness can proceed simultaneously (see Appendix 3 for Resuscitation 
Standards). 
Minimum Interruptions:  Training will emphasize that chest compressions should not be 
interrupted, except for required ventilations.  If endotracheal intubation or other advanced airway 
procedures are deemed medically necessary, the providers should proceed, but continue chest 
compressions with minimum interruption.  However, training will emphasize that interruption of 
chest compressions while securing the airway may dilute the theoretical benefit of the initial 
intervention.  Interruption of chest compressions for airway manipulations will be documented 
when feasible. 
ITD Use:  Training will emphasize that rescuers will use the ITD during initial airway 
management (either facemask or advanced airway). 
 
Analyze Later Arm 
AED analysis will not be initiated until the chest compression count reaches 300, after 
which a rescue shock will be administered if indicated. 
 
Analyze Early Arm 
 Analysis will be initiated as soon as defibrillation pads are in place and 50 compressions 
have occurred and a rescue shock will be administered if indicated. The rescuers will note the 
compression count or time that has been reached by the rescuer assigned to CPR.  After the 
initial analysis, the standard resuscitation protocol will be followed. 
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Arrival of Additional EMS Personnel 
 In tiered response systems, or when backup EMS crews arrive on scene, first-
responders delivering the chest compressions consistent with cluster assignment prior to initial 
ECG analysis should complete this intervention even if paramedics arrive on scene, and, if the 
subject has defibrillation pads in place, continue using the first crew’s equipment until the first 
ECG analysis (and shock, if indicated). 
 Additional personnel are encouraged to assist with ongoing activities that do not interrupt 
chest compressions or initial rhythm analysis.  For example, airway management, rotation of 
chest compressions, and placement of AED/monitor electrodes may benefit from additional 
personnel.  If sufficient personnel arrive, they may also begin attempts at IV access. 
 
Adherence to Protocol 
 Personnel will be discouraged from terminating the protocol prematurely. As intention-to-
treat principles apply, any breach of protocol will not alter the study group to which a patient has 
been assigned. 
 
Intervention – Compliance 
 The time interval from power-on to first ECG analysis (power-to-analysis interval) and to 
first rescue shock (power-to-shock) will be calculated from the time stamps on the electronic 
record. Explicit criteria will be used to define successful delivery of the intended therapy and this 
information will later be fed back to the EMS providers (Table 4). 
 
Table 4:  Intervention Compliance Time Intervals 
 
   Power-to-analysis interval  Power-to-shock interval 
Analyze Early 30-60 seconds   <90 seconds 
Analyze Later 180-200 seconds   180-220 seconds 
 
Outcome Measures 
 
Primary  
The primary outcome is survival to hospital discharge with modified Rankin score < 3. 
Patients who are transferred to another acute care facility (e.g., to undergo ICD placement) will 
be considered to be still hospitalized. Patients transferred to a non-acute ward or facility will be 
considered discharged.  
 
Secondary Outcomes 
The secondary outcomes are survival to discharge; MRS at 3 and 6 months following 
hospital discharge; Adult Lifestyle and Function (ALFI) version of the Mini-Mental Status Exam 
(MMSE) at 1, 3 and 6 months;(31, 32) Health Utilities Index III (HUI3) score(33) at 3 and 6 
months following hospital discharge; and Geriatric Depression Scale (T-GDS)(34) score at 3 
and 6 months (details in Section 4 and Appendix 4). 
 
Exploratory 
Cerebral Performance Category (CPC) will be assessed at discharge, 3 and 6 months 
following hospital discharge. 
 
In-Hospital Morbidity 
Number of hospital days and time interval from 911 call to patient death will be described 
for all hospitalized patients as measures of morbidity after resuscitation. 
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Analyses Methods 
 
Primary Efficacy Analysis 
 
The primary analysis of treatment efficacy will be based on a comparison across 
treatment arms of the observed proportion of patients in the efficacy population with 
neurologically intact (MRS ≤ 3) survival to hospital discharge. A two-sided level 0.05 hypothesis 
test will be used to test the null hypothesis of equal rates of such favorable events (H0: πAE = 
πAL) versus the alternative hypothesis that patients on the Analyze Late arm have a different 
probability of neurologically intact survival to hospital discharge than do patients on the Analyze 
Early arm (H1: πAE ≠ πAL). The data will be analyzed in the context of a generalized linear mixed 
effects model which includes a fixed effect for treatment arm and random effects for each 
randomization cluster. The test statistic comparing treatment arms will be the Wald statistic 
computed as the regression parameter estimate for the treatment indicator divided by its 
estimated standard error. The fixed sample upper one-sided P value corresponding to that Z 
statistic will be compared to the boundaries of the protocol defined group sequential stopping 
rule when expressed on the fixed sample P value scale. At the end of the study, analysis results 
will be summarized using point estimates of the difference in probability of favorable events, 
95% confidence intervals, and P values adjusted for the true sampling distribution imposed by 
the group sequential stopping rule. (See the discussion of the group sequential monitoring plan 
below.) 
 
Secondary Efficacy Analyses 
 
All secondary analyses of efficacy endpoints are directed toward finding supporting evidence for 
the findings of the primary efficacy analysis. As such, they will not be used as the primary basis 
for establishing superiority of one treatment strategy over the other. Hence, there is no plan to 
make any statistical adjustment for the multiple comparisons inherent in the secondary efficacy 
analyses, which include: 
 
Modified Rankin Score (MRS) at hospital discharge. The mean MRS at hospital discharge will 
be compared across treatment groups using a general linear mixed model including the binary 
variable indicating AL vs. AE assignment and random effects for the randomization clusters. For 
the purposes of this analysis, patients dying before admission to the hospital will be treated the 
same as admitted patients dying before hospital discharge and will be assigned an MRS of 6. 
 
Survival to hospital discharge.  This secondary analysis of treatment efficacy will be based on a 
comparison across treatment arms of the observed proportion of patients in the efficacy 
population with survival to hospital discharge. This analysis shall proceed in a manner entirely 
analogous to that for the primary efficacy endpoint.  
 
Neurologically intact survival to hospital discharge adjusted for prognostic variables. A 
secondary analysis of the primary endpoint will adjust for those pre-randomization variables 
which might reasonably be expected to predictive of favorable outcomes. Generalized linear 
mixed models will be used to model the proportion of subjects with neurologically intact (MRS ≤ 
3) survival to hospital discharge by AL vs. AE group adjusted for randomization cluster (random 
effect), site (dummy variables modeling the 11 ROC sites), patient sex, patient age (continuous 
variable), witnessed arrest (binary variable), location of arrest (public versus non-public), time of 
response (continuous variable modeling minutes between call to 911 and arrival of EMS), 
presenting rhythm (dummy variables modeling asystole, PEA, VT/VF, or unknown), and 
treatment assignment in the ITD/sham device intervention. The test statistic used to assess any 
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benefit of one strategy over the other will be computed as the generalized linear mixed model 
regression coefficient for the AL vs. AE treatment assignment divided by the estimated standard 
error. Statistical inference will be based on one-sided P values and 95% confidence intervals 
which adjust for the stopping rule used for the primary analysis. 
 
Post-discharge neurological function, quality of life, and depression. Surviving patients will be 
contacted post-discharge to obtain consent for additional follow-up via telephone with 
consenting patients or their proxies regarding cognition, quality of life, and depression. Primary 
emphasis will be placed on analysis of outcomes at 6 months post hospital discharge, though 
additional analyses will also compare these secondary endpoints 3 months after hospital 
discharge. Analyses of each of these outcomes at each time point will be compared across 
treatment groups using a general linear mixed model including the binary variable indicating AL 
vs. AE assignment and random effects for the randomization clusters.  Analyses will first be 
conducted conditional on survival to the relevant time point by using only data from those 
patients offering consent, as well as using data imputed from discharge data for those surviving 
patients refusing consent. The data missing due to lack of consent for follow-up will be multiply 
imputed using measurements of patient age, sex, length of hospital stay, incidence of major 
adverse outcomes during hospitalization, MRS at hospital discharge, and whether the patient 
was discharged to home or a nursing facility. Additional analyses of neurological function and 
quality of life will then incorporate measurements for patients dying prior to hospital admission, 
during hospitalization, or within 3 or 6 months post discharge. Dead patients will be assigned 
the worse category of neurological function and quality of life for each measurement.  
 
Morbidity As a measure of morbidity during hospitalization, the number of days hospitalized 
conditional upon survival to discharge will be compared across treatment groups using the t test 
which allows unequal variances. A similar analysis will also be conducted comparing the days of 
hospitalization for patients admitted to the hospital, but dying prior to hospital discharge. Finally, 
treatment groups will also be compared with respect to the number of days alive post hospital 
discharge during the first 6 months post OOHCA in order to incorporate information about both 
dead and surviving patients. In this analysis, data missing due to lack of consent for follow-up 
will be multiply imputed using data available at hospital discharge, and patients dying before 
hospital admittance or prior to hospital discharge will be scored as 0. 
 
Safety Analyses 
 
The incidence of adverse events will be recorded for all patients in the safety population 
and presented by treatment arm (AL vs. AE) to the DSMB for their review during the conduct of 
the study, as well as summarized and compared across treatment arms in the final report of 
study results. Statistical significance of differences in the incidence of safety endpoints plays a 
lesser role, due to the need to be cautious in the introduction of new treatments in a human 
population. Hence, emphasis is placed on the presentation of results, with statistical tests 
provided for guidance on the precision of estimates as indicated.  
Since both interventions, Analyze Early and Analyze Late, are in current use, there is no 
anticipation that the study itself will present any safety issue, for example, because of new or 
difficult procedures.  Indeed, one would expect a study benefit in any treatment arm because of 
the increased training and monitoring of CPR performance. Nevertheless specific measures that 
will be monitored include: 
 
Delay of treatment. Witnessed episodes of cardiac arrest with response times (911 call to 
arrival) of less than 4 minutes might be expected to respond to early defibrillation.  This 
subgroup of patients will be carefully monitored for potential harm from an Analyze Later 
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strategy.  The Data and Safety Monitoring Board will be asked to make recommendation 
concerning protocol modification, should any safety issue appear. 
  
Compliance with protocol. Patients with EMS witnessed arrest are to be treated with early 
analysis for defibrillation regardless of cluster randomization to AL or AE. The adherence of 
EMS providers to this aspect of the protocol will be closely monitored. In addition, sites will be 
monitored with respect to adherence to the guidelines for either the Analyze Late or Analyze 
Early strategies according to the cluster randomization scheme. In particular, adherence to 
protocol will be monitored and reported separately for times immediately preceding and 
following sites’ crossover from one strategy to the other.  The Data and Safety Monitoring Board 
will be asked to make recommendation concerning protocol modification, should any safety 
issue related to protocol adherence appear. 
 
Serious adverse events. The incidence of each serious adverse event, along with other major 
adverse medical or surgical outcomes identified during review of hospital records, will be 
tabulated by treatment arm and compared when indicated using Pearson’s chi squared test. In 
order to facilitate the identification of differences in rates of such events that might be due to 
greater survival to hospital admission and/or hospital discharge on one of the treatment arms, 
the incidence of any of the above specific events and/or death (either prehospital or during 
hospitalization) will be reported in a combined fashion and compared as indicated using 
Pearson’s chi squared statistic. 
 
Subgroup  Analyses 
 
Analyses will be performed in each subgroup, along with tests for statistically significant 
interactions. However, it is recognized that the study is not powered adequately to detect 
interactions, and thus all subgroup analyses are judged exploratory. 
 
Sample Size, and Study Duration 
 
The sample size for the factorial trial is driven by the power analysis for the ITD 
intervention. A full description of the assumptions that were used to estimate the sample size 
required for that intervention is given in section 2. The anticipated distribution of patients by 
presenting rhythm and whether arrest was EMS witnessed or not was estimated based on these 
assumptions (Table 5.) 
 
Table 5: Proportion of all EMS treated OOHCA patients according to presenting rhythm and EMS Witness 
status 
 
Presenting Rhythm EMS Witnessed EMS Unwitnessed Total 
Asystole 0.0231 0.4769 0.500 
Pulseless Electrical Activity (PEA) 0.0270 0.2230 0.250 
VT/VF 0.0499 0.2001 0.250 
TOTAL 0.1000 0.9000 1.000 
 
Eligibility criteria for the AL vs. AE intervention excludes subjects for whom the arrest 
was witnessed by EMS. The distribution of patients to the various treatment strategies by 
presenting rhythm was estimated by taking into account that patients with EMS Unwitnessed 
OOHCA will be randomized (by cluster) in a 1:1 ratio to the AE or AL strategies (Table 6). 
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Table 6: Proportion of all EMS treated OOHCA patients randomized to treatment combinations according to 
presenting rhythm and EMS Witness status 
 
EMS Witnessed CA or 
Seattle Medic One 
(AL vs. AE Ineligible) 
Analyze Early Analyze Late 
Total  
AE vs AL 
Randomized Initial Rhythm 
No 
Device Sham ITD 
No 
Device Sham ITD Sham ITD AE AL 
Asystole 0.000 0.018 0.018 0.000 0.116 0.116 0.116 0.116 0.232 0.232 
PEA 0.000 0.017 0.017 0.000 0.054 0.054 0.054 0.054 0.109 0.109 
VT/VF 0.015 0.020 0.020 0.029 0.034 0.034 0.049 0.049 0.097 0097 
TOTAL 0.015 0.055 0.055 0.029 0.204 0.204 0.219 0.219 0.438 0.438 
 
Based on ranges of estimates in published data and results of the ASPIRE trial, and 
allowing for 1-5% improvement due to greater quality control on CPR process in the clinical trial 
setting, It is estimated that in the absence of an ITD and when managed according to the 
Analyze Early (AE) strategy, the probability of survival to hospital discharge would be 1.05% for 
patients presenting with asystole, 4.02% for patients presenting with PEA, and 20.20% for 
VT/VF. These assumptions lead to an estimated probability of survival to hospital discharge of 
0.0609 when treated under the AE strategy with a sham valve. Assuming that 88.9% of such 
survivors would have acceptable neurological status (MRS ≤ 3), we thus estimate a rate of 
0.0541 for neurologically intact survival to hospital discharge under treatment with the AE 
strategy and a sham valve.  
Under the alternative hypothesis used for power calculations, the effect of the Analyze 
Late strategy on neurologically intact survival is presumed to vary by presenting rhythm. While 
patients with initial rhythms of asystole and PEA cannot expect to benefit from an Analyze Early 
versus Analyze Later protocol in the sense of potentially obtaining early defibrillation, they could 
benefit from the Analyze Later strategy by having fewer delays in blood circulation due to taking 
time for early analysis. We therefore hypothesize a 3% relative increase in survival for patients 
in the AL arm over the AE arm for these two rhythms. A relative benefit of 1.50 is hypothesized 
for those patients in the VT/VF, with the benefit occurring primarily in patients who would not 
respond rapidly to early defibrillation, though that group cannot be identified a priori. Applying 
these hypothesized effects to the numbers given above results in an estimated probability of 
survival to hospital discharge of 0.0838 for patients treated with an AL strategy in the absence 
of an ITD, with a corresponding hypothesized rate of 0.0745 for neurologically intact survival to 
discharge. Details of these calculations are provided below (Table 7). 
 
Table 7: Estimated proportions of all EMS treated OOHCA patients surviving to discharge and surviving to 
discharge with MRS ≤ 3 by AL vs. AE treatment arm and presenting rhythm 
 
Presenting Rhythm Stratum Weight 
Analyze Early 
Probability of 
Survival to 
Discharge 
AL / AE 
Relative 
Benefit 
AL Probability of 
Survival to 
Discharge 
Asystole 0.5299 0.0105 1.03 0.0108 
PEA 0.2478 0.0420 1.03 0.0433 
VT/VF 0.2224 0.2020 1.50 0.3030 
 
Probability of Survival to Discharge 
(weighted average) 
 0.0609  0.0838 
 
Probability of Neurologically Intact 
Survival to Discharge 
(88.9% of patients surviving to hospital 
discharge) 
 0.0541  0.0745 
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In the process of accruing 14,154 evaluable patients to the ITD/sham device 
intervention, it is estimated that approximately 15,423 patients with OOHCA will be treated by 
EMS at one of the participating ROC sites, with approximately 13,509 of these patients eligible 
to participate in the Analyze Late or Analyze Early interventions. Estimating that 98% of these 
patients will be judged evaluable, 13,239 patients will be used for the comparison of Analyze 
Late versus Analyze Early strategies. We therefore consider the ability of a two-sided level 0.05 
test with 13,239 subjects to reject a null hypothesis that the probability of neurologically intact 
survival to hospital discharge is 0.0541 on both treatment arms, with statistical power computed 
under the alternative hypothesis that the AL arm would instead have a 0.0745 probability of 
neurologically intact survival. The data will be analyzed in the context of a generalized linear 
mixed effects model which includes a fixed effect for treatment arm and random effects for each 
randomization cluster. The test statistic comparing treatment arms will be the Wald statistic 
computed as the regression parameter estimate for the treatment indicator divided by its 
estimated standard error. Power computations are based on formulas appropriate for a two-
sample test of binomial proportions using Pearson’s chi squared statistic. We incorporate into 
those computations an assumed 5% loss of efficiency due to the cluster randomization with 
crossover.  
 
The clinical trial will be conducted using a two-sided level 0.05 group sequential stopping 
rule based on up to three analyses (two interim analyses and the final analysis) after accruing 
approximately one-third, two-thirds, and all of the maximal sample size. The stopping rule 
corresponds to an O’Brien-Fleming design as described in more detail under the monitoring 
plan. Using that stopping rule, a sample size of 13,239 evaluable patients will provide 
approximately 99.6% power to reject the null hypothesis under the conjectured treatment effect.  
 
The 11 participating ROC sites are estimated to have approximately 10,000 OOHCA 
treatable by EMS each year, so it is estimated that accrual of 13,239 evaluable patients for the 
Analyze Late versus Analyze Early comparison will require 20 months. 
 
Effect of Clustering and Crossover Upon Required Sample Size 
 It is anticipated that the number of cardiac arrest episodes in each cluster will vary, as 
the underlying size of the geographic area and population served are variable. Some sites will 
cross a large geographic area over from one intervention to the other during the trial to reduce 
the expected number of episodes; others will cross monitor/defibrillators from one intervention to 
the other. Most cluster designs assume equal-sized clusters, but the presence of unequal 
cluster size has implications for sample size (Appendix 5). 
 
The clusters and annual expected number of cardiac arrests episodes in each site are 
shown below (Table 8). Since most clusters employ crossover, and those that do not have small 
expected numbers, the effective sample size of each cluster should be at least 95% efficient 
compared to individual randomization.  This is a conservative assumption since utilizing the 
crossover design is actually more efficient then even individual randomization. 
 
 Having close to 20 or more clusters at each site with no overly large cluster, as well as 
using crossover and randomizing so that each intervention is being used by half of the clusters 
at any time will provide reasonable balance between temporal factors, as well as system and 
patient factors. 
 
 We can think of no likely crossover effect except that compliance might be compromised 
by habit or forgetfulness at the time of crossover.  We will be monitoring compliance, and if non-
 38 
compliance is >2-fold higher in the 2 weeks following crossover than in the several months 
before at a site level, then all episodes from that 2-week period at that site will be dropped from 
the primary analysis.  Of course, measures would be taken by the local site to address the 
“crossover compliance” issue. 
 
 Other designs were taken into consideration, particularly individual episode 
randomization.  Devices (AEDs) are not currently capable of being programmed to randomize 
individual episodes and then provide correct prompts.  Other forms of individual randomization 
(e.g. envelope) would therefore result in expecting EMS providers to ignore existing prompts.  
The consensus of the ROC investigators was that this would create serious compliance issues 
and individual randomization was not seen as a viable option.  The simplest design is to invoke 
cluster design without crossover.  This method is less efficient then crossover, or individual, 
randomization.  Therefore clustering design with crossover is seen as the most efficient design 
from the choice of feasible and practical designs. 
 
 
Table 8:  Summary of ROC Site Cluster Plans 
 
 
Pop Served 
(#) 
Annual CA 
Treated (#) Cluster Type # of Clusters 
Toronto 2,456,800 1,777  geographic,  214 
   agency, station  
     
Alabama 1,278,936 485 rig 75 
     
Portland 1,444,219 604 agency, station 166 
   defib  
     
Pittsburgh 670,911 690 rig 124 
     
Seattle/King Co 1,191,204 555 agency, geographic 31 
     
Dallas 2,023,705 1,331 rig 151 
     
Ottawa 3,000,000 1,468 geographic,  246 
   agency, defib  
     
Milwaukee 928,018 794 station 61 
     
BC 3,115,331 1,364 geographic 32 
     
San Diego 2,900,000 2,161 rig 334 
     
Iowa 956,188 875 geographic 15 
     
Totals 19,965,312 12,104  1449 
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4. Factorial Implementation of Both Protocols 
 
Summary 
 
The background, significance, aims, and hypotheses of the ITD and Analyze Later versus 
Analyze Early trials have been previously described.  Investigators intend to implement these 
studies simultaneously (though staggered start and stop times may occur because of 
resource/regulatory logistics), capitalizing on the common infrastructure necessary to 
accomplish the studies, thereby improving efficiency and speed of their completion.  The 
following describes study issues common to both the ITD and Analyze Later versus Analyze 
Early studies including Study Setting, Study Population, Resuscitation Guidelines, Monitoring of 
CPR Process, Outcome Measures, Data Collection, Training, Data Safety Monitoring Strategy 
(DSMB), and Human Subjects. 
 
Setting 
 
The Resuscitation Outcomes Consortium (ROC) includes ten Regional Clinical Centers. These 
ROC sites are served by approximately 200 EMS agencies. The baseline characteristics of 
these ROC sites are summarized in Table 9. Of greater than 12,000 cardiac arrest episodes 
among the sites, annually, approximately 10,000 are treatable by EMS. 
Table 9: Distribution of Initial Cardiac Rhythm and Outcome for Cardiac Arrest Episodes Among ROC Sites 
 
  
Dallas Iowa Milwaukee Ottawa Ottawa Pittsburgh Portland Seattle Seattle Alabama Toronto San Diego Total 
EMS System Biotel     OPALS BC     King County 
Seattle 
EMS         
Year 
Reported 2003 2003 2004 2002 2003 
Average of 
1998-2002 2003 2003 2003 2004 2002 2004 
  
  
Population 
Served 2M 956k 928k 3M 3.1M 671k 1.4M 1.2M 600k 1.3M 2.5M 2.9M 20.6M 
VF or PVT 297 294 162 470 431 235 151 158 95 106 462 648 3509 
   Survived to 
   discharge 50 44 32 62 74 33 37 44 29 24 39 97 565 
   Received 
   <=1 shock 178 217 158 281 258 141 112 116 70 73 120 427 2151 
Asystole 676 349 437 601 577 289 211 235 147 285 817 1102 5726 
   Survived to 
   discharge 14 5 10 5 12 12 3 6 0 5 7 33 112 
PEA 358 232 195 397 356 166 242 162 91 94 498 411 3202 
   Survived to 
   discharge 25 12 18 9 7 10 15 16 12 6 12 21 163 
             Totals 
 40 
Cardiac 
arrests 1331 875 794 1468 1364 690 604 555 333 485 1777 2161 12437 
Survived to 
discharge 89 61 60 76 93 55 55 66 41 35 58 151 840 
Note:  Shaded numbers are estimated          
 
Study Population 
 
 Except for some specific situations, the inclusion and exclusion criteria for both ITD and 
Analyze Later protocols will be the same. 
 
Inclusion Criteria 
 All persons of local age of consent or older who suffer non-traumatic cardiopulmonary 
arrest outside of the hospital in the study communities with defibrillation and/or delivery of chest 
compressions provided by EMS providers dispatched to the scene and do not meet any of the 
exclusion criteria below.  
 
Common Exclusion Criteria 
– Do not attempt resuscitation (DNAR) orders; 
– Blunt, penetrating, or burn-related injury; 
– Patients with exsanguinations; 
– Known prisoners; 
– Known pregnancy. 
 
ITD Exclusion Criteria 
– Tracheostomy present; 
– CPR performed with any mechanical compression device (e.g. AutoPulse, Thumper, ACD-
CPR). 
– Ventilated with a mechanical device (e.g. automated transport ventilator).  Note: a bag-mask 
is not considered a mechanical ventilator device. 
– A non-ROC EMS agency/provider, for whom time call received at dispatch cannot be  
obtained, began CPR or placed pads. 
 
Analyze Later Exclusion Criteria 
– EMS witnessed arrests; 
– Non-EMS rhythm analysis (AED placed by police or lay responder); 
– Non-ROC EMS agency/provider on scene and began CPR or placed pads. 
 
Resuscitation Guidelines 
 
The ROC Investigators have developed and will disseminate consensus guidelines on 
how the patient with cardiac arrest should be treated in the prehospital, emergency department 
and hospital setting (see Appendix 3). 
 
Monitoring of CPR Process  
 
A long-term goal of the Resuscitation Outcome Consortium (ROC) is for all participating first 
EMS responders and ALS providers to have technology on, or adjunctive to, their automated 
(AED) and/or manual monitor/defibrillators that can monitor individual components of 
resuscitation. These data will serve as the basis for regular, systematic monitoring and review of 
the CPR process for purposes of quality improvement at each ROC site before and during 
clinical trials.  Such processes will assure the safety of CPR performance in the field. Also 
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feedback of this knowledge is essential to care delivery since improved quality assurance has 
been associated with improved outcomes after resuscitation.(67) Finally, it is essential to 
efficient trial conduct since low baseline rates of survival are associated with larger sample sizes 
to detect a clinically important difference.  
 
Rationale 
Recent studies have demonstrated that CPR is frequently not performed according to 
evidence-based guidelines in the out-of-hospital and in-hospital setting.(28, 29) Although these 
studies lacked power to detect a significant relationship between CPR process and patient 
outcome, a related study demonstrated that a greater rate of chest compressions was 
associated with a greater likelihood of achieving restoration of spontaneous circulation.(68) The 
importance of monitoring and improving CPR process was confirmed by the observation of 
potentially deleterious hyperventilation in the Milwaukee pilot study of ITD.(26)  
A variety of evolving technologies offer the ability to monitor CPR process either directly 
or indirectly through AEDs.  These include chest impedance (69) (used to monitor chest 
compression rate and ventilation rate(70)), chest acceleration(71) (used to monitor chest 
compression rate, depth, release, and duty cycle), and audio recording (used to monitor audible 
events during resuscitation).   Each of these measures has advantages and limitations.   For 
example, a recent prehospital study reported that even when obtaining data related to CPR 
process was emphasized, technical and signal quality limitations prevented its analysis in more 
than 25% of episodes(29).  In addition, there is also considerable site heterogeneity across the 
Consortium that precludes the use of a single manufacturer or a single CPR monitoring 
technology.  Accordingly, the Consortium has defined and will monitor a minimal data set 
pertinent to the CPR process but allow each participating site to individually specify and 
implement the means by which such data will be obtained.  Please see Appendix 2 for a list of 
how each EMS Agency will monitor CPR process. 
 
Method of Monitoring CPR Process 
Overview- In preparation for the start of formal CPR process monitoring and the proposed ROC 
cardiac arrest trial, an educational program will be developed and implemented at each site to 
refresh provider skills on chest compression and ventilation, with emphasis on uninterrupted 
chest compressions, minimizing of "hands-off" intervals, and avoidance of hyperventilation. 
All ROC clinical trial sites will implement a high-quality system for monitoring individual 
components of CPR, to include, at a minimum, the rate of chest compressions, the rate of 
ventilation, and the proportion of pulseless resuscitation time during which chest compressions 
are provided (i.e. CPR fraction).  Recent studies show no significant differences in these 
parameters during the first five minutes of resuscitation as compared with the entire 
resuscitation episode.(28, 29) It is anticipated that during the initial period interruption of CPR 
due to rhythm analysis or other procedures is more likely than throughout the resuscitation 
episode. After insertion of an advanced airway and initiation of ventilation that is asynchronous 
with chest compressions, hyperventilation is more likely than during the early resuscitation 
period. Therefore CPR process will be quantified during the first analyzable five minutes for 
100% resuscitations as well as ventilations throughout the resuscitation episode in those who 
receive an advanced airway, until a sustained return of spontaneous circulation or resuscitation 
efforts are terminated.  Sites will be encouraged to monitor the entire episode. 
Sites will be required to demonstrate an ability to adequately acquire and analyze these 
CPR process data, identify and attempt to correct any observed deficiencies, and meet 
minimum performance standards (Appendix 2 CPR Process Monitoring:  CPR Performance 
Standards) before being eligible to enroll patients in the present trial.  In addition, ongoing 
monitoring and review of CPR process, will be used throughout the conduct of the trial. 
 
 42 
Monitoring Devices- A range of monitoring/defibrillator devices will be deployed across the 
ROC sites that have capabilities to monitor CPR process.  These devices and their capabilities 
are summarized in Appendix 2 CPR Process Monitoring:  CPR Process Monitoring Devices. 
 
Specific Methods- BLS and ALS providers will be trained to turn on the power of their AED or 
monitor immediately upon recognition of a subject in cardiac arrest.  Monitoring hardware will be 
applied to the patient as soon as possible.  This power-on event will initiate the recording by the 
device, and serve as a surrogate marker for “time zero” of initiating CPR.  Each site will make 
efforts to maintain synchronization of monitor clocks with a common time standard (e.g. atomic 
clock time). 
 At the completion of every resuscitation attempt, the electronic record from the BLS and 
ALS devices used during the call will be obtained by the investigators.  All electronic records will 
be reviewed manually by using the commercial software specific to the device, assisted where 
available, by proprietary automated analysis software.  The record will be annotated from the 
time of power-on (“zero time”), and the parameters of resuscitation quantified during these 
periods (Appendix 2).  Determination of whether a resuscitation effort meets minimally 
acceptable CPR performance standards for the Consortium will be based on whether it meets 
acceptable chest compression rate, ventilation rate and CPR fraction criteria as defined in 
Appendix 2.   
 Use of immediate (real-time) feedback software will be at the discretion of individual 
ROC sites and EMS agencies.  Depending on system configuration, providers may be prompted 
by such software to modify the rate or depth of chest compressions, and to minimize 
interruptions in the provision of CPR.  When such feedback is deployed, prompts will conform to 
the same target ranges specified in ROC CPR performance standards.  Regardless of whether 
or not real-time feedback is provided, all resuscitations will be reviewed for adherence to the 
same performance standards, and a mechanism in place for remediation, if necessary.  CPR 
process data derived from resuscitations during which real-time feedback was provided will be 
designated by an appropriate identifier.  These sites may separately examine the impact of 
using real-time feedback in their systems. 
 
 
 
Outcome Measures 
 
Primary  
 The primary outcome for both studies is survival to hospital discharge with modified 
Rankin score < 3. Patients who are transferred to another acute care facility (e.g., to undergo 
ICD placement) will be considered still hospitalized. Patients transferred to a non-acute ward or 
facility will be considered discharged. 
 
Secondary 
 Note that additional background information, rationale for selection, and details about 
specific functional status measures are given in Appendix 4. An interesting methodological issue 
is how to measure post-discharge outcomes. Physician and neuropsychological evaluations are 
considered the gold standard for the diagnosis of cognitive impairment. However such methods 
are unlikely to be feasible and likely to be associated with a high proportion of missing data in a 
population that resides in such a diverse geographic area as that participating in the 
Resuscitation Outcomes Consortium. For example, data from the ROC EMS structures serve 
demonstrates that participating EMS agencies (72% reporting) serve a total catchment area of 
78,521 square miles. If the pattern of missingness is informative (e.g. patients from rural areas 
with delayed resuscitation less likely to be interviewed), then the post-discharge outcome data 
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are susceptible to bias. Therefore all post-discharge outcome assessments will be made by 
using measures validated for phone administration to increase the response rate. All 
assessments will be made by trained interviewers. 
 
Our criteria for choosing particular instruments to measure neurological status include 
prior data about reliability and reproducibility, availability of instruments suitable for a multicenter 
trial, and prior data in cardiac arrest survivors. The Modified Rankin Scale (MRS) has face 
validity and can be determined via review of the clinical record, in person or over the 
telephone.(72, 73) MRS has concurrent validity with other measures of neurological recovery 
after stroke and brain injury.(74, 75) MRS has prior use in a cohort of neurosurgical patients 
with in-hospital cardiac arrest(76) and in a cohort of survivors of out-of-hospital cardiac 
arrest.(77) 
 
 We are aware that CPC is less validated compared to some other measures that will be 
utilized in this study. CPC will be assessed by using a structured questionnaire via telephone 
administration (Appendix 4 of protocol). These latter questions were developed based on 
experience assessing outcomes after discharge in the OPALS study, PAD trial and ASPIRE 
trial.  However it should be recognized that these questions have not been validated in their 
current format. 
 
The Health Utilities Index (HUI) is a generic measure of health-related quality of life. 
(33) It has reliable interview, telephone, and proxy instruments with extensive validation in a 
multiple populations, including two cohort studies of survivors of cardiac arrest.(84, 85) HUI was 
positively correlated with bystander CPR, suggesting construct validity for measuring 
neurological injury incurred during cardiac arrest.(85)   
 
The Adult Lifestyle and Function (ALFI) version of the Mini-Mental Status Exam (MMSE) 
is a measure of cognitive status.(31, 32) ALFI-MMSE correlates with severity of cognitive 
impairment as measured by the Clinical Dementia Rating Scale class.(31) Compared to the 
brief neuropsychiatric screening test, which is a weighted score of the Trailmaking A,(86) Word 
Fluency,(87) Weschler Memory Scale-Mental Control and Logical Memory,(88) ALFI-MMSE had 
a sensitivity of 68% and specificity of 100% for mild cognitive impairment. The corresponding 
MMSE values were 67% and 100%.(31)   
 
  The telephone version of the Geriatric Depression Scale (T-GDS)(34) detects the 
presence or absence of depression. Using a cutoff of 10/11T-GDS has a sensitivity of 86% and 
specificity of 70% for detecting depression compared to a comprehensive assessment by a 
geriatric psychiatrist. 
 
Table 10:  Timing and Content of Secondary and Exploratory Outcome Measures 
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Exploratory Outcome 
 
Consensus statements recommend use of the Cerebral Performance Category (CPC) 
to assess functional outcomes after resuscitation from cardiac arrest.(78, 79)  CPC is a five-
point scale that was adapted from the Glasgow Outcome Scale.(80, 81)  CPC had limited 
discrimination between mild and moderate brain injury, and only moderate correlation with a 
generic measure of health-related quality of life in a small study that was limited by a high rate 
of loss to follow-up.(82)  However, CPC predicts long-term survival after resuscitation from 
cardiac arrest.(83)   
 
Method of Assessing Post Discharge Outcomes 
 
All post-discharge assessments will be performed by using instruments that will be made 
available in English and Spanish.  Study coordinators will be trained to administer these 
instruments prior to study implementation by using didactic instruction, standardized patients 
and mock interview of each other according to current standards.(89) Spanish-language 
translators will be used as required. Interviewers will be instructed to speak clearly and 
articulate distinctly; ascertain the interviewee’s ability to hear a spoken language at a 
conversational volume; try to ensure no one other than a proxy and the interviewee are present; 
if a precise answer is not given, probe for the correct response; exercise judgment about 
allowing sufficient time to answer a question before proceeding on to the next question; record 
the interviewee’s last response as their answer to each question. Only research staff that 
completed this training successfully will be allowed to perform post-discharge assessments.  
 
We are aware that some patients may be too impaired to complete an interview. 
Therefore, the ALFI-MMSE will be the instrument administered first during the three month 
interview. Patients who score >17 will be asked to complete the interview by self-report. 
Patients who score < 17 will be assessed further by interview of a proxy. We and others used a 
similar approach to assessment of post-discharge outcomes in the Public Access Defibrillation 
(PAD) trial. Contact details for the patient and their proxy will be identified at the time of 
notification of participation in hospital. Consent will be sought from the patient and their proxy for 
interview after discharge. 
 
In-Hospital Morbidity 
Number of hospital days and time interval from 911 call to patient death will be described 
for all hospitalized patients as measures of morbidity after resuscitation. 
 
Other Outcomes 
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 Other surrogate outcomes will be collected for descriptive purposes: 
i) Return of Spontaneous Circulation: (ROSC) defined as the documented presence of a 
measurable pulse and blood pressure at any time after initiation of resuscitative efforts.  There 
is no minimum duration for this return of spontaneous circulation. 
ii) Admission to Hospital. 
iii) Survival to 24 Hours. 
iv) Process Outcomes: a) Number of Shocks Required: The total number of defibrillatory 
shocks; b) Duration of Pulselessness: The duration of pulselessness (from 911 to ROSC). 
 
Data Collection 
 
Data Forms 
Appendix 6 contains draft data forms for both protocols. 
 
Source of Data Collection 
Data will be collected prospectively as patient care progresses. This will include a review 
of all the EMS patient care report(s), EMS dispatch times, EMS/fire/first responder electronic 
ECGs, emergency and hospital records. No additional studies or patient contact (except for 
notification of study participation) will be required for collection of this data up to hospital 
discharge.  
 
Data Common to Both Protocols 
Out-of-Hospital 
 Demographics, EMS response times (call receipt to arrival, arrival at patient side, etc.), 
witnessed arrest, bystander CPR, location of arrest, CPR process monitoring measures 
(ventilation rate, compression rate, CPR fraction), cause of arrest (cardiac vs. non cardiac), 
EMS therapies (drugs, shocks, advanced airway, hypothermia), first ECG rhythm, disposition, 
return of spontaneous circulation, potential adverse events. 
Emergency and Hospital  
 Major procedures, possible complications of intervention, admittance to the hospital, 
cause of arrest, ICU days, date of awakening, disposition at discharge, withdrawal of care (DNR 
status) as well as MRS and CPC at hospital discharge. 
Follow-up 
 Patients will be contacted by study personnel at 1 month after discharge and will have 
the ALFI-MMSE applied by telephone interview. They will be contacted by study personnel at 3 
months and 6 months to have the MRS, CPC, ALFI-MMSE, HUI and GDS applied by telephone 
interview. 
Initial ECG Rhythm 
 The initial ECG tracing will be analyzed off-line.  The individuals performing this analysis 
will be blind to the interpretation that was performed in real-time by the AED and/or rescuers.  
The entire tracing that is available for analysis will be provided, and three possible ECG rhythms 
will be defined. 
 Asystole will be defined as background electrical activity less than 0.2 mV in amplitude 
with <10 beats per minute average rate (e.g., a 6-second strip without ventricular complexes). 
 VF will be defined as irregular, disorganized ventricular electrical activity of variable 
amplitude exceeding 0.2 mV. 
 Pulseless electrical activity (PEA) will be defined as electrical activity with R-waves of 
any width at an average rate of >10 beats per minute (e.g., organized ventricular electrical 
activity with R waves of any width that occur more than once over a 6-second period).  The rate 
of PEA will be recorded as well. 
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Items Specific to ITD Protocol 
 Items specific to the ITD protocol will generally deal with events surrounding the use of 
the device; approximate time ITD attached, vomit with ITD, attachment of ITD to bag-mask or 
advanced airway, adverse/unusual events (device fills with fluid twice, device failure, patient 
complications) and protocol adherence. 
 
Items Specific to Analyze Later Protocol 
 Items specific to the Analyze Later protocol will generally deal with events surrounding 
the compliance with the assigned cluster.  Each event will be reviewed to determine whether the 
assigned protocol was followed.   
 
Data Entry 
The DCC will provide web-based HTML forms to collect necessary information from the 
RCCs. Web entry forms will have dynamic features such as immediate checks on data and 
relationships within a form and between forms.  Details and clarification about data items will be 
provided using pop-up windows and links to appropriate sections of the on-line version of the 
Manual of Operations.  Data encryption and authentication methods will be used. The DCC will 
build additional features into the web entry forms including: forms transmission history, access 
to past forms, tracking of data corrections, and the capability to save and re-load incomplete 
forms. 
 
Database Management 
The DCC will use a two-tiered database structure.  A front-end database serves the web 
entry needs, using a database management system well-suited to handling updates from 
multiple interactive users.  The data from this database will be transferred periodically (e.g. bi-
weekly) to a “warehouse” database, on which data queries for analyses and monitoring will be 
run.  Various versions of this database are kept as needed, e.g. for quarterly or DSMB reports.  
The “warehouse” database management system was selected for its ability to manage large 
quantities of data, to merge data from multiple databases as required, to handle complex and 
possibly changing relationships, and to produce analysis datasets that can be imported into a 
variety of statistical analysis packages. 
 
Training 
 
Overview 
The training objectives include the following (each detailed below): review of optimal 
CPR performance, scientific basis for and review of study protocols, practicum/”hands-on” 
session, and post-test.  It is anticipated that approximately 2 hours of didactic instruction and 1 
hour of practicum will be required. 
 
Optimal CPR Performance 
The purpose of this component is to provide training in optimal chest compression and 
ventilation skills for all participating EMS personnel and to standardize the performance of CPR 
across all ROC sites as much as possible.  This training component will be implemented either 
as part of the protocol training or as a separate training module prior to specific study training.  
Key concepts include: optimal chest compression rate (100/min) and depth (38-51 mm), correct 
hand position on the distal sternum, complete chest wall recoil with each compression, 
minimizing “hands-off” intervals, avoiding hyperventilation (target rate 10-12/min), and proper 
breath duration (<2 seconds for an unprotected airway and 1 second for a protected airway).  
Training will also emphasize maintaining a continuously tight facemask seal with the “E-C” hand 
technique (one airway rescuer) or two-handed technique (two airway rescuers) when using the 
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ITD and the use of ventilation timing assist lights with advanced airways (e.g., Combitube, 
laryngeal mask airway [LMA], or endotracheal tube).   
 
Scientific Basis for ITD and Analyze Later Protocols 
Level-appropriate presentation of the scientific principles underlying the ITD and Analyze 
Early versus Analyze Later studies will increase provider investment and improve protocol 
adherence.  This should include presentation of prior work in both animals and humans and 
justification for a randomized clinical trial, including discussion as to why these approaches 
require further investigation prior to widespread implementation. 
 
Study Protocols 
This section will include the following: overall study design, inclusion and exclusion 
criteria, the process of exception to informed consent under emergency circumstances, and the 
study protocol.  While the overall factorial design makes the analytic methodology somewhat 
complex, the operational protocol has been simplified for the purposes of training and actual trial 
implementation.  From the provider perspective, there are only two arms to the study, as an ITD 
will be applied to all eligible patients but the group assignment (active or sham device) will be 
unknown to the providers.  This creates an Analyze Early arm and an Analyze Later arm, both 
with ITD application existing as part of the study protocol.  The training will mandate that one of 
the providers be designated the “compressor”; this designation should occur prior to the patient 
encounter to avoid confusion about role assignments once an arrest is recognized.  The two 
study arms are then defined by the number of compressions delivered by the “compressor” 
before a pause for rhythm analysis and defibrillation attempts when indicated.  In the Analyze 
Later arm, a number of compressions equivalent to approximately 3 minutes (e.g. 300 if the 
local CPR protocol is 100 compressions per minute with ventilations interposed, 180 if the local 
protocol is a compression:ventilation ratio of 15:2) will be delivered, while in the Analyze Early 
arm a minimum of 50 compressions will be delivered (see schematics below).  The 
“compressor” should count the number of compressions out loud to alert the other providers as 
to the ongoing duration of chest compressions and to maintain an accurate count.  Visual 
reminders (such as a colored tag on the AED/defibrillator) designating “300” or “50” 
compressions will be used to enhance protocol compliance, especially with a crossover design.  
In addition, crews will be encouraged to review their designated number of compressions as 
part of the daily checklist.  The use of the term “compressor” should be encouraged, not only to 
enhance protocol compliance but also to underscore the importance of chest compressions 
during resuscitation.   
Training will define two tasks for the remaining provider(s): a) placement of the 
monitor/defibrillator pads and preparation for analysis/defibrillation, and b) proper application of 
the ITD/facemask, including maintenance of a continuously adequate seal during chest 
compressions and ventilations.  The first priority following initiation of chest compressions by the 
“compressor” is the rapid placement of defibrillator pads; the monitor/defibrillator should be 
“powered-up” immediately upon recognition of pulselessness or sooner.  The ITD and facemask 
should then be attached to the resuscitation bag and oxygen canister and a continuously tight 
seal maintained.  When additional personnel are available, the two tasks should be performed 
simultaneously.  Training will emphasize immediate use of the ITD with initial airway 
management and continued use throughout the resuscitation while chest compressions are 
being performed as well as dedication of a single individual to maintaining adequate mask seal 
using a two-handed facemask technique whenever possible.  Upon completion of rhythm 
analysis and defibrillation when indicated, standard ACLS procedure will ensue. Providers will 
receive specific training to transfer the ITD to the advanced airway and activate the ventilation 
assist timing lights on the ITD (both sham and active) once tube confirmation has occurred.  
Asynchronous ventilations should be performed using the assist timing lights as a guide.  The 
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proper ITD “clearing” procedure, indications for discontinuation of the ITD, and completion of 
study protocol will also be covered, including turnover report to ED personnel and retrieval of 
the ITD. 
 
 
 
 
Figure 5:  Training Scheme 
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Protocol Practicum 
 Providers will be given the opportunity to practice to proficiency each component 
of the protocol.  The number of providers used during these rehearsals should simulate 
actual clinical practice whenever possible.  The use of an AED or ALS defibrillator 
should also be dictated by clinical practice, using the identical brand and technology that 
will be available during the trial.  Various permutations of the study protocol should be 
presented, including each of the study arms as discussed above.  Specific assessment 
goals should emphasize inclusion/exclusion criteria, role assignment, correct number of 
compressions, maintenance of continuous tight facemask seal during CPR using “E-C” 
hand technique or two-handed technique, transfer of ITD to advanced airway and 
performance of optimal CPR (minimal “hands-off” time).  All EMS personnel need to 
demonstrate proficiency in adequately managing a factorial study cardiac arrest patient.  
See Appendix 7 for a list of training proficiency goals. 
 
Cognitive post-test 
 A cognitive post test will cover key enrollment procedures and may be completed 
online or as a written or verbal component of the training sessions.  A record of training 
completion will be maintained by each site or EMS agency  
 
Run-in Phase 
 After personnel have been formally trained, they will receive additional training 
through feedback during a run-in phase.  Compliance with the protocol and completion 
and submission of the data will be required before the DCC will notify the site that that 
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agency is now in the active phase of the trial.  Compliance monitoring includes:  correct 
inclusion/exclusion criteria, adherence to study protocol, CPR process measures 
reported, and correct completion of data elements including reporting of adverse events. 
 
DSMB and Monitoring Strategy 
 
Data Safety and Monitoring Committee 
 An independent data safety and monitoring committee will help ensure the safety 
of the trial by monitoring adverse outcomes throughout the trial and by reviewing 
outcome data for possible harm. In addition, the committee will review the results of the 
interim analyses.  The committee must review and approve the protocol before the study 
can commence.  The DSMB will evaluate the rate of adverse events between the 
treatment and control arms at intervals to be determined by the DSMB, expected to be 
approximately semi-annually and anticipated to correspond roughly to patient enrollment 
of one-third and two-thirds of total enrollment. The DSMB will also monitor primary and 
secondary study outcomes between the treatment and control groups.  The DCC will 
forward DSMB reports to study investigators, the Institutions Research Board, the Food 
and Drug Administration, and the NIH in accordance with federal regulations 45 CFR 
Part 46 Subpart A and 21 CFR 312 and the IDE regulations, as well as appropriate 
Canadian oversight bodies. 
 
Safety and Data Monitoring  
 The plans for monitoring protocol implementation/compliance, and data 
collection/quality are detailed elsewhere. Clinical centers will report all potential adverse 
events to the DCC as soon as possible.  These will be collected in both a structured 
(standard form) and open (describing any difficulties encountered) form.  All potentially 
serious adverse events will be reviewed by an events committee of ROC Investigators 
blinded as to treatment arm and further classified by:  a) Severity (life-threatening, 
serious, non-serious); and b) Expected vs. unexpected; and c) Relation to study device. 
For serious adverse events, the DCC will notify the DSMB as well as appropriate 
regulatory agencies, sites, and NIH promptly. 
The DCC will tabulate and report compliance, data quality, and non-serious 
adverse events on a regular basis. 
 
Proposed Interim Monitoring Plan 
 Each factor will be monitored independently by the DSMB and either study could 
be terminated, without terminating the other.  However, interactions will be evaluated.  
Interim analyses will be conducted after accrual of 1/3 and 2/3 of the sample size target 
(Appendix 8).   
 
Proposed Interaction and Extension Monitoring Plan 
 We are aware that some may believe that the ITD will be ineffective for patients 
who receive Analyze Early care.  Others may believe that this is not a realistic scenario.  
If it were true, it would require twice the duration to have the same power for observing 
the hypothesized effect in the Analyze Later cohort.  The outcome will be observed 
during the course of the study by the independent DSMB as described in Appendix 9. 
In the event that the Analyze Late vs Analyze Early (ALvE) intervention is 
terminated early due to demonstrated superiority of one rhythm analysis strategy over 
the other, the efficacy population for the ITD/sham device comparison will be restricted 
to those subjects treated under the rhythm analysis strategy found to be superior. The 
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number of subjects accrued to the study will be increased to achieve the planned 
maximal sample size in the superior rhythm analysis strategy arm. 
In the event that the ITD/sham device intervention is terminated early, future 
patients will receive no device, and the efficacy population for the ALvE treatment 
comparison will be otherwise unchanged. 
 
Human Subjects 
 
Protection Against Risks 
In accordance with the FDA, we will develop an adverse event reporting system 
to identify and treat any potential adverse events.  We intend to closely monitor the 
clinical course of all patients enrolled in this trial to identify any expected or unexpected 
adverse events. Data regarding adverse events will be collected in both a structured 
(standard form) and open (describing any difficulties encountered) format.  In 
accordance with the regulations 21 CFR 312.32, we have outlined the expected serious 
and non-serious adverse events, our plans to identify these and the time line for 
reporting them to the FDA, IRB and DMSB and other overseeing agencies.  
An additional risk to subjects in this proposal pertains to the potential for a breach in 
patient confidentiality. All study personnel involved in data collection and analysis will be 
required to sign a confidentiality agreement as required by the institutional review board. In 
addition, subjects will be identified in the database by a study number and links to specific 
identifiers will be kept in a separate secure location. Database files will be maintained on a 
password protected computer in a secure location. 
 
Recruitment and Informed Consent 
This study qualifies for exception from informed consent required for emergency 
research as outlined in FDA regulation 21CFR50.24. The study intervention needs to be 
administered quickly following the onset of cardiac arrest. In this uncontrolled setting the 
patient is unconscious. As a result, the patient is unable to provide consent for study 
enrollment. Legal next-of-kin are often not immediately available at the scene, nor is it 
practical for the prehospital provider to explain the study and receive consent while caring for 
a patient in cardiac arrest. Taken together, these issues provide sufficient support for an 
exception from consent in order to evaluate an intervention that may have significant outcome 
benefits to this patient population. We have outlined below each criterion stipulated in the 
regulations for this exception and how our study design applies to these criteria. 
 
Sec. 50.24 Exception from informed consent requirements for emergency 
research 
(1) The human subjects are in a life-threatening situation, available treatments are 
unproven or unsatisfactory, and the collection of valid scientific evidence, which 
may include evidence obtained through randomized placebo-controlled 
investigations, is necessary to determine the safety and effectiveness of particular 
interventions. 
The proposed trial is a factorial trial of use of either an active of sham ITD 
supplemented by either of two resuscitation strategies (Analyze Later and Analyze Early) 
in patients with nontraumatic out-of-hospital cardiac arrest. These patients are in an 
immediate life-threatening situation with a mortality approaching 95%. The standard of 
care for prehospital management of these patients includes the timely provision of CPR 
and advanced life support including airway management. 
 As reviewed in this proposal, previous studies of ITD have suggested a short-
term survival advantage with this device but have not been definitive.  These studies 
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attest to the safety of ITD in the cardiac arrest population and to the practicality of using 
them in the prehospital environment. The major limitations of previous studies are their 
lack of focus on the specific intervention and their lack of sufficient size to detect 
significant clinical differences in outcome.  Also, in contrast to the previous human 
studies, the present trial will evaluate the device in patients with unprotected airways in 
which case potentially harmful hyperventilation is less common.  Thus, critical evaluation 
of this intervention in humans has not been undertaken.   
 Animal and human data demonstrate the safety of Analyze Later.   Studies in 
animal models of cardiac arrest indicate that a period of artificial circulation prior to the 
initial rescue shock can increase the likelihood of successful defibrillation when VF and 
circulatory arrest lasts more than 3-4 minutes.  Small randomized trials in humans with 
cardiac arrest show that an initial period of CPR may or may not improve survival.  
However, the prior studies lacked concurrent control groups or were too small to detect 
meaningful differences in survival. Therefore, no study has adequately answered the 
question of whether an EMS provider, upon reaching a subject who has already 
developed cardiac arrest, should a) deploy a defibrillator and administer an immediate 
rescue shock or b) perform CPR for an interval prior to deploying the defibrillator and 
rescue shock.  
  We propose a large randomized trial focused on evaluation of these two 
interventions in the out-of-hospital cardiac arrest population, with sufficient statistical 
power to detect changes in outcome. Furthermore, an emphasis on the neurological 
outcome of resuscitated cardiac arrest patients will define the clinical utility of this 
resuscitation approach for these patients. 
 
(2) Obtaining informed consent is not feasible because: 
(i) The subjects will not be able to give their informed consent as a result of 
their medical condition; 
(ii) The intervention under investigation must be administered before 
consent from the subjects' legally authorized representatives is feasible; 
and 
(iii) There is no reasonable way to identify prospectively the individuals 
likely to become eligible for participation in the clinical investigation. 
The study interventions need to be administered as an early intervention after the 
onset of cardiac arrest (see discussion of therapeutic window below). In this uncontrolled 
setting the patient is unconscious and unable to provide consent for study enrollment. 
Legal next-of-kin are often not immediately available at the scene, nor is it practical for 
the prehospital provider to explain the study and receive consent while caring for the 
cardiac arrest patient. Since we are studying out-of-hospital cardiac arrest, which is 
frequently the first manifestation of cardiovascular disease, there is no way to 
prospectively identify individuals who are likely to become eligible for this trial. 
 
(3) Participation in the research holds out the prospect of direct benefit to the 
subjects because: 
(i) Subjects are facing a life-threatening situation that necessitates 
intervention; 
(ii) Appropriate animal and other preclinical studies have been conducted, 
and the information derived from those studies and related evidence 
support the potential for the intervention to provide a direct benefit to the 
individual subjects; and 
(iii) Risks associated with the investigation are reasonable in relation to 
what is known about the medical condition of the potential class of 
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subjects, the risks and benefits of standard therapy, if any, and what is 
known about the risks and benefits of the proposed intervention or activity. 
 
 (i) As defined, these patients with cardiac arrest are facing a life-threatening situation 
that requires immediate intervention. 
(ii) Previous animal and human studies have been conducted, and suggest the potential 
for a direct benefit to individual subjects in cardiac arrest via improved hemodynamics 
and short-term survival advantage. 
(iii) ITD administration has been tested in three previous clinical trials no serious adverse 
effects reported. Both Analyze Early and Analyze Late are currently used strategies.  
Three studies give inconsistent results, but no adverse effects have been noted. As 
discussed above, there are potential risks to subjects that may have not been observed 
in previous trials. We contend that these risks are reasonable in light of the potential 
benefits outlined in this proposal and the current poor outcome for patients with out-of-
hospital cardiac arrest. 
 
(4) The clinical investigation could not practicably be carried out without the 
waiver. 
 
This study could not be conducted without the waiver of consent due to the need 
to administer the interventions as early as possible after the onset of cardiac arrest. 
 
(5) The proposed investigational plan defines the length of the potential 
therapeutic window based on scientific evidence, and the investigator has 
committed to attempting to contact a legally authorized representative for each 
subject within that window of time and, if feasible, to asking the legally authorized 
representative contacted for consent within that window rather than proceeding 
without consent. The investigator will summarize efforts made to contact legally 
authorized representatives and make this information available to the IRB at the 
time of continuing review. 
 
There have been three clinical studies of ITD use during standard manual CPR 
for the treatment of patients with out-of-hospital cardiac arrest.  These demonstrated a 
potential survival benefit for patients treated with ITD vs. standard CPR. Animal models 
of cardiac arrest suggest that the ITD may increase venous return during the 
decompression phase of CPR.  Based on these data, coupled with the previous clinical 
trials, the therapeutic window for this agent is for the time of initial resuscitation, which 
occurs when CPR is administered by prehospital care providers, up to hospital 
discharge. 
It is well established that the probability of rescue shock success declines quickly 
during cardiac arrest.(49, 90) The decay in the probability of rescue shock success 
occurs over minutes, and approaches zero by 10-12 minutes.  Therefore, the Analyze 
Early vs. Analyze Late intervention must be performed within the first few minutes of 
treatment in order to be meaningful.  
Since this is an immediately life-threatening situation, it will not be possible to 
contact legal representatives at the time of study entry. We will make every effort to 
contact legal representatives after admission to the hospital to notify them that the 
patient was enrolled in a randomized trial. Requiring consent to review a hospital chart to 
determine the presence or absence of serious adverse events is likely to be associated 
with a biased estimate of the safety and efficacy of the intervention. Therefore we 
propose to use exception from informed consent for emergency consent, public 
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notification, community consultation, patient notification of enrollment, and waiver of 
documented informed consent to review clinical records.  
If legal representatives are not immediately available, research personnel will 
attempt to contact the subject’s legal representative as soon as feasible and a summary 
of these efforts will be documented in the patient’s chart. If the subject becomes 
competent during the study period then he/she will be approached by research 
personnel for notification of enrollment. 
 
(6) The IRB has reviewed and approved informed consent procedures and an 
informed consent document consistent with Sec. 50.25. These procedures and the 
informed consent document are to be used with subjects or their legally 
authorized representatives in situations where use of such procedures and 
documents is feasible. The IRB has reviewed and approved procedures and 
information to be used when providing an opportunity for a family member to 
object to a subject's participation in the clinical investigation consistent with 
paragraph (a)(7)(v) of this section. 
All procedures and consent forms will be approved by the Institutional Review 
Board (IRB) of the regional study site (or Research Ethics Boards (REBs) in Canada) 
prior to the onset of the trial. 
 
(7) Additional protections of the rights and welfare of the subjects will be 
provided, including, at least: 
(i) Consultation (including, where appropriate, consultation carried out by 
the IRB) with representatives of the communities in which the clinical 
investigation will be conducted and from which the subjects will be drawn; 
(ii) Public disclosure to the communities in which the clinical investigation 
will be conducted and from which the subjects will be drawn, prior to 
initiation of the clinical investigation, of plans for the investigation and its 
risks and expected benefits; 
(iii) Public disclosure of sufficient information following completion of the 
clinical investigation to apprise the community and researchers of the 
study, including the demographic characteristics of the research 
population, and its results; 
(iv) Establishment of an independent data monitoring committee to 
exercise oversight of the clinical investigation; and 
(v) If obtaining informed consent is not feasible and a legally authorized 
representative is not reasonably available, the investigator has committed, 
if feasible, to attempting to contact within the therapeutic window the 
subject's family member who is not a legally authorized representative, and 
asking whether he or she objects to the subject's participation in the 
clinical investigation. The investigator will summarize efforts made to 
contact family members and make this Information available to the IRB at 
the time of continuing review 
 (i) In U.S, centers, community consultation as outlined by the local IRB will be 
undertaken prior to IRB approval.  Similarly, the Canadian centers will follow the 
requirements of their local REBs. Since the population eligible for enrollment includes all 
citizens in the study regions it will not be possible to target any particular small group. 
The community consultation plan for each study site will have to be individualized to fit 
the IRB requirements. Attached is an example of a proposed plan for community 
consultation, which has been used in a prior ITD trial (Appendix 10). Feedback from the 
community will be obtained by research personnel regarding any concerns they may 
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have about potential enrollment. If requested, bracelets will be made available that could 
be worn by members of the community who do not want to participate. 
 (ii) & (iii) Public disclosures will be performed both prior to study enrollment and 
at the completion of the study in the form of multimedia press releases organized by the 
Resuscitation Outcomes Consortium. These will include plans for the study including 
potential risks and benefits and a summary of the results of the study upon completion. 
In the event that the press releases are not widely circulated, advertisements will also be 
placed in local papers describing the study. 
 (iv) An independent data monitoring committee will exercise oversight of the 
study as described below.  
 (v) We expect that all patients who meet the enrollment criteria will be 
unconscious. Any delay in medical care that would be required for the paramedic to 
attempt to obtain consent from the patient’s legal guardian would be life threatening. 
Thus it will not be feasible to attempt to obtain informed consent during the initial 
therapeutic window. 
Once enrolled in an emergency research trial, patients die in the field, die in the 
hospital or survive the event. Review of the clinical record is important to ascertain 
adverse events and important outcomes such as hospital discharge status.   This does 
not require further participation of the patient. 
The local ROC investigator will provide information about the emergency 
research study to the patient or their representative at the earliest feasible opportunity 
after administration of the intervention. Since in many cases this will be while the patient 
is still hospitalized, this will not include a request for consent for further 
participation/intervention, but will provide the patient/representative contact 
names/numbers for purposes of obtaining further information if desired.  Since only 
patients who survive several months after discharge will be asked for further 
participation (in the form of telephone administered functional status measures at 3 
months and 6 months), the timing of the request for consent for this participation will be 
determined by the local IRBs.    However, we suggest that it should be during the first 
month after discharge so that patients who die before that time are not inconvenienced 
with a decision and so that those who have not died have had time to recover sufficiently 
to make a reasoned decision. 
In summary, we shall notify patients enrolled under waiver of consent for 
emergency research as quickly as feasible, and seek consent from those who survive to 
discharge for ongoing participation. 
 
Please see Appendix 10 for a sample Exception to Consent plan. 
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